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ABSTRACT 
A preventative HIV-1 vaccine would contribute substantially to ending the AIDS 
epidemic. While the correlates of protection are unknown, broadly neutralizing HIV-1 
antibodies (bNAbs) can prevent infection in animal models. However these antibodies 
are rare even in natural infection, their epitopes are still being characterized, and all 
the factors underlying their development have yet to be elucidated. Characterising 
bNAb targets, and defining how bNAbs develop in HIV-1 infected people, might 
therefore provide blueprints for the rational design of an HIV-1 vaccine. Here, we 
characterized the broadly neutralizing plasma specificities of two individuals in the 
CAPRISA cohort, CAP248 and CAP257. This paved the way for the isolation of a 
monoclonal antibody (mAb) from each donor, targeting two recently described sites of 
vulnerability on the HIV-1 envelope trimer.  
The CAP248-2B mAb targets a glycan-independent epitope in the gp120-gp41 
interface, distinct from previously described epitopes. Using mutagenesis, protein 
crystallography, and electron microscopy, we identified key components of this epitope 
in the gp120 C terminus, and in gp41 upstream of the membrane proximal external 
region (MPER). Mutations that escaped CAP248-2B made heterologous strains up to 
100-fold more sensitive to MPER bNAbs. For CAP257, we described the sequential 
development of three distinct bNAb specificities, and analogous to CAP248 we 
showed that escape from the earliest bNAbs exposed the epitopes for later bNAbs. 
Immunotype toggling during early CAP257 escape pathways resulted in viral 
diversification that immediately preceded the development of neutralization breadth. 
Lastly, we isolated a strain-specific CD4 binding site (CD4bs) antibody called CAP257-
RH1, which recognises an N276 glycan-dependent epitope that overlapped with one 
of the CAP257 plasma bNAb specificities. CAP257-RH1 represents an early member 
of the CAP257 CD4bs response, and its strain-specificity could be attributed to a 
preference for unglycosylated V5 loops, found in an early minority population of 
autologous viral envelope sequences. This rare feature may be important for the 
induction of N276 glycan-dependent CD4bs antibodies.  
Thus, in this thesis we describe new targets for HIV-1 neutralizing antibodies, 
delineate the viral pathways that drove neutralization breadth, and identify unique viral 
variants that may potentially enhance the immunogenicity of the CD4bs and MPER. 
These data may serve as a roadmap for the induction of HIV-1 bNAbs by vaccination. 
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CHAPTER ONE: INTEGRATED NARRATIVE 
The purpose of this integrated narrative is to provide a full literature review, and then 
discuss how the results contained within this thesis contribute to the field as a whole. 
To assist the reader, first author publications that contribute to the chapters of this 
thesis are marked with an asterisk symbol (*), while co-author contributions made 
during the synthesis of this thesis are marked with a double asterisk (**).   
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VACCINES: WEAPONS OF MASS PROTECTION 
A vaccine is a biological preparation administered to an individual to improve immunity 
to a particular disease, and is usually derived from the causative agent itself. The 
earliest forms of vaccination (known as variolation) were performed by exposing 
healthy individuals to low doses of infectious material, such as the dried powdered 
scabs of someone who had recently recovered from an infection with Variola major 
(the causative agent for smallpox) (1, 2). The first accepted report of vaccination was 
a self-published treatise by Edward Jenner in 1798, describing the use of Variolae 
vaccinae (the causative agent for cow pox) inoculation as a means to protect against 
smallpox infection (3). A hundred years later, Louis Pasteur showed that when 
chickens were inoculated with live, attenuated cultures of the causative agent for fowl 
cholera (later identified as Pasteurella multocida) they became resistant to infection 
with unattenuated, virulent inoculums, thus providing the first example of a vaccine 
developed in the laboratory (4). In the ~135 years since then, vaccines have been 
developed for roughly two dozen human diseases, saving millions of lives each year.  
Many of the early vaccines were developed through attenuation of live pathogens, or 
the use of whole, killed pathogens (5) While these attenuated pathogens closely mimic 
natural infection, and probably best stimulate all arms of the immune system, they still 
have the potential to revert back to more virulent forms and cause fatal infection (1). 
This is epitomized by the Oral Polio Vaccine (OPV) (6), which is frequently used in the 
developing world because it is easier and cheaper to administer than the inactivated 
alternatives. Attenuation of poliovirus results from only a few mutations, which revert 
back to more neurovirulent forms after extended transmission in under-vaccinated 
communities, or replication in the gut of immunocompromised individuals (7, 8). The 
advent of genetic engineering provided a new alternative to vaccine design: the batch 
production of pure, recombinant antigens from a pathogen of interest, in a surrogate 
expression system. The hepatitis B virus surface antigen, expressed in yeast, was the 
first recombinant vaccine and conferred complete protection against hepatitis B 
infection (9, 10). Subsequently, recombinant sub-unit vaccines have been developed 
for Lyme disease, cholera, Human Papillomavirus (HPV), and meningitis, with several 
more in development. Despite these successes some diseases have evaded vaccine 
discovery, notably Acquired Immunodeficiency Syndrome (AIDS), which is caused by 
the Human Immunodeficiency Virus (HIV) - the subject pathogen of this thesis. 
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RAPID EMERGENCE OF A GLOBAL PANDEMIC 
HIV is a zoonotic lentivirus, having crossed the species barrier to humans from other 
old world simian primate species, probably somewhere around the turn of the 19th 
century (11, 12). Simian Immunodeficiency Viruses (SIVs) are endemic in over 40 
primate species, some of which have been infected for at least tens of thousands of 
years (12, 13). While these mostly represent established monophyletic infections, 
there is evidence for more recent zoonotic transmission between chimpanzee and 
gorilla simian species (14). The even more recent transmission of various SIV strains 
to humans has occurred at least twelve times, but the majority of these events were 
dead-end infections with limited secondary spread within human populations (12). 
Twice, transmission from sooty mangabeys has led to the established transmission of 
HIV-2 in west Africa (Groups A and B), however HIV-2 is largely non-pathogenic, and 
is being increasingly replaced by HIV-1 infection (15). HIV-1 can be divided into four 
known transmission events (Groups M, N, O, and P) of which only M and O show 
considerable secondary spread amongst humans. Group M and N are most closely 
related to SIV infecting chimpanzee sub-species found only in Cameroon, Gabon, and 
the Republic of Congo (Figure 1A) (16). Similarly, Group O and P share high homology 
with SIV from a gorilla sub-species that lives in the same region of Africa (Figure 1B) 
(17, 18). The transmission of group M and O likely occurred in southern Cameroon, 
and subsequently diversified throughout the Congo River Basin.  
Group M viruses have rapidly spread throughout the world, and as of 2014 there are 
34.3 million – 41.4 million people are living with HIV-1, with ~2 million new infections 
each year (http://www.unaids.org). The dissemination of group M relative to the other 
non-pandemic groups N, O, and P appears to have been driven largely by successful 
adaptations of the SIV virulence factor Vpu (described below) to the human viral 
restriction factor, tetherin (19). The oldest HIV-1 group M sequence fragments were 
recovered from the stored infected tissues of two individuals originally sampled in 1959 
and 1960, and potentially coincide with the spatiotemporal origins of the HIV-1 group 
M pandemic in Kinshasa (11, 20, 21). Today Kinshasa is home to such HIV-1 diversity 
that, unlike viruses from other parts of the world, those cannot be easily categorized 
into individual clades (Figure 1C) (22). The most globally prominent group M clades: 
A, B, C, and circulating recombinant form 01 (CRF01), cluster geographically, and 
therefore probably represent individual founder events that expanded in isolation.  
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Figure 1: Geographical distribution of SIVcpz and SIVgor, relative to the global 
diversity of HIV-1 group M 
A) A map of central and western Africa, showing the distribution of various common 
chimpanzee species, Pan troglodytes verus (gray), P. t. ellioti (purple), P. t. troglodytes 
(orange), P. t. schweinfurthii (blue), and of the bonobo P. paniscus (yellow). Yellow 
spheres mark regions where SIV-infected chimpanzees were found, and white 
spheres where they were not. B) Geographical distribution of western and eastern 
gorilla species, G. gorilla (green) and G. beringei (brown), with SIV infections indicated 
and in A. C) Geographic clustering of the most prominent HIV-1 group M clades. An 
inset of central Africa shows the high level of clade diversity found within the region, 
indicative of the age of the local epidemic there. The pie charts have been sized 
relative to the number of people living with HIV-1 in each region, with regional clade-
bias probably representing individual founder events. Figure 1A and 1B were taken 
from (12), while Figure 1C was taken from (23). 
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Clade B represents the oldest and most globally dispersed pandemic clade, having 
first spread to Haiti (possibly in the 1960s), where it circulated for some years before 
distinct emigration events into North or Central America, and then the rest of the world 
(24), including South Africa (25). The South African clade B epidemic spread almost 
exclusively in males, but by the late 1980s clade C had begun to emerge, and 
coincided with increased infection rates in women (26). At this time, clade C epidemics 
were already established in many other countries of southern Africa, and have since 
evolved in India, Ethiopia, and more recently in select regions of Brazil, West Asia, 
and Oceania. Collectively clade C viruses now contribute to roughly half of all new 
infections each year (Figure 1C). This rapid expansion of a single founder event into 
an epidemic-associated clade is linked to the stable transmission of HIV within specific 
populations at high-risk for infection. These include people who share needles 
(predominantly for intravenous drug use), people who regularly engage in anal sex, 
and people who have frequent unprotected sex with multiple partners.  
In South Africa, the clade C epidemic disproportionately affects young women, 
particularly those from impoverished backgrounds, who are at high risk for infection 
from older, wealthier men (27). This is particularly significant because South Africa 
has more than 6 million HIV infections, more than any other country worldwide. HIV-1 
prevalence rates in the south eastern province of KwaZulu-Natal can be as high as 
40% (28), and the HIV-1 prevalence amongst South African women aged 15-24 is 3.5 
times than men of the same age, an imbalance that is partially driven by poverty, 
gender inequality, early sexual debut, and poor retention in the education system (29). 
To better understand the risk factors that predispose this ‘key population’ of women to 
HIV-1 infection, and develop effective intervention strategies, the Centre for the AIDS 
Programme of Research in South Africa established an acute infection study cohort 
(CAPRISA 002) in 2004 comprised of approximately 250 high-risk women from both 
metropolitan and rural areas of KwaZulu-Natal (30). In this thesis, we study two 
CAPRISA 002 participants, CAP248 and CAP257, who developed HIV-1 broadly 
neutralizing antibodies. The information gained from these studies will hopefully inform 
the development of an HIV-1 vaccine designed to mimic these protective responses 
in healthy people. Vaccination provides a discreet long-term intervention strategy for 
women who, for various reasons, are unable to negotiate first-line HIV prevention 
strategies such as condom use or monogamous sexual relationships.   
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THE HIV-1 PROTEOME 
Mammalian lentiviruses have a gene structure that is millions of years old (Figure 2A), 
and encodes the three essential polyproteins called group-specific antigen (Gag), 
polymerase (Pol), and envelope (Env), as well as two essential transcription regulating 
elements trans-activator (Tat) and regulator of expression of viral proteins (Rev) (31). 
Several additional accessory proteins with host-specific functions have also arisen 
over the course of lentiviral evolution, and primate lentiviruses can be distinguished by 
having viral protein R (Vpr), negative factor (Nef), and often viral protein unique (Vpu)-
like genes, as well as the absence of deoxyuridine triphosphatase (dUTPase) (32). 
The known HIV-1 proteome is briefly described in Figure 2B. Gag and GagPol 
polyproteins are expressed on cytoplasmic polysomes, and co-localize at the host cell 
plasma membrane with the env gene products that are expressed and processed in 
endoplasmic reticulum polysomes and the golgi apparatus respectively (33, 34). The 
assembled virions bud from the cell, and are then processed by HIV protease into the 
functional, infectious viral particle in a process termed viral maturation (33).  
The Gag polyprotein is sub-divided into the matrix protein (p17, MA), capsid protein 
(p24, CA), nucleocapsid protein (NC), p6 protein, and two short spacer peptides (SP1, 
p2 and SP2, p1). The complex is directed towards cholesterol-rich lipid rafts, where it 
inserts into the membrane via post-translational myristoylation of the MA N terminus 
(35). The myristic acid (MYR), normally sequestered in a hydrophobic pocket, is 
released allosterically following interactions between the cationic MA N terminus and 
negatively charged fatty acids in the plasma membrane (36). MA proteins assemble 
into a trimer, and are also involved in recruiting the trimeric surface antigens encoded 
by Env (37). The viral capsid is made up of ~12 pentameric and ~200 hexameric forms 
of CA, which are cleaved from MA and then from SP1 by maturation to condense the 
capsid around the viral genomic RNA (38). The capsid proteins are also cleaved from 
NC which are zinc finger proteins, responsible for the specific condensing and 
packaging of two copies of viral RNA into the complete virion, as well as protecting 
and shuttling these into the host cell nucleus after infection and subsequent uncoating 
of the capsid (39, 40). The last of the Gag proteins, p6, is a recruitment factor for both 
viral proteins (like Vpr) as well as the host cell ESCRT (endosomal sorting complexes 
required for transport) machinery that are necessary for viral budding (33).  
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Figure 2: The HIV-1 Proteome 
A) A linear schematic of the ~10 kb HIV-1 genome is shown, with each of the various 
HIV-1 genes encoding the viral proteome indicated in their respective reading frames. 
Gag or Env structural genes are boxed in blue or yellow respectively, Pol enzyme 
genes are boxed in green, and the essential or accessory regulatory factors are boxed 
in red or purple respectively. B) The entire HIV- proteome as it is packaged into 
infectious virions is shown, coloured as in A. Some crystal structures (such as Vif) are 
of partial protein fragments, as the complete structure still needs to be elucidated.   
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Pol is expressed as part of the GagPol polyprotein at ~5% total Gag expression, 
directing the incorporation of viral enzymes protease (PR), reverse transcriptase (RT), 
and integrase (IN) into the mature virions. These Pol proteins are all highly conserved 
and constitute the main targets for anti-retroviral drugs (41). The viral RNA itself also 
folds into key secondary structures that regulate its interactions with other molecules 
(42), and is packaged into virions with a host cell transfer RNA molecule for the amino 
acid lysine (tRNALys3) which serves as a primer for reverse transcription after infection 
of a new target cell (43). HIV-1 RT exists as a heterodimer of one polymerase domain 
that synthesizes the viral complementary DNA, and a second ribonuclease H domain 
that degrades the original RNA strand (44). The newly synthesized double stranded 
viral DNA is then inserted into the host genome by IN (45). The accessory protein Vpr, 
which is associated with p6 in the virus, plays a key role in nuclear import of the pre-
integration complex, and arrests the cell cycle in G2 facilitating HIV-1 integration 
through the action of cellular DNA repair enzymes (46).  
The other accessory proteins Vif, Vpu, and Nef all contribute towards evading the host 
immune response and disease progression. Vif is present in almost all lentiviruses, 
and functions to bring the host apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3G (APOBEC3G) and E3 ubiquitin-protein isopeptide ligase complex 
together (47). Subsequent polyubiquitination of APOBEC3G is a proteasome targeting 
signal that results in its degradation. APOBEC3G that is not destroyed is packaged 
into the viral core, where it deaminates cytidine causing hypermutation of the viral 
genome (48). As alluded to above, HIV-1 Vpu functions to block the action of host 
tetherin, which would normally colocalise with Env in lipid rafts where it cross-links viral 
particles to the plasma membrane (49). In monkeys, SIV Nef performs this function 
but cannot bind to human tetherin (50). Vpu also assembles into ion-channels (which 
may be linked to anti-tetherin activity), and together with Nef and Env function to 
downregulate CD4 expression in the host cells (51, 52). Nef is an even more complex 
adapter protein than Vpu, affecting a multitude of cellular interactions (53, 54).  
Lastly, Env is the sole protein expressed on virion surfaces, where it is responsible for 
mediating viral entry (discussed below). As such, it is relatively immunogenic and the 
sole target for neutralizing antibodies, thus forming one of the principle components 
for the rational design of a recombinant HIV vaccine.   
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THE HIV-1 ENVELOPE TRIMER 
The env gene is transcribed in the rough endoplasmic reticulum as a single 
glycoprotein (gp160) that oligomerizes into a trimer, and is then cleaved by furin-like 
host cellular proteases in the Golgi apparatus into the surface unit gp120, and the 
transmembrane protein gp41 (34). Concomitantly with translation, the gp160 
protomers are stabilized through several disulphide bonds, and extensively 
glycosylated with both N- and O- linked glycans that altogether make up almost half 
its molecular weight (55). Unlike other HIV-1 proteins that are packaged in abundance, 
the Env trimer is sparsely incorporated into viral membranes which appear to have 
~14 functional trimeric spikes per virion (56). In addition, gp160 is also aberrantly 
processed into forms that are not entry competent, such as gp160 monomers and 
dimers, uncleaved Env, or prematurely triggered post-fusion conformations of gp41 
(57). These aberrant forms of gp160 expose decoy epitopes for non-neutralizing 
antibodies that do not bind to native, pre-fusion envelope trimers. Together with the 
extremely sequence variable nature of the env gene, these unusual features all make 
HIV-1 Env trimers difficult to neutralize by the human humoral immune system.  
The three gp120 sub-units include all of the binding sites that engage with various host 
cell receptors. Historically, gp120 is divided into five conserved (C1 – C5) and five 
hypervariable (V1 – V5) regions which are sequentially interspersed with each other 
in a linear sequence (Figure 3A). In the tertiary structure of native unliganded Env, 
gp120 can also be divided into the inner domain (ID), outer domain (OD), and trimer 
association domain (TAD) (Figure 3B) (58, 59). The three IDs exist at the trimer axis 
where they interact with gp41, and are not accessible to neutralizing antibodies, 
whereas the OD and TAD are more antigenically exposed (58, 60). In accordance C1 
– C5 comprise the core of the trimer, while V1 – V5 extend out from the TAD and OD, 
forming the most solvent exposed and distal regions from the trimer axis (Figure 3C) 
(58, 61). The TAD at the trimer apex is comprised of V1, V2, and V3 (59). While V1 is 
extremely diverse in both sequence and length, V2 is generally conserved in both 
sequence and structure, and its variable loop region is confined to a relatively short 
sequence structurally adjacent to V1 (62). Similarly V3 is relatively conserved as an 
important component of the co-receptor binding site (63), though it is more variable 
clade B strains (where it was identified) and is associated with coreceptor switching.   
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Figure 3: Structure of the HIV-1 Envelope 
A) A linear schematic of the gp160 sequence is shown. For gp120, the trimer 
association domain is shown in red, the inner domain in orange, and the outer domain 
in yellow. Key regions of the gp41 ectodomain are coloured as follows: fusion peptide 
(FP) in pink, fusion peptide proximal region in purple (FPPR), heptad repeat helix 1 
(HR-1) in blue, immunodominant cysteine loop region in cyan, heptad repeat helix 2 
(HR-2) in green, and the membrane proximal external region (MPER) in brown. The 
transmembrane region and cytoplasmic tail of gp41 is coloured black and grey 
respectively. B) The Env trimer is shown in cartoon, with two gp120 and two gp41 
protomers coloured dark and light grey respectively. The remaining gp120-gp41 
heterodimer is coloured as in A, and labelled in a zoomed inset. In addition the N and 
C termini of gp120 and the relative position of the viral membrane are indicated. C) A 
single gp120 monomer is shown in cartoon and the conserved regions C1 – C5 are 
coloured in grey. The hypervariable loops V1 (blue), V2 (red), V3 (orange), V4 (yellow), 
and V5 (green) are indicated. The standard amino acid numbering system for Env is 
based on a reference sequence of the tissue culture laboratory adapted (TCLA) clade 
B strain HXB2, as it is defined on the LANL HIV Sequence Database. This numbering 
system is used throughout this integrated narrative, as well as in the publications 
below. An explanation can be found at the following link:  
(http://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/HXB2.html)  
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The three gp41 proteins form the hydrophobic core of the Env ectodomain, and contain 
all of the viral machinery necessary to fuse with the host cell (64). In the linear 
sequence, gp41 ectodomain is divided into the fusion peptide (FP), the fusion peptide 
proximal region (FPPR), heptad repeat helix-1 (HR-1), the immunodominant cysteine 
loop region, heptad repeat helix-2 (HR-2), and the membrane proximal external region 
(MPER) (Figure 3A and 3B). A short transmembrane region separates the gp41 
ectodomain from the ~150 amino acid long cytoplasmic tail, which regulates Env 
incorporation, intracellular trafficking, and surface expression, as well as a number of 
cellular functions that influence infectivity and disease progression (65, 66).  
The critical components for CD4 binding are all located in the OD of gp120, which has 
a stable β barrel structure (61, 67). The primary host receptor, CD4, initially engages 
with the OD, causing subtle rearrangements in the ID, and facilitating the dissolution 
of the TAD (Figure 4A) (68). In this CD4 bound form, the base of V1V2 rearranges to 
form part of the bridging sheet, providing additional stabilizing interactions with CD4 
to complete the CD4 binding site (CD4bs), while the released V3 loop extends towards 
the host cell membrane and forms an important component of the coreceptor binding 
site (CoRbs) (60, 69). The coreceptor CCR5 is critical for the binding and entry of all 
but a few anomalous HIV-1 strains (70, 71). CXCR4 using strains (synonymous with 
the onset of AIDS) sometimes emerge late in infection (rarely in clade C), and this 
switch in coreceptor tropism is largely determined by the sequence of V3 (70). Strains 
that have become CD4 independent, or are able to use alternate coreceptors such as 
CCR1, CCR2b, CCR3, CCR8, CCR9, CX3CR1, CXCR4, and CXCR6 are even rarer, 
and probably evolve in the presence of unusual selection pressures, or are tissue-
culture adapted strains (72-75). The CoRbs in its entirety is shielded by V1V2 in the 
TAD, and only properly exposed on entry-mediating Env after CD4 engagement. This 
CD4 bound conformation of Env is often referred to as the “open conformation”, 
because these rearrangements expose a number of highly immunogenic epitopes for 
non-neutralizing antibodies. One of these epitopes overlaps with a region of V2 that is 
able to bind the host cell integrin α4β7 (76). While this receptor binding site is not 
exposed on entry-competent trimers, it is accessible on many forms of incorrectly 
processed, aberrant forms of Env, and might serve to traffic virions toward the gut-
associated lymphoid tissues which are rapidly depleted during acute HIV-1 infection 
(77). In addition, there is evidence for the clustering of Env on the virion surface, and 
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the co-localization of α4β7 and CD4 suggests a role for α4β7 in stabilizing the 
interaction between Env and CD4 (56, 78). We have identified viral strains with specific 
V2 sequences (P/SDI/V) that bind better to α4β7 than strains with the global 
consensus for this site (LDI/L/V) (79)**. These α4β7 high-binding strains clustered 
geographically, forming a distinct phylogeny that probably expanded from one or two 
founder populations in South Africa. Similarly to α4β7, non-critical interactions 
between Env and a host dendritic cell specific C-type lectin (DC-SIGN) have also been 
described (80). DC-SIGN is highly expressed in mucosal tissues, and like α4β7, may 
facilitate the capture and dissemination of free virions (81).  
The FP is cleaved from the gp120 C terminus during viral maturation, and retracts from 
the solvent into a pocket at the protomer interface, but surprisingly remains relatively 
solvent exposed (82). The FP, FPPR, and N-terminal portions of HR-1 together form 
a relatively dynamic unit that sits between two adjacent gp120 protomers. This is held 
in place through interactions between the FPPR and a tryptophan clasp formed by a 
region between the cysteine loop and HR-2 that wraps around the N and C termini of 
gp120, near the viral membrane (58, 82-84). When CD4 binds to gp120, the 
movements responsible for shifting Env into the open conformation translate down the 
gp120 termini, facilitating the release of the FPPR which subsequently results in 
shedding of monomeric gp120 (85). In tandem with gp120 release the HR-1 helix 
uncoils, driving the FP into the host cell membrane, and the fully formed HR-1 and 
HR-2 helices collapse into a stable 6-helix bundle, bringing the host and viral 
membranes closer together (Figure 4B) (86-88). The MPER of gp41 is also relatively 
hydrophobic and associates with the viral membrane. CD4 binding is associated with 
exposure of MPER epitopes (89-91), and it is thought that through this process the 
MPER pulls the viral membrane towards the host cell. This collapsed gp41 stabilizes 
the formation of pores in the viral and host cell membranes, facilitating viral entry (92).  
THE CHALLENGE OF AN HIV-1 VACCINE  
Live attenuated viruses closely mimic natural infection, and thus elicit highly effective 
immune responses that efficiently stimulate all arms of the immune system. Early 
studies suggested that macaques inoculated with attenuated SIV were protected 
against infection by more pathogenic strains (93). In support of these data, six 
individuals of the Sydney Blood Bank Cohort who had all been infected with an 
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Figure 4: HIV-1 Membrane Fusion 
A) A cartoon representation of Env in the closed pre-fusion (left) and open CD4-
liganded conformations (right). V1V2 is coloured red and V3 is colured orange. The 
rest of gp120 is shown in yellow and gp41 in blue. The V2 and V3 loops are labelled 
in both conformations to illustrate the structural rearrangements that occur after CD4 
(shown in green) binding. The α4β7 binding site, which is occluded in the pre-fusion 
conformation but exposed on more open conformations of Env, is indicated in black. 
The possible 20 Å translocation of Env and subsequent exposure of the MPER after 
CD4 engagement is shown relative to the location of the viral membrane. B) A cartoon 
representation of the gp41-mediated fusion events. Each gp120 is stably bound in the 
open conformation by CD4 and CCR5. This promotes gp120 dissociation from gp41, 
and the concomitant release of the fusion peptide which is driven into the host cell 
membrane by HR-1 helix formation. Finally the entire gp41 complex collapses into a 
highly stable 6-helix bundle that fuses the host and viral membranes. 
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attenuated HIV-1 strain lacking nef/LTR, derived from the contaminated blood 
products of a single individual, all showed delayed disease progression (94). However, 
in both the macaque and human examples of infection with attenuated SIV or HIV, this 
eventually led to AIDS-related immunological damage (95-97). In the most extreme of 
circumstances, the high mutability of HIV can even facilitate partial rebuilding of the 
attenuated virulence factors (98). These data strongly attest to the dangers of a live 
attenuated HIV-1 vaccine, and as such various recombinant HIV-1 antigens are being 
tested as HIV-1 vaccine candidates for the prevention of infection.  
More than 200 HIV vaccine trials have been conducted since 1988, culminating in the 
three different approaches that have now been tested in large-scale phase III vaccine 
efficacy trials (99). The first two of these, the AIDSVAX trials, focused on the past 
successes of using surface antigen proteins to induce neutralizing antibody responses 
to the pathogen. Unfortunately, immunization with the recombinant surface antigen of 
HIV-1 failed to protect or delay disease progression in both vaccine trials, casting 
doubt as to the relevance of antibody-based vaccines for preventing HIV-1 infection 
(100, 101). The second approach was to use non-replicative adenovirus type-5 (Ad5) 
vectors engineered to express various internal HIV proteins (not subject to antibody-
mediated neutralization) that might stimulate a protective cell-mediated immune 
response. However, these Ad5 vectors also failed to induce protective immunity, and 
unexpectedly there was a suggestion from the STEP trial that individuals who were 
already Ad5-seropositive pre-vaccination had enhanced acquisition of HIV-1 (102-
104). These data might suggest that stimulating either the humoral or cellular arms of 
the immune system independently fails to induce protective immunity. One theory is 
that an effective HIV-1 vaccine might need to elicit both infection limiting antibodies to 
prevent initial viral dissemination, as well as a cellular capability to rapidly kill those 
cells that do get infected, and thus prevent the establishment of a viral reservoir.  
This hypothesis was tested in the third approach to a phase III HIV-1 vaccine efficacy 
trial, RV144. This trial was designed to elicit both antibody and cellular immune 
functions by combining the initial AIDSVAX recombinant monomeric gp120 vaccine 
antigens with a canarypox vector based prime (ALVAC vCP1521), that like the Ad5 
vector was designed to present various HIV-1 gene products (Env, Gag, and PR) to 
the cellular immune system. Remarkably, results from the RV144 trial showed a 
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modest 31.2% efficacy for the prevention of HIV-1 infection in some statistical 
analyses (105). These results were not without controversy though, since they were 
interpreted from very limited data with only 51 infections in the vaccine arm (8197 
enrolled) and 74 infections in the placebo arm (8198 enrolled). Even more surprising 
was the finding that this modest vaccine efficacy did not correlate with neutralizing 
antibodies or cellular immunity, but rather with binding antibodies that targeted the V2 
region of gp120 at a site that overlaps with both known neutralizing antibody epitopes, 
as well as a binding site for the α4β7 integrin (106, 107). Each of these are described 
in more detail below. Confounding the correlates results even further was the 
suggestion that IgA binding antibodies to a different epitope commonly associated with 
non-neutralizing antibody effector functions actually correlated inversely with 
protection (106). While the mechanisms of protection from HIV-1 are clearly not yet 
fully understood, these data have greatly rejuvenated hopes of developing an HIV 
vaccine. Efforts are currently underway to both repeat and understand the results of 
RV144, as well as to design better vaccine immunogens that might also be able to 
elicit the types of immune responses expected to protect against HIV-1 infection.  
Historically, most vaccines have worked through the action of neutralizing antibodies 
(108). Further rationale for pursuing neutralizing antibodies for HIV-1 vaccination 
comes from passive immunization studies in animal models, showing that infusions 
with neutralizing antibodies provided superior protection from infection with chimeric 
simian / human immunodeficiency viruses (SHIVs) when compared to non-neutralizing 
antibodies (109-111). This large difference between the protective effects of 
neutralizing and non-neutralizing antibodies could explain why the RV144 trial or 
previous HIV-1 vaccine trials have failed to provide sufficient protection (Since no 
vaccine immunogen to date has been able to elicit cross-reactive neutralizing 
antibodies). A large number of both neutralizing and non-neutralizing antibodies have 
been isolated from HIV-1 infected individuals (see below), including the isolation of 
several highly potent, and broadly cross-clade reactive neutralizing antibodies since 
2009 (112)*. These latter antibodies all bind with higher affinities to native, pre-fusion 
Env than to the monomeric gp120 proteins used in most vaccine trials, and most are 
able to prevent infection through passive immunization studies (113, 114). This has 
opened up the possibility of using these antibodies in passive immunotherapy in 
humans. To date, two of these antibodies have been tested in separate phase I clinical 
Chapter 1: Integrated Narrative  
 16 
trials where they were shown to be both safe, and able to reduce viral load (115-117). 
However, reminiscent of HIV-1 anti-retroviral monotherapy, escaped viral variants 
emerged as antibody levels tapered, and in some individuals resistant viruses were 
already present pre-vaccination. Therefore, it is likely that combinations of three / four 
antibodies will be needed for HIV-1 immunotherapeutic applications (118).  
In addition to their therapeutic benefits, these broad and potent antibodies have 
facilitated an unparalleled characterization of the HIV-1 Env in its native, pre-fusion 
state, culminating in the rational design of next-generation stabilized Env immunogens 
with reduced exposure of non-neutralizable epitopes (119, 120). Early immunogenicity 
studies with Env trimers showed a promising induction of neutralizing antibodies, 
although these were still strain-specific for the vaccine strain (121). It is hoped that a 
greater understanding of how broad and potent antibodies normally develop in vivo, 
coupled with the design of stable, trimeric, pre-fusion Env immunogens will greatly 
expedite the rational design of an effective HIV-1 vaccine.  
THE BASIC STRUCTURE OF AN ANTIBODY 
Antibodies are large 150 kDa molecules comprised of two 50 kDa heavy chain and 
two 25 kDa light chain proteins. Each heavy chain is formed by the recombination of 
variable heavy (VH), diversity (D), and joining (J) genes, that are then fused to the 
constant gene segments (122). Similarly, the two light chains of the antibody are 
formed from the recombination of variable lambda (Vλ) or variable kappa (Vκ) genes 
and the light chain J gene, which is also joined to constant regions. The recombined 
V(D)J regions of both heavy and light chains, together with the first constant domain, 
form the two antigen binding fragments (Fab) of the antibody (123). The remaining 
constant domains assemble into the single glycosylated antibody crystallizable 
fragment (Fc) which interacts with various cellular receptors to mediate a plethora of 
effector functions. The Fab domains can be further subdivided into the framework 
regions (FWRs), which fold into a stable β barrel structure, and the conformationally 
diverse complementarity determining regions (CDRs) which determine antibody 
specificity (124). Both heavy and light chain CDR-1 and CDR-2 loops are encoded for 
by the variable genes alone, while the CDR-3 loops are formed directly from V(D)J 
recombination events and are thus the most diverse in both sequence, length, and 
structure.  
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The stochastic nature of V(D)J recombination results in an extremely diverse pool of 
naïve B cells that migrate to the germinal centres, where they may encounter antigens 
to which they are able to bind (usually with relatively low affinities) (125). Some of 
these B cells are autoreactive and almost always deleted, but those that bind to a 
compatible antigen then begin to undergo successive rounds of affinity maturation 
through somatic hypermutation (126). B cells expressing mutated antibodies with 
higher affinity for the antigen than their predecessors are selected for additional clonal 
expansion and further maturation. Specific DNA sequence motifs guide this process 
towards the CDRs, but as B cells become highly mutated through constant stimulation, 
maturation can also occur in the FWRs, particularly in FWR-H3 (125, 127). The 
numbering of antibody sequences, as well as the way CDRs are classified, is done 
using several different systems that give slightly different loop locations and lengths. 
For the purposes of this narrative, the Kabat numbering system will be used 
throughout.  
THE HUMORAL RESPONSE TO HIV-1 NATURAL INFECTION 
Antibody responses to HIV-1 can be divided into three categories: binding (also called 
non-neutralizing) antibodies, strain-specific neutralizing antibodies, and broadly 
neutralizing antibodies (bNAbs) (128). Non-neutralizing antibodies are the first to 
appear within days of infection, and target epitopes on a variety of HIV-1 gene products 
such as aberrant Env and monomeric gp120. These include post-fusion gp41 
epitopes, followed by epitopes in the CD4bs, CoRbs, V2 (RV144-like antibodies), and 
V3 that are only exposed in the open conformation (129). These are also the types of 
antibodies most frequently elicited by current vaccination strategies. The rapid 
development of anti-gp41 responses appears to be driven by a population of 
established antibodies that are cross-reactive with commensal gut bacteria (130, 131). 
HIV-1 tissue culture laboratory adapted (TCLA) strains are neutralized by some of 
these non-neutralizing antibodies, particularly those that bind epitopes in the CD4bs 
or V3. These TCLA viruses have evolved a more open Env conformation in the 
absence of in vivo immune pressures, and are classified as tier-1 “easy-to-neutralize” 
strains (132). Tier-1 viruses sporadically emerge in blood, but are rapidly neutralized 
and do not represent transmitted/founder strains (133).  
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Figure 5: The basic structure of an antibody 
A schematic showing an example of the initial recombination and gene rearrangement 
events that lead to the production of an antibody. The variable light (VL) and variable 
heavy (VH) chain genes are drawn as closed yellow and red blocks respectively, while 
the D genes, J genes, and constant genes are each shown as green, grey, and open 
boxes. The CDR loops regions for the heavy and light chains are indicated on both the 
schematic of the final recombined gene segment, as well as on the variable domain 
region of a model antibody shown in cartoon view. The light chain CDR loop regions 
L1, L2, and L3 are shown in brown, pink, and purple respectively, while the heavy 
chain CDR loop regions are shown in dark blue, light blue, and green respectively. 
The full length antibody is also shown on the right, the heavy and light chains coloured 
red and yellow as above, and the domains that make up the Fab and Fc fragments 
are indicated.   
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Therefore, while tier-1 strains are frequently used to assess the effectiveness of HIV-
1 vaccine responses, a successful vaccine will likely need to elicit antibodies that are 
able to neutralize tier-2 strains, which comprise the majority of transmitted / founder 
viral variants, and have a harder to neutralize phenotype due to a more closed Env 
conformation.  
The first tier-2 neutralizing antibodies develop after months of infection, but are almost 
always strain-specific. This strain-specificity is largely determined by the targeting of 
hypervariable regions, and autologous neutralizing antibody responses have been 
mapped to V1, V2, V4, V5, as well as the α2 helix in gp120 (134-137). Conversely, 
bNAbs usually take years to develop but target highly conserved regions of the Env 
trimer (138, 139). While all individuals eventually develop some level of cross-reactive 
neutralization, only ~20% of infected individuals develop truly broad neutralizing 
antibody activity that is capable of neutralizing 40% - 99% of the globally circulating 
HIV-1 strains (139-143). Monoclonal antibodies have been isolated from a large 
number of individuals with broad serum neutralizing activity, and their epitopes have 
been extensively characterized using structural biology and phenotypic mutagenesis 
studies. The strategies used to isolate bNAbs, the unusual features that enable broad 
neutralization, and the targets for these bNAbs are discussed in Chapter 2 of this 
thesis, which is a review published in Current Opinions in HIV and AIDS (112)*, but 
bNAb targets will also be briefly discussed below for the purposes of this narrative.  
HIV-1 BROADLY NEUTRALIZING ANTIBODY TARGETS 
The targets for bNAbs on HIV-1 Env trimers are often divided into five epitope clusters 
that were roughly defined by the first antibody isolated for each site: the V2 site, the 
N332 supersite, the CD4bs, the gp120-gp41 interface, and the MPER. The first HIV-1 
bNAbs were isolated in the 1990’s, and target epitopes on monomeric gp120 (b12 
targets the CD4bs while 2G12 targets the N332 supersite) or linear peptides of gp41 
(2F5 and 4E10 target the MPER) (144-147). Of these, only 4E10 was truly broad, but 
lacked the neutralization potency exhibited by other the bNAbs, and together with 2F5 
was unfavorably autoreactive (148). It was not until two decades later that the first 
broad and potent neutralizing antibodies were isolated (PG9 and PG16 which target 
the V2 site), identifying novel quaternary structure specific epitopes only present on 
native pre-fusion trimers (149). The V2 site is comprised of a short, mostly cationic 
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peptide in V2 (between position 165 and 171), and two highly conserved glycans at 
position N156 and N160 (62). This epitope overlaps considerably with the antibodies 
isolated from RV144 vaccinees, but the vaccine-induced antibodies do not bind 
glycan, and recognize a different conformation of V2 from that which is bound by the 
V2 bNAbs and other conformation dependent V2 non-neutralizing antibodies (150, 
151). Furthermore, the V2 bNAb epitopes do not overlap with the α4β7 binding site.  
Almost all of the subsequently identified V2 bNAbs share a common epitope with PG9, 
and therefore often possess similar mechanisms of neutralization that involve 
unusually long, anionic (often tyrosine sulphated) CDR-H3 loops of between 24 and 
37 amino acids long (152-156). The average CDR-H3 length is 11 to 14 amino acids, 
and CDR-H3 lengths required by V2 bNAbs are extremely rare in the naïve B-cell pool 
and often autoreactive (157). As part of a large collaborative effort, we isolated a family 
of V2 bNAbs from CAP256 (a participant of the CAPRISA 002 cohort) with the longest 
CDR-H3 loops described to date. CAP256 antibodies were particularly broad against 
clade C strains, and differed from other V2 bNAbs in the extent to which they were 
dependent on the glycans at positions N156 or N160 (156)**. We later showed that 
members of the CAP256-VRC26 antibody lineage were sensitive to N160 mutations 
in a potency-dependent manner, with the least potent antibodies being the most 
heavily glycan dependent (158)**. Thus, the breadth of a bNAb response is enhanced 
by its ability to bind glycans where the peptide contacts may be suboptimal, however 
the most potent bNAb interactions still rely almost entirely on peptide-peptide contacts. 
This is probably because a high affinity for the host-derived glycans would increase 
the autoreactivity of the antibody.  
The isolation of PG9 and PG16 was possible after significant advancements in the 
ability to culture B cells, and screen their activity in high-throughput neutralization 
assays. Soon after this, additional broad and potent antibodies with N332 glycan 
dependent epitopes were isolated by the same method (154). Like the V2 antibodies, 
these new N332 dependent bNAbs use long CDR-H3 loops of between 18 and 24 
amino acids to extend between multiple glycans and make a limited number of 
peptide-peptide contacts (159, 160). This is in contrast to the first N332-dependent 
bNAb isolated, 2G12 (CDR-H3 length of 14), which binds exclusively to glycans 
through a unique mechanism of variable heavy (VH) chain domain exchange between 
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the two Fab arms, creating a third antigen binding site at the VH-VH interface (161). 
The new N332 glycan dependent bNAbs could be divided into two groups, those that 
also dependent on the glycan at N301 and/or amino acids of V3 (PGT121-PGT134 
and 10-1074), and those that are substantially reliant on glycans at N386 and N392, 
and contact amino acids at the base of V4 (PGT135-PGT137) (154, 162, 163). 
Together with 2G12, these bNAbs define a glycan supersite of at least three distinct 
sites of vulnerability that overlap the glycan at N332 (160). Of these, the PGT121 
lineage is the most well described, where various members evolved to recognize the 
glycans at positions N137, N156, N301, and N332 with varying affinities (83, 162, 163).  
The CD4bs is currently the most extensively characterized of the bNAb targets, and 
at least 20 different bNAbs lineages have been isolated. The majority of these are 
derived from the VH1-2 or VH1-46 germline genes, and despite developing in different 
donors display a structurally convergent mechanism of neutralization, even in cases 
where the sequences differed by >50% (164, 165). These antibodies mimic CD4 in 
the way their VH domains interact with gp120, and the two complexes bear remarkable 
overall structural likeness (166). This is key to the breadth of this bNAb class, because 
even slight deviations in the angle of approach to the CD4bs can result in extensive 
clashes with the TAD or ID of gp120 in the native pre-fusion trimer (167). This binding 
angle allows for a diverse repertoire of CDR-H3 lengths, which can range between 12 
and 23 amino acids within a single VH-gene-restricted CD4bs bNAb lineage (168).  
An important component of the interaction that orients all of the VH-gene-restricted 
antibodies with respect to the CD4bs is a salt bridge between a VH1-2/46 germline 
encoded R71 in the CDR-H2 and D368 in gp120, which mimics the interactions 
between R59 of CD4 (in the equivalent C’’ sheet) and D368 (164-166, 169). In the 
case of bNAbs that are derived from the VH1-2 germline, the light chain CDR-L3 is 
always five amino acids long to prevent clashes with loop D in gp120, and the 
associated N276 glycan (170). This is less of a restriction for VH1-46 germline-derived 
antibodies because the light chain is oriented a further ~6 Å out of the CD4 binding 
site (171).  
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Figure 6: Broadly Neutralizing Antibody Epitopes 
A surface view of the Env trimer is shown in grey, with various bNAb epitopes indicated 
with coloured mesh. The variable loops V1, V2, V4, and V5 are shown in cartoon and 
coloured cyan. An additional solvent-exposed, hypervariable region made up of the α2 
helix and β14 sheet is indicated. Top view depicts the trimer from the angle of the host 
cell, while the side view shows an angle parallel with the viral membrane. BNAbs that 
bind to epitopes in V2 (red) or the CD4bs (light green) target highly overlapping 
surfaces and can be grouped into single sites of vulnerability. In contrast, bNAb 
epitopes in the N332 supersite or the gp120-gp41 interface overlap only marginally, 
and are shown with separate colours (labelled in the key). The MPER (black) is 
modelled in the 10E8 bound conformation, but is dynamic and can shift the rest of Env 
to vertically, bringing it closer to the viral membrane (indicated).   
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In contrast, and as presented as part of this thesis (Chapter 4), we describe N276 
glycan dependent CD4bs bNAbs in the plasma of CAPRISA 002 participant CAP257, 
and together with work from another laboratory define a similar epitope for the 
monoclonal CD4bs bNAb HJ16 (172)* (173). HJ16 forms part of a newly described 
class of CD4bs bNAbs that have CDR H3-dominated paratopes, allowing for a greater 
diversity in VH gene usage (171). The other current members of this class, VRC13, 
VRC16, and CH103 do not require the N276 glycan for effective neutralization, and all 
use positively charged amino acid side chains to interact directly with D368 in gp120. 
However, both HJ16 and the CAP257 plasma bNAbs described in this thesis are not 
dependent on interactions with D368 in gp120. More recently, yet another N276 glycan 
dependent bNAb, 179NC75, was isolated with a similar D368-independent epitope, 
suggesting a common mechanism of neutralization shared with HJ16, CAP257, and 
other CD4bs bNAbs that potentially have yet to be described (174). A better 
understanding of this glycan target in the CD4bs will expand our knowledge of the 
vulnerabilities that could be exploited for an effective HIV-1 vaccine immunogen. No 
crystal structure is currently available for 179NC75, and the structure of HJ16 bound 
to gp120 does not include the N276 glycan. Thus, in Chapter 5 of this thesis, we 
contribute to characterizing the N276 CD4bs target by determining the cocrystal 
structure of an N276 glycan dependent CD4bs neutralizing antibody isolated from 
CAP257, bound to gp120. While the CAP257 monoclonal antibody did not display 
broad neutralization against a panel of ~200 heterologous viruses, these data describe 
at the atomic level, one possible mechanism of how neutralizing CD4bs antibodies 
might recognize the N276 glycan.  
The N276 glycan is also critical for the neutralization of bNAb 8ANC195, which binds 
to the gp120-gp41 interface (175). While 8ANC195 binds better to the pre-fusion 
closed conformation, it is also able to bind to Env after it has engaged CD4 and 
rearranged into a more open conformation (176). The epitopes for 8ANC195 and two 
other gp120-gp41 interface bNAbs, 35O22 and PGT151, were characterized in 2014, 
and represent three distinct but slightly overlapping epitopes that define a new bNAb 
target (58, 177-179). These are described in detail in Chapter 2 of this thesis (112)*. 
Since the publication of that review, the epitope for PGT151 has been described at 
higher resolution (82), and additional bNAb epitopes have been identified in the gp120-
gp41 interface (180). Remarkably, all of these antibodies make contacts with the 
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fusion peptide and fusion peptide proximal region, which are substantially more 
solvent exposed than previously thought, identifying these as common bNAb targets. 
3BC315 is one such bNAb for which the epitope has been structurally characterized 
by cryogenic electron microscopy (cryo-EM). Like 35O22, 3BC315 approaches Env 
close to the viral membrane, but unlike previous interface bNAbs 3BC315 bridges both 
the gp120-gp41 and gp41-gp41 interfaces, destabilizing the interactions that hold 
together native pre-fusion Env trimers (180). 3BC315 also differs from the other 
interface bNAbs in that its mechanism of neutralization is not glycan dependent, 
despite having an epitope that is substantially occluded by the N88 glycan. This same 
glycan is the target of number of newly described gp120-gp41 interface bNAbs.  
In Chapter 3 of this thesis, we describe the isolation and characterization of the 
monoclonal antibody CAP248-2B, which targets a distinct epitope in the vicinity of the 
gp120-gp41 interface. The antibody binds Env with the same membrane proximal 
angle of approach as 35O22 and 3BC315, and appears to partially overlap the gp41-
gp41 bridging epitope of 3BC315, but also reaches under gp41 to make unique, critical 
contacts with the gp120 C terminus. The gp120 C terminus has not been targeted by 
previously described HIV-1 bNAbs, and CAP248-2B is unique amongst the interface 
targeting bNAbs in that it binds to the viral membrane proximal gp41-gp120 interface. 
Collectively, these antibodies completely encircle the Env trimer, implicating the entire 
pre-fusion gp41 protomer as a vaccine target (112)*. CAP248-2B uses an unusually 
long CDR-L3 loop to bind to the viral membrane. Similarly, bNAbs that target the 
MPER all use long hydrophobic CDR-H3 loops to anchor themselves at the trimer-
membrane interface (90, 181, 182). The MPER, as a bNAb target, can be further 
divided into three conformationally distinct epitopes: an N-terminal region (bound by 
2F5 and m66.6), a C-terminal region (bound by 4E10 and 10E8) and an elbow region 
between the two epitopes (bound by Z13e1) (183-187). The conformational diversity 
of the MPER when visualized in complex with different bNAbs suggests that this region 
requires a highly plastic structure to facilitate its function in membrane fusion. This 
intrinsic flexibility allows the base of the trimer to lift up to 20 Å from the viral 
membrane, facilitating access to the MPER, as well as the epitopes for gp120-gp41 
interface targeting bNAbs like CAP248-2B (82). Like 8ANC195, the MPER bNAbs are 
able to bind to both the open and closed forms of Env, but for MPER bNAbs the Env-
CD4 interactions appear to enhance the frequency with which the MPER accessible 
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conformation is sampled (82, 179, 188). It should also be noted that while the MPER 
itself is a linear peptide epitope, more recent structural data of 4E10 in the presence 
of lipids and 10E8 bound to fully native pre-fusion trimers implicates other proximal 
regions of gp41, as well as the viral membrane, as components of the greater MPER 
site of vulnerability (82).  
MAPPING PLASMA NEUTRALIZING RESPONSES 
The identification of novel bNAb epitopes has traditionally been driven by the isolation 
and subsequent characterisation of monoclonal antibodies. Defining bNAb epitopes in 
plasma is more challenging, as these generally comprise only a minor fraction of the 
total antibody response to Env. Early attempts at mapping bNAb responses were 
flawed through the use of tier-1 isolates (189-192). These viruses have a number of 
normally non-neutralizing epitopes exposed in the context of their functional Env, for 
which multiple antibody lineages are often present at high titre in all HIV-1 infected 
plasma, and thus overwhelm any bNAb neutralization signals. Many of the newer 
bNAbs are glycan dependent, complicating the mapping data because removing these 
conserved components of the glycan shield can expose epitopes for non-neutralizing 
antibodies, or affect the processing of neighbouring glycans (193). Nevertheless, early 
plasma mapping studies defined key mapping strategies such as the use of chimeras 
between sensitive and resistant viruses to approximate general neutralization 
determinants (such as the TAD or MPER), or the use gp120 or MPER peptides to 
adsorb out the neutralizing fraction from the other plasma antibodies (191, 194). These 
experiments, coupled with alanine scanning mutagenesis or the introduction of key 
resistance mutations to known monoclonal bNAbs, allows for fine-mapping of the 
neutralization determinants. Despite this, most cohort mapping studies still list a large 
number of plasmas as targeting unknown epitopes (139, 142, 189, 191, 192, 195, 
196). Our early efforts in this thesis suggested the existence of additional quaternary 
structure specific bNAb epitopes that were not V2-directed, which we and others 
postulated might target novel gp41 epitopes (172)*. These observations were later 
confirmed through the isolation of gp120-gp41 interface monoclonal bNAbs by us and 
other research groups.  
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Using the CAPRISA 002 cohort we have previously identified seven individuals with 
broadly neutralizing plasma, and were able to map the bNAb epitopes of four of them 
(139). In this thesis, we map the bNAb epitopes for two additional CAPRISA 002 
participants, CAP248 and CAP257, with a unique approach using longitudinally 
derived autologous Env sequences to identify bNAb selection pressure (172)*(197)**. 
Escape mutations were validated when neutralization resistance was conferred by 
their introduction into sensitive heterologous viruses. While CAP248 plasma mapped 
to a novel gp120-gp41 interface epitope, we also identified additional confounders of 
plasma mapping for participant CAP257: the simultaneous presence of multiple bNAb 
lineages at similar time points, as well as the presence of previously undescribed 
dependencies within known bNAb targets (172)*. In the latter example, the power of 
longitudinal sequences facilitated the identification of critical neutralization 
determinants, such as the N276 glycan dependent CD4bs bNAbs in CAP257 plasma, 
or the glycan independent V2 antibodies in CAP256 (172)*(198). Multiple specificities 
could be accurately teased apart by introducing autologous mutations from each 
specificity into a single virus. Thus, mapping studies such as those described in this 
thesis have defined the bNAb targets of polyclonal plasma responses, characterized 
how viral escape influenced the development of bNAbs, and in turn have aided in the 
isolation monoclonal bNAbs from infected individuals (192, 198-201). 
DESIGNING IMMUNOGENS TO TARGET BNAB PRECURSORS 
In most instances, the UCAs or germline reverted (gHgL) precursors of bNAbs interact 
only weakly with an autologous virus from relatively early in infection (but these 
precursors are largely unable to bind or neutralize heterologous Envs), suggesting a 
requirement for specific germline reactive Env immunogens to engage naïve B cell 
precursors of bNAbs (156)**(202, 203). BNAbs that target the CD4bs bind primarily to 
the OD of gp120, and the use of OD minimalist antigens has been explored as a way 
to focus the immune response towards this epitope (67, 204-210). These OD 
constructs were extensively reengineered to produce proteins with high affinity for 
mature bNAbs, and reduced affinity for non-neutralizing CD4bs antibodies, but they 
still failed to bind bNAb precursors. More recently, the glycan at position N276 was 
identified a major obstruction for the engagement of gHgL reverted bNAbs from the 
VH-gene-restricted class of CD4bs bNAbs (211, 212). Antigens engineered without 
this glycan were able to activate B cells expressing these precursor antibodies in a 
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calcium flux assay. In addition, using these same antigens, immunization of mice 
engineered to express the heavy chain germline reverted genes for VRC01 or 3BNC60 
(both VH1-2-gene-restricted CD4bs bNAbs), selected for neutralization compatible 
endogenous mouse light chains (211, 213, 214). Support for this immunization 
strategy has been found in archived viral sequences from donor 45, from whom 
VRC01 was isolated, which have similar potential bNAb-initiating immunotypes at 
positions 276 and 278 in loop D of Env (117, 199, 212, 215). These Env variants may 
represent a minor population of the total viral population at a given time point. Rare 
autologous viral variants that engage neutralizing antibody precursors have also been 
described for a V2 bNAb lineage (216), and for the CAP257-RH1 monoclonal antibody 
in this thesis. In the case of CAP257-RH1, this early N276 glycan dependent CD4bs 
antibody requires the absence of glycans in V5, a feature that also enhances binding 
to the gHgL version of VH-gene-restricted bNAbs. We suggest that these data might 
add to the design of vaccine immunogens that could activate B cells able to target 
N276-glycan dependent CD4bs epitopes, and might function cooperatively with N276 
deleted immunogens to elicit a wider variety of CD4bs bNAb precursors. No doubt a 
major challenge for these types of immunization strategies will be the specific 
expansion of B cell clones that are able to evolve into bNAbs, over those that are 
intolerant of fully glycosylated Envs.  
BNAB DEVELOPMENT IN VIVO AS A VACCINE BLUEPRINT 
Understanding why bNAbs only develop after multiple years of infection, and how they 
acquire broad neutralizing activity has clear implications for HIV-1 vaccine design. 
From the current literature there are three mechanisms of virus-antibody co-evolution 
that contribute to bNAb development (217): the creation or exposure of a bNAb epitope 
through viral escape mutations, and the diversification of a bNAb epitope (and 
subsequently the bNAb) through the presentation of multiple viral immunotypes. In the 
first two instances, the creation or exposure of bNAb epitopes can be driven by 
selection pressure from both strain-specific, or broadly neutralizing antibodies 
(172)*(197)**(202). These antibodies might target completely unrelated epitopes, such 
as the CAP257 escape mutations in V2 that potentially disrupted inter-protomer TAD 
interactions, and therefore possibly allowed for greater sampling of an open Env 
conformation which would in turn expose the CD4bs to bNAbs (172)*, or CAP248 
escape mutations in the gp120-gp41 interface that exposed the MPER. They may also 
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target epitopes that overlap significantly with bNAbs, but rely critically on unusual 
immunotypes or the rare absence of a conserved glycan (197)**(218-221), such as 
the strain-specific CD4bs antibody isolated from CAP257. In the latter case, the bNAb 
epitope diversifies to escape these early strain-specific antibodies, and this diversity 
almost always precedes the acquisition of some neutralization breadth in the plasma, 
whether the bNAb is from the same antibody lineage as the strain-specific antibodies 
or not (156)**(172)*(197)**(203, 222).  
Three studies have now described how bNAbs can develop from a strain-specific 
precursor, and we have also documented the evolution of a broadly neutralizing 
antibody lineage targeting the V2 site, in CAPRISA 002 participant CAP256 (156)**. 
The CAP256-VRC26 bNAb lineage developed a maximum breadth of ~60% roughly 
2.5 years after B cell transcripts could first be detected by deep sequencing (158)**. 
This was a substantially shorter timeframe than the 4 - 6 years it took for the CH103 
and CH235 lineages, both CD4bs bNAbs isolated from the same donor (CH505), to 
develop to 55% and 90% breadth respectively (203, 223). Despite early CD4 mimicry 
by the CH235 unmutated common ancestor (UCA), this lineage still had mutations 
accumulating to 26% divergence from germline before achieving >90% neutralization 
breadth (223). These sequentially acquired mutations conferred breadth through 
tolerance for epitope diversity, or the ability to recognize other proximal conserved 
residues (217, 223). However, the requirement for such high levels of somatic 
hypermutation in natural infection probably contributes to the time it takes for bNAbs 
to develop significant breadth. Furthermore, in some instances epitope diversity also 
drives the bNAb lineage towards strain-specificity through critical interactions with rare 
escape residues. This results in highly mutated, off-track lineages that no longer 
contribute to plasma neutralization breadth (155, 216).  
By designing immunogens that mimic selected pathways to breadth from natural 
infection, bNAbs with lower mutation levels might be elicited more rapidly by 
vaccination with sequential antigens expressing various common immunotypes. 
Understanding exactly which mutations are key to preferentially driving neutralization 
breadth may better inform vaccine design, and could prevent over engagement of the 
competing off-track lineages that will inevitably be co-stimulated by immunization.  
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CONCLUSIONS 
In this thesis, we contribute to the identification of novel targets for bNAbs, and to 
understanding how viral escape mutations shape bNAb evolution in vivo. As a 
consequence of these data, we suggest several rare mutations in Env that might prove 
useful in increasing the antigenicity of B cell priming immunogens targeting bNAb 
precursors. These blueprints provided by natural infection may inform vaccine design, 
and future work will aim to characterize the responses elicited by these unusual 
immunogens in conjunction with their associated sequential immunization strategies.  
 
REFERENCES 
1. Plotkin SA. 2003. Vaccines, vaccination, and vaccinology. J Infect Dis 
187:1349-1359. 
2. Weiss RA, Esparza J. 2015. The prevention and eradication of smallpox: a 
commentary on Sloane (1755) 'An account of inoculation'. Philos Trans R Soc 
Lond B Biol Sci 370. 
3. Jenner E. 1798. An Inquiry into the Causes and Effects of the Variolae 
Vaccinae, a Disease Discovered in Some of the Western Countries of England, 
Particularly Gloucestershire, and Known by the Name of “The Cow Pox”. 
Printed for the Author, by Sampson Low. 
4. Pasteur L. 1880. [TRANSLATED] Of Infectious Diseases, Especially the 
Disease of Chicken Cholera. C R Acad Sci Paris 90:248-249. 
5. Plotkin S. 2014. History of vaccination. Proc Natl Acad Sci U S A 111:12283-
12287. 
6. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, 
Spigland I, Koch MA, Barnes JM, Rhim JS. 1960. Live, orally given poliovirus 
vaccine. Effects of rapid mass immunization on population under conditions of 
massive enteric infection with other viruses. JAMA 173:1521-1526. 
7. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DM, Schild GC, Almond 
JW. 1984. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral 
poliovirus vaccine. Nucleic Acids Res 12:7787-7792. 
8. Chumakov K, Ehrenfeld E, Wimmer E, Agol VI. 2007. Vaccination against 
polio should not be stopped. Nat Rev Microbiol 5:952-958. 
9. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman 
MR. 1984. Human hepatitis B vaccine from recombinant yeast. Nature 307:178-
180. 
10. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. 1982. Synthesis 
and assembly of hepatitis B virus surface antigen particles in yeast. Nature 
298:347-350. 
11. Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, Tatem 
AJ, Sousa JD, Arinaminpathy N, Pepin J, Posada D, Peeters M, Pybus OG, 
Lemey P. 2014. HIV epidemiology. The early spread and epidemic ignition of 
HIV-1 in human populations. Science 346:56-61. 
12. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold 
Spring Harb Perspect Med 1:a006841. 
Chapter 1: Integrated Narrative  
 30 
13. Worobey M, Telfer P, Souquiere S, Hunter M, Coleman CA, Metzger MJ, 
Reed P, Makuwa M, Hearn G, Honarvar S, Roques P, Apetrei C, Kazanji M, 
Marx PA. 2010. Island biogeography reveals the deep history of SIV. Science 
329:1487. 
14. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, Loul S, Butel 
C, Liegeois F, Bienvenue Y, Ngolle EM, Sharp PM, Shaw GM, Delaporte E, 
Hahn BH, Peeters M. 2006. Human immunodeficiency viruses: SIV infection 
in wild gorillas. Nature 444:164. 
15. Rowland-Jones SL, Whittle HC. 2007. Out of Africa: what can we learn from 
HIV-2 about protective immunity to HIV-1? Nat Immunol 8:329-331. 
16. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, 
Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, 
Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, 
Hahn BH. 2006. Chimpanzee reservoirs of pandemic and nonpandemic HIV-
1. Science 313:523-526. 
17. D'Arc M, Ayouba A, Esteban A, Learn GH, Boue V, Liegeois F, Etienne L, 
Tagg N, Leendertz FH, Boesch C, Madinda NF, Robbins MM, Gray M, 
Cournil A, Ooms M, Letko M, Simon VA, Sharp PM, Hahn BH, Delaporte E, 
Mpoudi Ngole E, Peeters M. 2015. Origin of the HIV-1 group O epidemic in 
western lowland gorillas. Proc Natl Acad Sci U S A 112:E1343-1352. 
18. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemee V, 
Damond F, Robertson DL, Simon F. 2009. A new human immunodeficiency 
virus derived from gorillas. Nat Med 15:871-872. 
19. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler 
J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, 
Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, 
Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. 
Tetherin-driven adaptation of Vpu and Nef function and the evolution of 
pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421. 
20. Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD. 1998. An 
African HIV-1 sequence from 1959 and implications for the origin of the 
epidemic. Nature 391:594-597. 
21. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, 
Muyembe JJ, Kabongo JM, Kalengayi RM, Van Marck E, Gilbert MT, 
Wolinsky SM. 2008. Direct evidence of extensive diversity of HIV-1 in Kinshasa 
by 1960. Nature 455:661-664. 
22. Rambaut A, Robertson DL, Pybus OG, Peeters M, Holmes EC. 2001. 
Human immunodeficiency virus. Phylogeny and the origin of HIV-1. Nature 
410:1047-1048. 
23. Hemelaar J. 2012. The origin and diversity of the HIV-1 pandemic. Trends Mol 
Med 18:182-192. 
24. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. 
2007. The emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad 
Sci U S A 104:18566-18570. 
25. Ras GJ, Simson IW, Anderson R, Prozesky OW, Hamersma T. 1983. 
Acquired immunodeficiency syndrome. A report of 2 South African cases. S Afr 
Med J 64:140-142. 
26. van Harmelen J, Wood R, Lambrick M, Rybicki EP, Williamson AL, 
Williamson C. 1997. An association between HIV-1 subtypes and mode of 
transmission in Cape Town, South Africa. Aids 11:81-87. 
Chapter 1: Integrated Narrative  
 31 
27. Abdool-Karim Q, Abdool-Karim SS. 2002. The evolving HIV epidemic in 
South Africa. Int J Epidemiol 31:37-40. 
28. Nel A, Mabude Z, Smit J, Kotze P, Arbuckle D, Wu J, van Niekerk N, van 
de Wijgert J. 2012. HIV incidence remains high in KwaZulu-Natal, South Africa: 
evidence from three districts. PLoS One 7:e35278. 
29. Abdool Karim SS, Abdool Karim Q, Baxter C. 2015. Antibodies for HIV 
prevention in young women. Curr Opin HIV AIDS 10:183-189. 
30. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray 
CM, Abdool Karim Q, Grobler A, Barnabas N, Iriogbe I, Abdool Karim SS. 
2008. Establishing a cohort at high risk of HIV infection in South Africa: 
challenges and experiences of the CAPRISA 002 acute infection study. PLoS 
ONE 3:e1954. 
31. Gifford RJ. 2012. Viral evolution in deep time: lentiviruses and mammals. 
Trends Genet 28:89-100. 
32. Gifford RJ, Katzourakis A, Tristem M, Pybus OG, Winters M, Shafer RW. 
2008. A transitional endogenous lentivirus from the genome of a basal primate 
and implications for lentivirus evolution. Proc Natl Acad Sci U S A 105:20362-
20367. 
33. Freed EO. 2015. HIV-1 assembly, release and maturation. Nat Rev Microbiol 
13:484-496. 
34. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 envelope glycoprotein 
biosynthesis, trafficking, and incorporation. J Mol Biol 410:582-608. 
35. Lalonde MS, Sundquist WI. 2012. How HIV finds the door. Proc Natl Acad Sci 
U S A 109:18631-18632. 
36. Saad JS, Miller J, Tai J, Kim A, Ghanam RH, Summers MF. 2006. Structural 
basis for targeting HIV-1 Gag proteins to the plasma membrane for virus 
assembly. Proc Natl Acad Sci U S A 103:11364-11369. 
37. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI. 1996. 
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix 
protein: implications for membrane association and assembly. Proc Natl Acad 
Sci U S A 93:3099-3104. 
38. Zhao G, Perilla JR, Yufenyuy EL, Meng X, Chen B, Ning J, Ahn J, 
Gronenborn AM, Schulten K, Aiken C, Zhang P. 2013. Mature HIV-1 capsid 
structure by cryo-electron microscopy and all-atom molecular dynamics. Nature 
497:643-646. 
39. Levin JG, Mitra M, Mascarenhas A, Musier-Forsyth K. 2010. Role of HIV-1 
nucleocapsid protein in HIV-1 reverse transcription. RNA Biol 7:754-774. 
40. Muriaux D, Darlix JL. 2010. Properties and functions of the nucleocapsid 
protein in virus assembly. RNA Biol 7:744-753. 
41. Arts EJ, Hazuda DJ. 2012. HIV-1 antiretroviral drug therapy. Cold Spring Harb 
Perspect Med 2:a007161. 
42. Watts JM, Dang KK, Gorelick RJ, Leonard CW, Bess JW, Jr., Swanstrom 
R, Burch CL, Weeks KM. 2009. Architecture and secondary structure of an 
entire HIV-1 RNA genome. Nature 460:711-716. 
43. Kleiman L. 2002. tRNA(Lys3): the primer tRNA for reverse transcription in HIV-
1. IUBMB Life 53:107-114. 
44. Katz RA, Skalka AM. 1994. The retroviral enzymes. Annu Rev Biochem 
63:133-173. 
45. Chiu TK, Davies DR. 2004. Structure and function of HIV-1 integrase. Curr Top 
Med Chem 4:965-977. 
Chapter 1: Integrated Narrative  
 32 
46. Bukrinsky M, Adzhubei A. 1999. Viral protein R of HIV-1. Rev Med Virol 9:39-
49. 
47. Rose KM, Marin M, Kozak SL, Kabat D. 2004. The viral infectivity factor (Vif) 
of HIV-1 unveiled. Trends Mol Med 10:291-297. 
48. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene 
that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 
418:646-650. 
49. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is 
antagonized by HIV-1 Vpu. Nature 451:425-430. 
50. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, 
Johnson WE, Westmoreland S, Evans DT. 2009. Species-specific activity of 
SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS 
Pathog 5:e1000429. 
51. Strebel K. 2014. HIV-1 Vpu - an ion channel in search of a job. Biochim Biophys 
Acta 1838:1074-1081. 
52. Wildum S, Schindler M, Munch J, Kirchhoff F. 2006. Contribution of Vpu, 
Env, and Nef to CD4 down-modulation and resistance of human 
immunodeficiency virus type 1-infected T cells to superinfection. J Virol 
80:8047-8059. 
53. Basmaciogullari S, Pizzato M. 2014. The activity of Nef on HIV-1 infectivity. 
Front Microbiol 5:232. 
54. Geyer M, Fackler OT, Peterlin BM. 2001. Structure--function relationships in 
HIV-1 Nef. EMBO Rep 2:580-585. 
55. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. 
1990. Assignment of intrachain disulfide bonds and characterization of potential 
glycosylation sites of the type 1 recombinant human immunodeficiency virus 
envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol 
Chem 265:10373-10382. 
56. Zhu P, Liu J, Bess J, Jr., Chertova E, Lifson JD, Grise H, Ofek GA, Taylor 
KA, Roux KH. 2006. Distribution and three-dimensional structure of AIDS virus 
envelope spikes. Nature 441:847-852. 
57. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, 
Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM. 2006. Nature 
of nonfunctional envelope proteins on the surface of human immunodeficiency 
virus type 1. J Virol 80:2515-2528. 
58. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, 
Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, 
Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes 
BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors 
M, Kwong PD. 2014. Structure and immune recognition of trimeric pre-fusion 
HIV-1 Env. Nature 514:455-461. 
59. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, Haim H, Yang X, Sodroski 
J. 2012. Subunit organization of the membrane-bound HIV-1 envelope 
glycoprotein trimer. Nat Struct Mol Biol doi:10.1038/nsmb.2351. 
60. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson 
WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope 
glycoprotein. Nature 393:705-711. 
61. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 
1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 
receptor and a neutralizing human antibody. Nature 393:648-659. 
Chapter 1: Integrated Narrative  
 33 
62. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder 
R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, 
Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, 
Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, 
Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, 
Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, 
Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong 
PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing 
antibody PG9. Nature 480:336-343. 
63. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. 1996. 
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for 
chemokine-mediated blockade of infection. Nat Med 2:1244-1247. 
64. Bartesaghi A, Merk A, Borgnia MJ, Milne JL, Subramaniam S. 2013. 
Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-
electron microscopy. Nat Struct Mol Biol 20:1352-1357. 
65. Postler TS, Desrosiers RC. 2013. The tale of the long tail: the cytoplasmic 
domain of HIV-1 gp41. J Virol 87:2-15. 
66. Santos da Silva E, Mulinge M, Perez Bercoff D. 2013. The frantic play of the 
concealed HIV envelope cytoplasmic tail. Retrovirology 10:54. 
67. Joyce MG, Kanekiyo M, Xu L, Biertumpfel C, Boyington JC, Moquin S, Shi 
W, Wu X, Yang Y, Yang ZY, Zhang B, Zheng A, Zhou T, Zhu J, Mascola JR, 
Kwong PD, Nabel GJ. 2013. Outer domain of HIV-1 gp120: antigenic 
optimization, structural malleability, and crystal structure with antibody VRC-
PG04. J Virol 87:2294-2306. 
68. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, 
Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, 
Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski 
J, Hendrickson WA, Arthos J. 2002. HIV-1 evades antibody-mediated 
neutralization through conformational masking of receptor-binding sites. Nature 
420:678-682. 
69. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, 
Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005. 
Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028. 
70. Gorry PR, Ancuta P. 2011. Coreceptors and HIV-1 pathogenesis. Curr 
HIV/AIDS Rep 8:45-53. 
71. Ray N, Doms RW. 2006. HIV-1 coreceptors and their inhibitors. Curr Top 
Microbiol Immunol 303:97-120. 
72. Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, 
Mascola JR, Agopian K, Holm GH, Mehle A, Taylor J, Farzan M, Wang H, 
Ellery P, Willey SJ, Clapham PR, Wolinsky SM, Crowe SM, Gabuzda D. 
2007. Changes in the V3 region of gp120 contribute to unusually broad 
coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. 
Virology 362:163-178. 
73. Bhattacharya J, Peters PJ, Clapham PR. 2003. CD4-independent infection 
of HIV and SIV: implications for envelope conformation and cell tropism in vivo. 
AIDS 17 Suppl 4:S35-43. 
74. Cilliers T, Nhlapo J, Coetzer M, Orlovic D, Ketas T, Olson WC, Moore JP, 
Trkola A, Morris L. 2003. The CCR5 and CXCR4 coreceptors are both used 
by human immunodeficiency virus type 1 primary isolates from subtype C. J 
Virol 77:4449-4456. 
Chapter 1: Integrated Narrative  
 34 
75. Cilliers T, Willey S, Sullivan WM, Patience T, Pugach P, Coetzer M, 
Papathanasopoulos M, Moore JP, Trkola A, Clapham P, Morris L. 2005. 
Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology 
339:136-144. 
76. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, 
Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, 
Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, 
Kottilil S, Goode DJ, Fauci AS. 2008. HIV-1 envelope protein binds to and 
signals through integrin alpha4beta7, the gut mucosal homing receptor for 
peripheral T cells. Nat Immunol 9:301-309. 
77. Haase AT. 2005. Perils at mucosal front lines for HIV and SIV and their hosts. 
Nat Rev Immunol 5:783-792. 
78. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, 
Kottilil S, Macleod K, O'Shea A, Patel N, Van Ryk D, Wei D, Pascuccio M, 
Yi L, McKinnon L, Izulla P, Kimani J, Kaul R, Fauci AS, Arthos J. 2009. The 
integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-
cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci 
U S A 106:20877-20882. 
79. Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer 
CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, 
Williamson C, Moore PL, Morris L. 2015. South African HIV-1 subtype C 
transmitted variants with a specific V2 motif show higher dependence on 
alpha4beta7 for replication. Retrovirology 12:54. 
80. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, 
Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor 
CG, van Kooyk Y. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding 
protein that enhances trans-infection of T cells. Cell 100:587-597. 
81. Geijtenbeek TB, van Kooyk Y. 2003. DC-SIGN: a novel HIV receptor on DCs 
that mediates HIV-1 transmission. Curr Top Microbiol Immunol 276:31-54. 
82. Lee JH, Ozorowski G, Ward AB. 2016. Cryo-EM structure of a native, fully 
glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043-1048. 
83. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, 
Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. 2013. Crystal 
structure of a soluble cleaved HIV-1 envelope trimer. Science 342:1477-1483. 
84. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, 
Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. 2013. Cryo-EM 
structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 
342:1484-1490. 
85. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. 1990. Dissociation of 
gp120 from HIV-1 virions induced by soluble CD4. Science 250:1139-1142. 
86. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. 1997. 
Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430. 
87. Chan DC, Fass D, Berger JM, Kim PS. 1997. Core structure of gp41 from the 
HIV envelope glycoprotein. Cell 89:263-273. 
88. Tan K, Liu J, Wang J, Shen S, Lu M. 1997. Atomic structure of a thermostable 
subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94:12303-12308. 
89. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR. 2003. 
Redox-triggered infection by disulfide-shackled human immunodeficiency virus 
type 1 pseudovirions. J Virol 77:5678-5684. 
90. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, Xia SM, Rits-Volloch 
Chapter 1: Integrated Narrative  
 35 
S, Sun L, Harrison SC, Haynes BF, Chen B. 2009. Role of HIV membrane in 
neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 
106:20234-20239. 
91. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B. 2008. A fusion-
intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. 
Proc Natl Acad Sci U S A 105:3739-3744. 
92. Markosyan RM, Cohen FS, Melikyan GB. 2003. HIV-1 envelope proteins 
complete their folding into six-helix bundles immediately after fusion pore 
formation. Mol Biol Cell 14:926-938. 
93. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992. 
Protective effects of a live attenuated SIV vaccine with a deletion in the nef 
gene. Science 258:1938-1941. 
94. Learmont J, Tindall B, Evans L, Cunningham A, Cunningham P, Wells J, 
Penny R, Kaldor J, Cooper DA. 1992. Long-term symptomless HIV-1 infection 
in recipients of blood products from a single donor. Lancet 340:863-867. 
95. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, 
Anderson DC, O'Neil S, Ruprecht RM. 2003. Live attenuated, nef-deleted SIV 
is pathogenic in most adult macaques after prolonged observation. AIDS 
17:157-166. 
96. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia 
RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS. 
1999. Immunologic and virologic status after 14 to 18 years of infection with an 
attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl 
J Med 340:1715-1722. 
97. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson 
R, Greene MF, McClure HM, Martin LN, Ruprecht RM. 1999. Live attenuated, 
multiply deleted simian immunodeficiency virus causes AIDS in infant and adult 
macaques. Nat Med 5:194-203. 
98. Whitney JB, Ruprecht RM. 2004. Live attenuated HIV vaccines: pitfalls and 
prospects. Curr Opin Infect Dis 17:17-26. 
99. Esparza J. 2013. A brief history of the global effort to develop a preventive HIV 
vaccine. Vaccine 31:3502-3518. 
100. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp 
HIVVSG. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 
120 vaccine to prevent HIV-1 infection. J Infect Dis 191:654-665. 
101. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven 
F, Hu D, Tappero JW, Choopanya K, Bangkok Vaccine Evaluation G. 2006. 
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent 
recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in 
Bangkok, Thailand. J Infect Dis 194:1661-1671. 
102. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, 
Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, 
Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN, Step Study 
Protocol T. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 
vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-
of-concept trial. Lancet 372:1881-1893. 
103. Gray G, Buchbinder S, Duerr A. 2010. Overview of STEP and Phambili trial 
results: two phase IIb test-of-concept studies investigating the efficacy of MRK 
adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 
5:357-361. 
Chapter 1: Integrated Narrative  
 36 
104. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, 
Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, 
Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank 
I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori 
DC, Kublin J, McElrath MJ, Corey L, Gilbert PB, Team HS. 2013. Efficacy 
trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369:2083-2092. 
105. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, 
Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, 
Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, 
Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael 
NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to 
prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220. 
106. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam 
SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico 
AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang 
Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, 
Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, 
Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, 
Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael 
NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy 
trial. N Engl J Med 366:1275-1286. 
107. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, 
Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska 
M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, 
Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, 
Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, 
Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong 
PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH. 
2012. Increased HIV-1 vaccine efficacy against viruses with genetic signatures 
in Env V2. Nature 490:417-420. 
108. Plotkin SA. 2015. Increasing Complexity of Vaccine Development. J Infect Dis 
212 Suppl 1:S12-16. 
109. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder 
MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx 
DL. 1999. Protection of Macaques against pathogenic simian/human 
immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. 
J Virol 73:4009-4018. 
110. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, 
Willey R, Cho MW, Martin MA. 1999. Neutralizing antibody directed against 
the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus 
infections of macaque monkeys. Nat Med 5:204-210. 
111. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop 
DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP. 2011. Limited 
or no protection by weakly or nonneutralizing antibodies against vaginal SHIV 
challenge of macaques compared with a strongly neutralizing antibody. Proc 
Natl Acad Sci U S A 108:11181-11186. 
112. Wibmer CK, Moore PL, Morris L. 2015. HIV broadly neutralizing antibody 
targets. Curr Opin HIV AIDS 10:135-143. 
113. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, 
Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR. 2012. 
Chapter 1: Integrated Narrative  
 37 
Highly potent HIV-specific antibody neutralization in vitro translates into 
effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci 
U S A 109:18921-18925. 
114. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, 
Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie 
JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. 2014. 
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than 
those to the CD4 receptor. Sci Transl Med 6:243ra288. 
115. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Jr., Buckley N, 
Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, 
Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, 
Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, 
Fatkenheuer G, Schlesinger SJ, Nussenzweig MC. 2015. Viraemia 
suppressed in HIV-1-infected humans by broadly neutralizing antibody 
3BNC117. Nature 522:487-491. 
116. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, 
Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, Hendel CS, Pegu 
A, Conan-Cibotti M, Sitar S, Bailer RT, Narpala S, McDermott A, Louder M, 
O'Dell S, Mohan S, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli 
E, Mascola JR, Graham BS, Team VRCS. 2015. Safety, pharmacokinetics 
and neutralization of the broadly neutralizing HIV-1 human monoclonal 
antibody VRC01 in healthy adults. Clin Exp Immunol 182:289-301. 
117. Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, Wu X, Mascola JR. 
2015. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 
binding site neutralizing antibodies. J Virol 89:4201-4213. 
118. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist 
M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong 
R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, 
Morris L, Montefiori DC, Korber B, Seaman MS. 2016. Optimal Combinations 
of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade 
C Infection. PLoS Pathog 12:e1005520. 
119. de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien JP, 
van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, 
Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, 
Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, 
Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward 
AB, Sanders RW. 2015. Immunogenicity of Stabilized HIV-1 Envelope Trimers 
with Reduced Exposure of Non-neutralizing Epitopes. Cell 163:1702-1715. 
120. Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, 
Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou 
T, Ahlsen G, Bailer RT, Chambers M, Chuang GY, Doria-Rose NA, Druz A, 
Hallen MA, Harned A, Kirys T, Louder MK, O'Dell S, Ofek G, Osawa K, 
Prabhakaran M, Sastry M, Stewart-Jones GB, Stuckey J, Thomas PV, 
Tittley T, Williams C, Zhang B, Zhao H, Zhou Z, Donald BR, Lee LK, Zolla-
Pazner S, Baxa U, Schon A, Freire E, Shapiro L, Lee KK, Arthos J, Munro 
JB, Blanchard SC, Mothes W, Binley JM, et al. 2015. Crystal structure, 
conformational fixation and entry-related interactions of mature ligand-free HIV-
1 Env. Nat Struct Mol Biol 22:522-531. 
121. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, 
Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, 
Chapter 1: Integrated Narrative  
 38 
Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, 
Medina-Ramirez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, 
Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, 
Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. 
2015. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like 
envelope trimers. Science 349:aac4223. 
122. Tonegawa S. 1983. Somatic generation of antibody diversity. Nature 302:575-
581. 
123. Harris LJ, Larson SB, Hasel KW, McPherson A. 1997. Refined structure of 
an intact IgG2a monoclonal antibody. Biochemistry 36:1581-1597. 
124. Satow Y, Cohen GH, Padlan EA, Davies DR. 1986. Phosphocholine binding 
immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol 
190:593-604. 
125. Li Z, Woo CJ, Iglesias-Ussel MD, Ronai D, Scharff MD. 2004. The generation 
of antibody diversity through somatic hypermutation and class switch 
recombination. Genes Dev 18:1-11. 
126. MacLennan IC. 1994. Germinal centers. Annu Rev Immunol 12:117-139. 
127. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson 
NO, Honjo T. 1999. Specific expression of activation-induced cytidine 
deaminase (AID), a novel member of the RNA-editing deaminase family in 
germinal center B cells. J Biol Chem 274:18470-18476. 
128. Euler Z, Schuitemaker H. 2012. Cross-reactive broadly neutralizing 
antibodies: timing is everything. Front Immunol 3:215. 
129. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, 
Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self 
SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg 
ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson 
AS, Haynes BF. 2008. Initial B-cell responses to transmitted human 
immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG 
antibodies followed by plasma anti-gp41 antibodies with ineffective control of 
initial viremia. J Virol 82:12449-12463. 
130. Trama AM, Moody MA, Alam SM, Jaeger FH, Lockwood B, Parks R, Lloyd 
KE, Stolarchuk C, Scearce R, Foulger A, Marshall DJ, Whitesides JF, 
Jeffries TL, Jr., Wiehe K, Morris L, Lambson B, Soderberg K, Hwang KK, 
Tomaras GD, Vandergrift N, Jackson KJ, Roskin KM, Boyd SD, Kepler TB, 
Liao HX, Haynes BF. 2014. HIV-1 envelope gp41 antibodies can originate from 
terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell 
Host Microbe 16:215-226. 
131. Liao HX, Chen X, Munshaw S, Zhang R, Marshall DJ, Vandergrift N, 
Whitesides JF, Lu X, Yu JS, Hwang KK, Gao F, Markowitz M, Heath SL, 
Bar KJ, Goepfert PA, Montefiori DC, Shaw GC, Alam SM, Margolis DM, 
Denny TN, Boyd SD, Marshal E, Egholm M, Simen BB, Hanczaruk B, Fire 
AZ, Voss G, Kelsoe G, Tomaras GD, Moody MA, Kepler TB, Haynes BF. 
2011. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are 
polyreactive and highly mutated. J Exp Med 208:2237-2249. 
132. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey 
RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis 
VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, 
Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env 
pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439-1452. 
Chapter 1: Integrated Narrative  
 39 
133. Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, 
Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori 
M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, 
Kamanga G, Cohen MS, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, 
Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, 
Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF. 2015. Strain-
Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies 
Select Neutralization-Resistant Viruses. Cell Host Microbe 18:354-362. 
134. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, 
Williamson C, Morris L. 2008. The C3-V4 region is a major target of 
autologous neutralizing antibodies in human immunodeficiency virus type 1 
subtype C infection. J Virol 82:1860-1869. 
135. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, 
Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L. 2009. 
Limited neutralizing antibody specificities drive neutralization escape in early 
HIV-1 subtype C infection. PLoS Pathog 5:e1000598. 
136. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA. 
2007. Role of V1V2 and Other Human Immunodeficiency Virus Type 1 
Envelope Domains in Resistance to Autologous Neutralization during Clade C 
Infection. J Virol 81:1350-1359. 
137. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos 
JN, Mokili JL, Muldoon M, Mulenga J, Allen S, Hahn BH, Shaw GM, 
Blackwell JL, Korber BT, Hunter E, Derdeyn CA. 2007. Unique Mutational 
Patterns in the Envelope {alpha}2 Amphipathic Helix and Acquisition of Length 
in gp120 Hypervariable Domains Are Associated with Resistance to Autologous 
Neutralization of Subtype C Human Immunodeficiency Virus Type 1. J Virol 
81:5658-5668. 
138. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. 2011. 
Characteristics of the earliest cross-neutralizing antibody response to HIV-1. 
PLoS Pathog 7:e1001251. 
139. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, 
Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L. 
2011. The neutralization breadth of HIV-1 develops incrementally over four 
years and is associated with CD4+ T cell decline and high viral load during 
acute infection. J Virol 85:4828-4840. 
140. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, 
Schuitemaker H. 2010. Cross-reactive neutralizing humoral immunity does not 
protect from HIV type 1 disease progression. J Infect Dis 201:1045-1053. 
141. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, 
Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, 
Mascola JR, Connors M. 2009. Frequency and phenotype of human 
immunodeficiency virus envelope-specific B cells from patients with broadly 
cross-neutralizing antibodies. J Virol 83:188-199. 
142. Sather DN, Stamatatos L. 2010. Epitope specificities of broadly neutralizing 
plasmas from HIV-1 infected subjects. Vaccine 28 Suppl 2:B8-12. 
143. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. 
2014. Prevalence of broadly neutralizing antibody responses during chronic 
HIV-1 infection. AIDS 28:163-169. 
144. Burton DR, Barbas CF, 3rd, Persson MA, Koenig S, Chanock RM, Lerner 
RA. 1991. A large array of human monoclonal antibodies to type 1 human 
Chapter 1: Integrated Narrative  
 40 
immunodeficiency virus from combinatorial libraries of asymptomatic 
seropositive individuals. Proc Natl Acad Sci U S A 88:10134-10137. 
145. Barbas CF, 3rd, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, 
Zebedee SL, Persson MA, Nara PL, Norrby E, et al. 1992. Recombinant 
human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. 
Proc Natl Acad Sci U S A 89:9339-9343. 
146. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, 
Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal 
antibody 2G12 defines a distinctive neutralization epitope on the gp120 
glycoprotein of human immunodeficiency virus type 1. J Virol 70:1100-1108. 
147. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, 
Katinger H. 1993. A conserved neutralizing epitope on gp41 of human 
immunodeficiency virus type 1. J Virol 67:6642-6647. 
148. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, 
Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. 
2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 
antibodies. Science 308:1906-1908. 
149. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin 
T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey 
SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, 
Burton DR. 2009. Broad and potent neutralizing antibodies from an African 
donor reveal a new HIV-1 vaccine target. Science 326:285-289. 
150. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, 
Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori 
DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, 
Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, 
Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia 
J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, 
Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. 2013. Vaccine Induction of 
Antibodies against a Structurally Heterogeneous Site of Immune Pressure 
within HIV-1 Envelope Protein Variable Regions 1 and 2. Immunity 38:176-186. 
151. Pan R, Gorny MK, Zolla-Pazner S, Kong XP. 2015. The V1V2 Region of HIV-
1 gp120 Forms a Five-Stranded Beta Barrel. J Virol 89:8003-8010. 
152. Gorman J, Soto C, Yang MM, Davenport TM, Guttman M, Bailer RT, 
Chambers M, Chuang GY, DeKosky BJ, Doria-Rose NA, Druz A, Ernandes 
MJ, Georgiev IS, Jarosinski MC, Joyce MG, Lemmin TM, Leung S, Louder 
MK, McDaniel JR, Narpala S, Pancera M, Stuckey J, Wu X, Yang Y, Zhang 
B, Zhou T, Program NC, Mullikin JC, Baxa U, Georgiou G, McDermott AB, 
Bonsignori M, Haynes BF, Moore PL, Morris L, Lee KK, Shapiro L, Mascola 
JR, Kwong PD. 2016. Structures of HIV-1 Env V1V2 with broadly neutralizing 
antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol 
23:81-90. 
153. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, 
Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang 
B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, 
Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, 
Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, 
Haynes BF. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 
conformational epitope-specific broadly neutralizing antibodies and their 
inferred unmutated common ancestors. J Virol 85:9998-10009. 
Chapter 1: Integrated Narrative  
 41 
154. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang 
SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen 
OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, 
Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of 
HIV by multiple highly potent antibodies. Nature 477:466-470. 
155. Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, 
Briney B, Lee JH, Le KM, Lee PS, Hua Y, Seaman MS, Moore JP, Ward AB, 
Wilson IA, Sanders RW, Burton DR. 2014. Recombinant HIV envelope trimer 
selects for quaternary-dependent antibodies targeting the trimer apex. Proc 
Natl Acad Sci U S A 111:17624-17629. 
156. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky 
BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran 
HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, 
Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell 
RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, 
Program NCS, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, 
Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong 
PD, Shapiro L, Mascola JR. 2014. Developmental pathway for potent V1V2-
directed HIV-neutralizing antibodies. Nature 509:55-62. 
157. Briney BS, Willis JR, Crowe JE, Jr. 2012. Human peripheral blood antibodies 
with long HCDR3s are established primarily at original recombination using a 
limited subset of germline genes. PLoS One 7:e36750. 
158. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang 
GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, 
Druz A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell 
S, Pegu A, Schmidt SD, Staupe RP, Sutton MS, Wang K, Wibmer CK, 
Haynes BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, 
Mascola JR. 2015. New Member of the V1V2-Directed CAP256-VRC26 
Lineage That Shows Increased Breadth and Exceptional Potency. J Virol 
90:76-91. 
159. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, 
Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, 
Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, 
Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson 
WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent 
and broad neutralizing antibody recognizes and penetrates the HIV glycan 
shield. Science 334:1097-1103. 
160. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, 
Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua 
Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, 
Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. 2013. 
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope 
glycoprotein gp120. Nat Struct Mol Biol 20:796-803. 
161. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, 
Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek 
RA, Katinger H, Burton DR, Wilson IA. 2003. Antibody domain exchange is 
an immunological solution to carbohydrate cluster recognition. Science 
300:2065-2071. 
162. Garces F, Sok D, Kong L, McBride R, Kim HJ, Saye-Francisco KF, Julien 
JP, Hua Y, Cupo A, Moore JP, Paulson JC, Ward AB, Burton DR, Wilson 
Chapter 1: Integrated Narrative  
 42 
IA. 2014. Structural evolution of glycan recognition by a family of potent HIV 
antibodies. Cell 159:69-79. 
163. Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, 
Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, 
Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, 
Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, 
Poignard P. 2013. The effects of somatic hypermutation on neutralization and 
binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS 
Pathog 9:e1003754. 
164. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, 
Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, 
Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, 
Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural 
convergence of broad and potent HIV antibodies that mimic CD4 binding. 
Science 333:1633-1637. 
165. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, 
Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang 
Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam 
NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors 
M, Program NCS, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong 
PD, Mascola JR. 2011. Focused evolution of HIV-1 neutralizing antibodies 
revealed by structures and deep sequencing. Science 333:1593-1602. 
166. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Do Kwon Y, Scheid JF, 
Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel 
GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent 
neutralization of HIV-1 by antibody VRC01. Science 329:811-817. 
167. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera 
M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, 
Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. 2009. 
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 
gp120. Science 326:1123-1127. 
168. Wu X, Zhang Z, Schramm CA, Joyce MG, Kwon YD, Zhou T, Sheng Z, 
Zhang B, O'Dell S, McKee K, Georgiev IS, Chuang GY, Longo NS, Lynch 
RM, Saunders KO, Soto C, Srivatsan S, Yang Y, Bailer RT, Louder MK, 
Program NCS, Mullikin JC, Connors M, Kwong PD, Mascola JR, Shapiro 
L. 2015. Maturation and Diversity of the VRC01-Antibody Lineage over 15 
Years of Chronic HIV-1 Infection. Cell 161:470-485. 
169. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-
Tran HR, Chuang GY, Joyce MG, Do Kwon Y, Longo NS, Louder MK, 
Luongo T, McKee K, Schramm CA, Skinner J, Yang Y, Yang Z, Zhang Z, 
Zheng A, Bonsignori M, Haynes BF, Scheid JF, Nussenzweig MC, Simek 
M, Burton DR, Koff WC, Program NCS, Mullikin JC, Connors M, Shapiro L, 
Nabel GJ, Mascola JR, Kwong PD. 2013. Multidonor analysis reveals 
structural elements, genetic determinants, and maturation pathway for HIV-1 
neutralization by VRC01-class antibodies. Immunity 39:245-258. 
170. West AP, Jr., Diskin R, Nussenzweig MC, Bjorkman PJ. 2012. Structural 
basis for germ-line gene usage of a potent class of antibodies targeting the 
CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A 109:E2083-2090. 
171. Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, 
Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder 
Chapter 1: Integrated Narrative  
 43 
MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, 
Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, 
Georgiev IS, Gindin T, Peng HP, Yang AS, Program NCS, Mullikin JC, Gray 
MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza 
JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West 
AP, Jr., Bjorkman PJ, Scheid JF, Nussenzweig MC, et al. 2015. Structural 
Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 
Donors. Cell 161:1280-1292. 
172. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson 
C, Morris L, Moore PL. 2013. Viral escape from HIV-1 neutralizing antibodies 
drives increased plasma neutralization breadth through sequential recognition 
of multiple epitopes and immunotypes. PLoS Pathog 9:e1003738. 
173. Balla-Jhagjhoorsingh SS, Corti D, Heyndrickx L, Willems E, Vereecken K, 
Davis D, Vanham G. 2013. The N276 glycosylation site is required for HIV-1 
neutralization by the CD4 binding site specific HJ16 monoclonal antibody. PLoS 
One 8:e68863. 
174. Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, 
Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, 
Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC. 2015. A 
New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts 
Pressure on HIV-1 In Vivo. PLoS Pathog 11:e1005238. 
175. Scharf L, Scheid JF, Lee JH, West AP, Jr., Chen C, Gao H, Gnanapragasam 
PN, Mares R, Seaman MS, Ward AB, Nussenzweig MC, Bjorkman PJ. 2014. 
Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope 
spike. Cell Rep 7:785-795. 
176. Scharf L, Wang H, Gao H, Chen S, McDowall AW, Bjorkman PJ. 2015. 
Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States 
of HIV-1 Env. Cell 162:1379-1390. 
177. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, 
Derking R, van Gils MJ, Liang CH, McBride R, von Bredow B, Shivatare 
SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, 
Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson 
IA, Sanders RW, Poignard P, Burton DR. 2014. Broadly Neutralizing HIV 
Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation 
of gp41 on Cleaved Envelope Trimers. Immunity 
doi:10.1016/j.immuni.2014.04.009. 
178. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, 
Cupo A, Julien JP, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, 
Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. 2014. Structural 
Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 
Interface on Intact HIV-1 Env Trimers. Immunity 
doi:10.1016/j.immuni.2014.04.008. 
179. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, 
Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van 
Gils MJ, de la Pena AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, 
Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward 
AB, Mascola JR, Kwong PD, Connors M. 2014. Broad and potent HIV-1 
neutralization by a human antibody that binds the gp41-gp120 interface. Nature 
515:138-142. 
180. Lee JH, Leaman DP, Kim AS, Torrents de la Pena A, Sliepen K, Yasmeen 
Chapter 1: Integrated Narrative  
 44 
A, Derking R, Ramos A, de Taeye SW, Ozorowski G, Klein F, Burton DR, 
Nussenzweig MC, Poignard P, Moore JP, Klasse PJ, Sanders RW, Zwick 
MB, Wilson IA, Ward AB. 2015. Antibodies to a conformational epitope on 
gp41 neutralize HIV-1 by destabilizing the Env spike. Nat Commun 6:8167. 
181. Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, Seaman MS, Chen B. 
2014. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-
proximal region of gp41. J Virol 88:1249-1258. 
182. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, Wyatt R, Zwick 
MB, Nabel GJ, Mascola JR, Kwong PD. 2010. Relationship between antibody 
2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third 
complementarity-determining region. J Virol 84:2955-2962. 
183. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, Dawson PE, 
Burton DR, Zwick MB, Wilson IA. 2009. A conformational switch in HIV gp41 
revealed by the structures of overlapping epitopes recognized by neutralizing 
antibodies. J Virol. 
184. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD. 
2004. Structure and mechanistic analysis of the anti-human immunodeficiency 
virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78:10724-
10737. 
185. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, 
Burton DR, Wilson IA. 2005. Broadly neutralizing anti-HIV antibody 4E10 
recognizes a helical conformation of a highly conserved fusion-associated motif 
in gp41. Immunity 22:163-173. 
186. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi 
H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang 
B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 
2012. Broad and potent neutralization of HIV-1 by a gp41-specific human 
antibody. Nature 491:406-412. 
187. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev 
IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD. 2014. 
Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. 
J Virol 88:2426-2441. 
188. Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, Song L, Qiao Z, Wang JH, Wagner 
G, Reinherz EL. 2008. HIV-1 broadly neutralizing antibody extracts its epitope 
from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-
63. 
189. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren 
A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, 
Haynes BF, Mascola JR, Morris L. 2009. Antibody specificities associated 
with neutralization breadth in plasma from human immunodeficiency virus type 
1 subtype C-infected blood donors. J Virol 83:8925-8937. 
190. Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, 
Shaw GM, Mascola JR, Morris L. 2009. Broad neutralization of human 
immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 
membrane proximal external region. J Virol 83:11265-11274. 
191. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu 
X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R. 2009. 
Analysis of neutralization specificities in polyclonal sera derived from human 
immunodeficiency virus type 1-infected individuals. J Virol 83:1045-1059. 
192. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu 
Chapter 1: Integrated Narrative  
 45 
X, Wood B, Self S, Kalams S, Stamatatos L. 2009. Factors associated with 
the development of cross-reactive neutralizing antibodies during human 
immunodeficiency virus type 1 infection. J Virol 83:757-769. 
193. Pritchard LK, Spencer DI, Royle L, Bonomelli C, Seabright GE, Behrens 
AJ, Kulp DW, Menis S, Krumm SA, Dunlop DC, Crispin DJ, Bowden TA, 
Scanlan CN, Ward AB, Schief WR, Doores KJ, Crispin M. 2015. Glycan 
clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to 
broadly neutralizing antibodies. Nat Commun 6:7479. 
194. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw 
GM, Connors M, Wyatt RT, Mascola JR. 2007. Broad HIV-1 neutralization 
mediated by CD4-binding site antibodies. Nat Med 13:1032-1034. 
195. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat 
SK, Poignard P, Burton DR. 2010. A limited number of antibody specificities 
mediate broad and potent serum neutralization in selected HIV-1 infected 
individuals. PLoS Pathog 6:e1001028. 
196. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba 
N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, 
Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw 
GM, Mascola JR, Haynes BF, Montefiori DC, Morris L. 2011. Polyclonal B 
cell responses to conserved neutralization epitopes in a subset of HIV-1-
infected individuals. J Virol 85:11502-11519. 
197. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, 
Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, 
Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, 
Swanstrom RI, Seaman MS, Williamson C, Morris L. 2012. Evolution of an 
HIV glycan-dependent broadly neutralizing antibody epitope through immune 
escape. Nat Med 18:1688-1692. 
198. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen 
WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool 
Karim SS, Williamson C, Pinter A, Morris L, Study C. 2011. Potent and 
broad neutralization of HIV-1 subtype C by plasma antibodies targeting a 
quaternary epitope including residues in the V2 loop. J Virol 85:3128-3141. 
199. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, 
Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff 
DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, 
Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies 
broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-
861. 
200. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, Chen B, 
Parks R, Foulger A, Jaeger F, Donathan M, Bilska M, Gray ES, Abdool 
Karim SS, Kepler TB, Whitesides J, Montefiori D, Moody MA, Liao HX, 
Haynes BF. 2011. Isolation of a human anti-HIV gp41 membrane proximal 
region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 
6:e23532. 
201. Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, Moore PL, 
Foulger A, Yu JS, Lambson B, Abdool Karim S, Whitesides J, Tomaras 
GD, Haynes BF, Morris L, Liao HX. 2011. Isolation of a monoclonal antibody 
that targets the alpha-2 helix of gp120 and represents the initial autologous 
neutralizing-antibody response in an HIV-1 subtype C-infected individual. J 
Virol 85:7719-7729. 
Chapter 1: Integrated Narrative  
 46 
202. Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, Cai F, Hwang KK, 
Song H, Zhou T, Lynch RM, Alam SM, Moody MA, Ferrari G, Berrong M, 
Kelsoe G, Shaw GM, Hahn BH, Montefiori DC, Kamanga G, Cohen MS, 
Hraber P, Kwong PD, Korber BT, Mascola JR, Kepler TB, Haynes BF. 2014. 
Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing 
antibodies. Cell 158:481-491. 
203. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, 
Schramm CA, Zhang Z, Zhu J, Shapiro L, Program NCS, Mullikin JC, 
Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori 
DC, Parks R, Lloyd KE, Scearce RM, Soderberg KA, Cohen M, Kamanga 
G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce 
MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, 
Korber BT, Kwong PD, Mascola JR, Haynes BF. 2013. Co-evolution of a 
broadly neutralizing HIV-1 antibody and founder virus. Nature 496:469-476. 
204. Yang X, Tomov V, Kurteva S, Wang L, Ren X, Gorny MK, Zolla-Pazner S, 
Sodroski J. 2004. Characterization of the outer domain of the gp120 
glycoprotein from human immunodeficiency virus type 1. J Virol 78:12975-
12986. 
205. Chen H, Xu X, Jones IM. 2007. Immunogenicity of the outer domain of a HIV-
1 clade C gp120. Retrovirology 4:33. 
206. Chen H, Xu X, Lin HH, Chen SH, Forsman A, Aasa-Chapman M, Jones IM. 
2008. Mapping the immune response to the outer domain of a human 
immunodeficiency virus-1 clade C gp120. J Gen Virol 89:2597-2604. 
207. Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, 
Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ. 2009. Enhanced 
exposure of the CD4-binding site to neutralizing antibodies by structural design 
of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. 
J Virol 83:5077-5086. 
208. Bhattacharyya S, Rajan RE, Swarupa Y, Rathore U, Verma A, Udaykumar 
R, Varadarajan R. 2010. Design of a non-glycosylated outer domain-derived 
HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. 
J Biol Chem 285:27100-27110. 
209. Qin Y, Banasik M, Kim S, Penn-Nicholson A, Habte HH, LaBranche C, 
Montefiori DC, Wang C, Cho MW. 2014. Eliciting neutralizing antibodies with 
gp120 outer domain constructs based on M-group consensus sequence. 
Virology 462-463:363-376. 
210. Yokoyama M, Naganawa S, Yoshimura K, Matsushita S, Sato H. 2012. 
Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop. PLoS 
One 7:e37530. 
211. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, 
Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. 2013. Engineering 
HIV envelope protein to activate germline B cell receptors of broadly 
neutralizing anti-CD4 binding site antibodies. J Exp Med 
doi:10.1084/jem.20122824. 
212. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, 
Huang PS, Macpherson S, Jones M, Nieusma T, Mathison J, Baker D, 
Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. 
2013. Rational HIV Immunogen Design to Target Specific Germline B Cell 
Receptors. Science doi:10.1126/science.1234150. 
213. Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin 
Chapter 1: Integrated Narrative  
 47 
AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo 
A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Bjorkman PJ, 
Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC. 2015. 
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin 
Mice. Cell 161:1505-1515. 
214. Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, Skog PD, 
Thinnes TC, Bhullar D, Briney B, Menis S, Jones M, Kubitz M, Spencer S, 
Adachi Y, Burton DR, Schief WR, Nemazee D. 2015. HIV-1 VACCINES. 
Priming a broadly neutralizing antibody response to HIV-1 using a germline-
targeting immunogen. Science 349:156-161. 
215. Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose 
N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR. 2012. Selection 
pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved 
CD4-binding site. J Virol 86:5844-5856. 
216. Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, 
Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, Abdool Karim SS, 
Shapiro L, Williamson C, Kwong PD, Mascola JR, Morris L, Moore PL. 
2015. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 
broadly neutralizing antibodies. Nat Med 21:1332-1336. 
217. Moore PL, Williamson C, Morris L. 2015. Virological features associated with 
the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol 
23:204-211. 
218. Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, 
Huang X, Kulp D, Osawa K, Muranaka J, Stewart-Jones G, Destefano J, 
O'Dell S, LaBranche C, Robinson JE, Montefiori DC, McKee K, Du SX, 
Doria-Rose N, Kwong PD, Mascola JR, Zhu P, Schief WR, Wyatt RT, 
Whalen RG, Binley JM. 2015. Vaccine-Elicited Tier 2 HIV-1 Neutralizing 
Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches 
Proximal to the CD4 Binding Site. PLoS Pathog 11:e1004932. 
219. Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, 
Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong 
PD, Mascola JR. 2011. Immunotypes of a quaternary site of HIV-1 vulnerability 
and their recognition by antibodies. J Virol 85:4578-4585. 
220. Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, 
Cohen S, Staudinger R, Zolla-Pazner S. 2005. Identification of a new 
quaternary neutralizing epitope on human immunodeficiency virus type 1 virus 
particles. J Virol 79:5232-5237. 
221. Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K, Zhang R, 
Sutherland LL, Scearce RM, Bowman CM, Stolarchuk C, Lloyd KE, Parks 
R, Eaton A, Foulger A, Nie X, Karim SS, Barnett S, Kelsoe G, Kepler TB, 
Alam SM, Montefiori DC, Moody MA, Liao HX, Morris L, Santra S, Harrison 
SC, Haynes BF. 2016. Structural Constraints of Vaccine-Induced Tier-2 
Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. 
Cell Rep 14:43-54. 
222. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, 
Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran 
S, Hunter E, Kong XP, Derdeyn CA. 2013. Viral Escape from Neutralizing 
Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous 
Neutralization Breadth. PLoS Pathog 9:e1003173. 
223. Bonsignori M, Zhou T, Sheng Z, Chen L, Gao F, Joyce MG, Ozorowski G, 
Chapter 1: Integrated Narrative  
 48 
Chuang GY, Schramm CA, Wiehe K, Alam SM, Bradley T, Gladden MA, 
Hwang KK, Iyengar S, Kumar A, Lu X, Luo K, Mangiapani MC, Parks RJ, 
Song H, Acharya P, Bailer RT, Cao A, Druz A, Georgiev IS, Kwon YD, 
Louder MK, Zhang B, Zheng A, Hill BJ, Kong R, Soto C, Program NCS, 
Mullikin JC, Douek DC, Montefiori DC, Moody MA, Shaw GM, Hahn BH, 
Kelsoe G, Hraber PT, Korber BT, Boyd SD, Fire AZ, Kepler TB, Shapiro L, 
Ward AB, Mascola JR, Liao HX, et al. 2016. Maturation Pathway from 
Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell 
doi:10.1016/j.cell.2016.02.022. 
 
Chapter 2: HIV Broadly Neutralizing Antibody Targets  Wibmer et al., 2015 
Antibodies for prevention and therapy   
March 2015 | Volume 10 | Issue 3 | p 135-143 49 
CHAPTER TWO: HIV BROADLY NEUTRALIZING ANTIBODY TARGETS 
A review published in Current Opinion in HIV and AIDS:  
May 2015 - Volume 10 - Issue 3 - p 135-143.  
Wolters Kluwer Health Lippincott Williams & Wilkins© 
  
Chapter 2: HIV Broadly Neutralizing Antibody Targets  Wibmer et al., 2015 
Antibodies for prevention and therapy   
March 2015 | Volume 10 | Issue 3 | p 135-143 50 
REVIEW 
HIV broadly neutralizing antibody targets 
Constantinos Kurt Wibmera,b, Penny L. Moorea,b,c, and Lynn Morrisa,b,c 
 
Purpose of review 
To provide an update on neutralizing antibody targets in the context of the recent 
HIV-1 envelope trimer structure, describe new antibody isolation technologies, and 
discuss the implications of these data for HIV-1 prevention and therapy.  
Recent findings 
Recent advances in B-cell technologies have dramatically expanded the number of 
antibodies isolated from HIV-infected donors with broadly neutralizing plasma 
activity. These, together with the first high-resolution crystal and cryo-electron 
microscopy (cryo-EM) structures of a cleaved, prefusion HIV-1 trimer, have defined 
new regions susceptible to neutralization. This year, three epitopes in the gp120–
gp41 interface were structurally characterized, highlighting the importance of 
prefusion gp41 as a target. Similar to many other broadly neutralizing antibody 
epitopes, these new antibodies define a target that is also highly glycan dependent. 
Collectively, the epitopes for broadly neutralizing antibodies now reveal a continuum 
of vulnerability spanning the length of the HIV-1 envelope trimer. 
Summary 
Progress in the last year has provided support for the use of rationally stabilized 
whole HIV-1 trimers as immunogens for eliciting antibodies to multiple epitopes. 
Furthermore, the increasing number of broad and potent antibodies with the potential 
for synergistic/complementary combinations opens up new avenues for preventing 
and treating HIV-1 infection. 
Keywords 
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INTRODUCTION 
The HIV-1 envelope (Env) glycoprotein 
spike mediates viral entry, and is the sole 
target of neutralizing antibodies. The 
entry-mediating form exists as a trimer 
composed of three host receptor binding 
gp120 molecules, noncovalently linked to 
three gp41 transmembrane fusion 
proteins. gp120 is heavily glycosylated 
and shielded by the hypervariable regions 
(loops V1–V5, the a2 helix, and b14 
sheet), whereas gp41 is more conserved, 
less solvent exposed, and less 
glycosylated. As a result of host immune 
pressures Env is the most diverse of all 
HIV proteins with up to 30% variation 
between different genetic subtypes. 
Amino acid substitution, insertions 
/deletions, and glycan shifting occur 
predominantly in the variable regions that 
are most easily accessed by neutralizing 
antibodies. The dominant neutralizing 
antibody response is therefore strain 
specific, however over the course of HIV-
1 infection most individuals develop 
antibodies with some level of cross-
reactivity [1]. Those with the greatest 
breadth have been the source of new 
broadly neutralizing antibodies (bNAbs) 
[2]. Characterizing the epitopes of these 
bNAbs has led to high resolution 
structures of the HIV-1 Env trimer 
[3,4,5&&], allowing us to more clearly 
define sites of vulnerability that might be 
exploited for HIV-1 vaccine design and 
antibody mediated therapy. 
TECHNOLOGIES FOR THE 
ISOLATION OF NEW BROADLY 
NEUTRALIZING ANTIBODIES 
The first bNAbs to HIV-1 (b12, 2G12, 2F5, 
and 4E10) were isolated by phage display 
or B-cell immortalization, selected for 
binding to Env peptides or monomeric 
proteins, and generally limited in breadth 
and/or potency. The ability to culture 
 
 Technological advances have 
significantly improved our ability to map 
plasma bNAb specificities and isolate relevant 
mAbs. 
 The gp120–gp41 interface is revealed 
as a new bNAb target. 
 At least five broadly defined bNAb 
targets exist that form a continuum of 
vulnerability spanning the length of the HIV-1 
Env trimer. 
 New mAb combinations show 
unprecedented levels of cross-clade coverage 
and potency providing opportunities for 
preventive and therapeutic applications of 
bNAbs. 
 Structure and immunogenicity studies 
of bNAb epitopes on the HIV-1 Env trimer may 
foster the design of better vaccines able to 
elicit bNAbs. 
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memory B cells, together with high-
throughput neutralization assays that 
allowed for direct functional screening, 
led to the isolation of several new 
antibodies targeting novel quaternary 
structure specific epitopes, as well as 
more potent antibodies to previously 
identified sites [6–8,9&&,10&&]. New 
bNAbs to previously known targets (but 
possessing greater breadth and potency) 
have also been identified using structure-
guided methods to design sorting 
antigens for labelling B cells by flow 
cytometry [11,12]. Unlike B-cell culture 
this technique does not rely on potent 
neutralization to identify bNAbs, but it is 
limited by the specific mode of 
recognition. More recently, quaternary 
structure specific bNAbs have been 
isolated using native, cleaved, prefusion 
trimers as sorting antigens, which appear 
to preferentially bind neutralizing 
antibodies [13&&]. The successful 
isolation of bNAbs has been aided by first 
mapping the neutralization specificities in 
donor plasma, to tailor an appropriate 
selection technique [14,15]. In addition 
bioinformatics approaches have been 
used to predict specificities and design 
targeted approaches for the isolation of 
bNAbs [16–18]. Once a B-cell lineage has 
been identified the use of next-generation 
sequencing to mine the repertoire allows 
for literally hundreds of related variants to 
be identified [19–22]. A major obstacle of 
next-generation sequencing however is 
the inability to identify naturally occurring 
heavy-chain and light-chain antibody 
pairs. This was overcome when Georgiou 
et al. devised a method of pairing heavy-
chain and light-chain PCR products prior 
to sequencing [23]. Information on the 
targets for bNAbs, as well as 
neutralization, sequence, and structural 
data on the monoclonal antibodies 
(mAbs) that have been isolated is being 
extensively catalogued into two new 
publically available databases: CATNAP 
on the LANL website: 
(http://www.hiv.lanl.gov/components/seq
uence/HIV/neutralization/main.comp) 
and bNAber [24], providing useful 
resources for the field. 
 
BROADLY NEUTRALIZING 
ANTIBODY TARGETS 
The isolation of exceptionally broad and 
potent bNAbs has enabled the 
identification of five roughly defined 
targets on the HIV-1 Env, such as the V2 
site, the N332 supersite, the CD4 binding 
site (CD4bs), the gp120–gp41 interface, 
and the membrane proximal external 
region (MPER). Identifying multiple 
bNAbs with similar epitopes has 
pinpointed minimal sites of vulnerability, 
whose recognition confers the greatest 
neutralization breadth. However as 
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discussed below, new bNAbs with novel 
epitopes have revised our understanding 
of how these distinct sites partially merge 
in the context of the trimer. 
THE V2 SITE 
The V2 site at the trimer apex is formed 
from the converging, sequence 
conserved regions of the V1V2 domain 
and the V3 loop [3,4,25]. It is protected by 
densely packed glycans (particularly 
those at positions N156 and N160) and 
the hypervariable loops V1 and V2 [26]. 
Access to the underlying peptide epitope 
is only possible by antibodies with 
unusually long (between 26 and 39 amino 
acids), anionic heavy chain 
complementarity determining region loop 
three (CDR-H3) [7,14,26]. Anti-V2 bNAbs 
generally bind poorly to monomeric 
gp120 or scaffolded V1V2s [7,14]. In the 
case of the prototypical V2 antibody PG9, 
this quaternary specificity was partially 
explained by the fact that the antibody 
binds to N160 glycans from two separate 
protomers [27,28]. However, for some 
relatives of the CAP256-VRC26 lineage 
which targets a similar epitope, broad 
neutralization was not dependent on the 
N160 glycan [14]. Despite these 
differences, the actual peptide epitope 
determined by mutagenesis is minimal for 
both the PG9 and CAP256-VRC26 
antibodies, made up of a short mostly 
cationic stretch of seven amino acids 
(position 165–171). For PG9 the 
underlying peptide comprises less than 
25% of the epitope, with the rest of the 
epitope predominantly formed by the 
glycans at N156 and N160 [7,14,26,29]. 
The conserved nature of these glycans, 
and the small peptide footprint, likely 
contributes to the breadth of this class of 
antibodies. 
THE N332 SUPERSITE 
The N332 supersite is composed of a 
number of overlapping glycan-dependent 
epitopes [30]. V3 epitopes lie structurally 
proximal to the V2 site [4], and are the 
most well described within the N332 
supersite. Antibodies targeting V3 show a 
similar mechanism to V2 site recognition, 
in that they access a minimal eight 
residue peptide epitope between 
positions 323 and 330 via long (20–26 
amino acids) CDR-H3s [31]. Two such 
antibodies, PGT121 and PGT128, are 
highly dependent on the glycans at 
positions N301 and N332 [6], but somatic 
variants of PGT121 also depend on 
glycans in V1 (N137) and V2 (N156) [4]. 
In this way PGT121-like antibodies can 
recognize a different side of the N156 
glycan that is critical to most anti-V2 
bNAbs (Fig. 1). PGT130 was isolated 
from the same donor as PGT128, but 
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FIGURE 1. The V2 site overlaps with the N332 supersite. The HIV-1 envelope (Env) trimer is 
shown in light (gp120) and dark (gp41) grey surface view. An expanded graphic of the V2 and 
N332 sites is shown in the zoomed in box. Epitopes in V2 (red), V3 (orange), or V4 (yellow) are 
defined as residues within 5 Å of broadly neutralizing antibodies (bNAbs) PG9, PGT122/PGT128, 
or PGT135, respectively. Regions of overlap between epitopes are shown with mottled colours 
red/orange for V2-V3, and orange/yellow for V3–V4. Key glycans are shown as spheres, labelled, 
and coloured according to their epitopes. Glycans predicted to be a part of the 2G12 epitope are 
coloured dark grey, and bordered with a dotted line. Glycans N156, N332, and N392 that are bound 
by bNAbs targeting different epitopes are asterisked. Proximal hypervariable regions V1 and α2 
are shown in light grey. Figure based on protein databank accession code 4TVP. 
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represents an alternate branch of the B-
cell lineage that preferentially recognizes 
a glycan at N334 [6,32]. The N334 and 
N332 glycans are mutually exclusive, and 
thus in both donors somatic variants have 
evolved to recognize different 
immunotypes of the V3 site, indicative of 
the role for viral diversification in driving 
bNAb maturation, that ultimately 
accounts for total plasma neutralization 
breadth [32,33]. bNAb PGT135 defines a 
second epitope in the N332 supersite that 
does not involve V3, but rather contacts 
amino acids at the base of the V4 loop 
[30]. This mAb binds predominantly to the 
apolar face of the N332 glycan (unlike 
PGT128), and recognizes additional 
glycans at positions N295, N386, and 
N392 [30]. A third epitope, defined by the 
bNAb 2G12 overlaps the PGT135 epitope 
but unusually does not involve any 
peptide contact (Fig. 1). Rather, 2G12 
uses a rare variable heavy (VH) chain 
domain swap to create a large paratope 
capable of binding to the terminal sugars 
of four glycans on the silent face of gp120 
(N295, N332, N339, and N392) [34]. 
Thus, while 2G12 does not actually 
penetrate the glycan shield, it does share 
the recognition of key glycans with 
PGT135. The isolation of additional 
bNAbs with specificities similar to 
PGT135 or 2G12 will help to better define 
the vulnerabilities within this supersite.  
 
THE CD4 BINDING SITE 
In contrast to bNAbs targeting V2 or 
N332, antibodies targeting the CD4bs 
generally make minimal glycan contacts. 
Only one mode of recognition at the 
CD4bs has been extensively described, 
that of VH1-2 or VH1-46 derived bNAbs, 
typified by VRC01 and 8ANC131. The 
germline precursors of these bNAbs have 
specific genetic signatures that mimic 
CD4 binding, such as R71 in the heavy 
chain that, like R59 of CD4, interacts with 
D368 in the highly conserved CD4 
binding loop of gp120 [12,35]. VH12 
bNAbs also have unusually short CDR-L3 
loops to avoid clashes with the glycan at 
position N276 in the D loop of gp120 [36–
38]. Conversely the bNAb HJ16 derived 
from the VH3-30 gene does not interact 
with D368, and is entirely dependent on 
the glycan at position N276 for 
neutralization, defining a second subsite 
within the CD4bs [39,40]. This glycan is 
sometimes bound by VRC01-like 
antibodies, but is not critical to their 
neutralization [41]. HJ16 and other non-
VH1-2/1-46 derived CD4bs bNAbs have 
long CDR-H3 loops important for their 
binding, but are still limited in their angle 
of approach to gp120 by extensive 
glycosylation and the quaternary nature 
of the trimer [15,42]. Cryoelectron 
microscopy (cryo-EM) structures have 
Chapter 2: HIV Broadly Neutralizing Antibody Targets  Wibmer et al., 2015 
Antibodies for prevention and therapy   
March 2015 | Volume 10 | Issue 3 | p 135-143 56 
shown that some CD4bs bNAbs such as 
PGV04 may actually interact with the 
glycans that closely border the CD4bs 
(N276, N363, and N386) as well as the 
N301 glycan from the V3 loop of an 
adjacent protomer [3]. These data also 
suggest contact between the positively 
charged amino acids in V3, and an 
anionic insertion in the PGV04 heavy-
chain framework region 3 (FWR3). The 
contribution of these additional contacts 
to neutralization is unclear considering 
many CD4bs bNAbs induce a 
conformation of gp120 that would 
rearrange the V1V2 and V3 loops. 
Nonetheless the complexity of the CD4bs 
has previously been underestimated. 
 
 
FIGURE 2. The CD4bs adjoins the gp120–gp41 interface. The HIV-1 envelope trimer is shown 
in light (gp120) and dark (gp41) grey surface view. An expanded graphic of the CD4bs and gp120–
gp41 interface sites are shown in the zoomed out box. Epitopes for VRC01 (green), 8ANC195 
(purple), 35O22 (brown), or PGT151 (blue) are defined as residues within 5 Å of each respective 
broadly neutralizing antibody (bNAb). Key glycans are shown as spheres, labelled, and coloured 
according to the epitopes they comprise. Regions that make up more than one epitope are shown 
with mottled colours, and glycans that are bound by bNAbs targeting different epitopes are 
asterisked. The hypervariable region V5 is shown in light grey.  
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THE gp120–gp41 INTERFACE 
The N276 glycan described above is also 
the target for bNAb 8ANC195 (Fig. 2), 
recently shown to bind an epitope in the 
gp120–gp41 interface [43&&]. This mAb is 
dependent on glycans at positions N234 
and N276, and uses a four amino acid 
insertion to thrust the Fab heavy-chain 
FWR3 between these two glycans, 
contacting R456 at the distal most tip 
[43&&]. The 8ANC195 CDR-H3 is 22 amino 
acids long, but is not used to penetrate 
the glycan shield. Rather the CDR-H3 
folds back towards the light chain forming 
part of a wider paratope that makes 
significant contact with the 7-stranded b-
sandwich (the gp41 interacting region) of 
gp120 [43&&]. The affinity for gp120 is 
sufficient that 8ANC195 was isolated 
using a stabilized gp120 core, but docking 
of the Fab–gp120 complex into the 
prefusion trimer revealed potential 
interactions between the 8ANC195 light 
chain and gp41 near the N637 glycan. 
Deep sequencing in the 8ANC195 donor 
showed that the stabilized core 
specifically selected for a single branch of 
the bNAb lineage. More genetically 
diverse antibodies, created by pairing 
related heavy-chain and light-chain 
variants, exhibited increased potencies 
that were attributed almost entirely to light 
chain–gp41interactions [43&&].  
 
 
Thus, 8ANC195 was the first of several 
recently identified bNAbs targeting 
epitopes in the gp120– gp41 interface 
[9&&,10&&,43&&,44]. Two new antibodies 
published in 2014, PGT151 and 35O22, 
were also shown to target the gp120– 
gp41 interface [5&&,9&&,10&&,45&&]. Unlike 
8ANC195, these bNAbs do not bind 
monomeric gp120. bNAb 35O22 (isolated 
from the same donor as MPER bNAb 
10E8) binds immediately adjacent to 
8ANC195 near N234 (Fig. 2), close 
enough to contact the seven stranded b-
sandwich via an eight amino acid FWR3 
insertion [5&&]. This bNAb epitope is 
remarkably low on the trimer, seemingly 
incompatible with the presence of the viral 
membrane, and it is speculated that 
certain rearrangements induced by CD4 
are required for its binding [9&&]. 
Neutralization by 35O22 was 
incompatible with glycosylation of the 
N625 sequon, but still critically dependent 
on the N625 residue [5&&]. bNAb PGT151 
binds between the 8ANC195 and 35O22 
epitopes, over a cavity between gp160 
protomers [45&&]. Unlike 35O22, it has a 
specific requirement for cleaved trimers, 
and a maximum observed stoichiometry 
of two antigen binding fragments (Fabs) 
per trimer, suggesting an allosteric 
alteration of the third binding site after the 
first two Fabs have bound [45&&].  
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This binding mechanism also allows 
PGT151 to stabilize native, cleaved Env 
trimers from cell membranes. Both 35O22 
and PGT151 have highly glycan-
dependent epitopes, with 35O22 
neutralization dependent on the glycans 
at N88, N230, and N241 in gp120, and 
neutralization of PGT151 requiring gp41 
glycans N611 and N637 [9&&,10&&]. Based 
on proximity, PGT151 was also predicted 
to interact with glycans in gp120 (N262, 
N276, N230, N234, N241, and N448) 
though these interactions are not critical 
for neutralization [45&&]. This glycan 
dependence results in varied 
neutralization plateaus for both bNAbs. 
For 35O22, neutralization plateaus were 
improved (higher levels of maximum 
inhibition indicating enhanced potency) 
when pseudoviruses were grown in 
kifunensine, indicating a role for high 
mannose glycans in its epitope [9&&]. In 
contrast, PGT151 could not neutralize 
kifunensine or 293S-grown 
pseudoviruses (glycosylated only with 
mannose rich glycans), and bound 
directly to triantennary and 
tetraantennary complex glycans 
[10&&,45&&]. As virus grown in peripheral 
blood mononuclear cells appears to have 
greater proportions of complex glycan, 
PGT151-like antibodies may exhibit 
better potencies in vivo [10&&]. 
THE MEMBRANE PROXIMAL 
EXTERNAL REGION 
Epitopes in the MPER of gp41 are almost 
exclusively contained within a linear, α-
helical stretch of amino acids that links 
the transmembrane domain to the 
ectodomain of gp41. The MPER can be 
divided into an N-terminal and C-terminal 
helix around a kink at position 674, used 
to define various overlapping epitopes. 
bNAb 2F5 binds to the N-terminal helix, 
Z13e1 binds to the elbow between 
helices, while 4E10 and 10E8 bind to an 
epitope in the C-terminal helix. The 
hydrophobic C-terminus of the MPER is 
partially buried in the viral membrane and 
is thought to play a critical role in fusion 
with the host membrane. It is therefore 
highly conserved, and antibodies 4E10 
and 10E8 are some of the broadest yet 
identified [8,46]. bNAbs targeting the 
MPER often interact with the viral 
membrane via long CDR-H3 loops, which 
may promote higher than normal levels of 
autoreactivity for these types of 
antibodies [47]. The precise location and 
conformation of the MPER in the 
prefusion HIV-1 trimer is not yet known, 
and further characterization will be 
necessary to determine the proximity of, 
and relationship between, epitopes in this 
site and those in the gp120–gp41 
interface. 
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A CONTINUUM OF 
VULNERABILITY 
The increased availability of bNAbs 
targeting novel sites, or variants of 
previously described sites, has blurred 
the definition of distinct bNAb epitopes. 
For instance CD4bs antibodies, once 
almost exclusively classified by their 
sensitivity to mutations at D368, now 
include a new group typified by HJ16 that 
are largely glycan dependent and 
insensitive to mutations at D368 [39,40]. 
Similarly V2 antibodies, previously 
defined as being N160 glycan dependent, 
now also include antibodies such as 
CAP256-VRC26 that target the same 
protein epitope but are not necessarily 
sensitive to glycan deletion [14]. These 
antibodies might be described as 
targeting subsites within the greater 
CD4bs or V2 site of vulnerability. This 
paradigm currently does not apply to the 
N332 dependent antibodies PGT128, 
PGT135, and 2G12, whose epitopes 
have mostly nonoverlapping peptide 
components (Figs. 1 and 3). One way to 
characterize these larger epitope clusters 
has been to define glycan supersites [30]. 
Based on these criteria, the glycan at 
position N276, which is the target for 
CD4bs antibodies (such as HJ16) and 
certain gp120–gp41 interface antibodies 
(e.g. 8ANC195) might now also be 
classified as a glycan supersite (Figs. 2 
and 3). Other glycans, such as those at 
positions N156, N386, and in the newly 
described gp120–gp41 epitope cluster, 
are bound by antibodies targeting two 
distinct epitopes, but only form a critical 
component for one (Figs. 1 and 2). These 
glycans do not yet meet the requirements 
of a supersite (though isolation of 
additional mAbs may change this), but 
they may contribute towards the affinity 
maturation of bNAbs at both sites. Thus, 
it seems that bNAb epitopes form a 
continuum of vulnerability that includes 
conserved residues stretching from the 
trimer apex to the MPER (Fig. 3). The 
glycans which protect these regions, 
divide up the continuum into sites of 
vulnerability, but also because of their 
conservation become targets for 
neutralization themselves. 
IMPROVED NEUTRALIZATION 
COVERAGE 
Vaccine-induced bNAbs ideally need to 
protect against infection from all viral 
subtypes, and therefore those that target 
highly conserved epitopes are likely to be 
most effective. First-generation bNAbs, 
such as b12, 2F5, and 2G12, had fairly 
restricted breadth, and were often more 
effective against subtype-matched 
heterologous viruses [46]. More recently 
isolated bNAbs show much greater 
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FIGURE 3. A continuum of broadly neutralizing antibody (bNAb) targets. A graphic of the HIV-1 
envelope (Env) trimer is shown and surface coloured for broadly defined epitopes in V2 (red), V3 
(orange), V4 (yellow), the CD4bs (green), and the gp120–gp41 interface (brown, purple, and blue 
for 8ANC195, 35O22, and PGT151, respectively). Overlap between these epitopes through 
recognition of common glycans or amino acids is indicated with mottling of the relevant colours. 
The highly accessible positions of hypervariable regions V1, V2, a2, V4, b14, and V5 (coloured in 
cyan) are indicated with arrows. The first residue of the MPER (truncated in the HIV-1 trimer 
structure 4TVP) is indicated with an asterisk. 
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breadth [2], although even among the 
broadest bNAbs coverage (and/or 
potency) varies between subtypes 
[7,9&&,14]. Subtype preference was also 
seen using large panels of chronic sera, 
which showed increased potency of 
plasmas against subtype matched 
viruses [48]. Notably, however, this effect 
was reduced in older and more diversified 
subtypes, suggesting that the 
significance of this observation for 
vaccine design will decrease overtime 
[48]. Differential coverage may occur for 
other reasons – bNAbs to the N332-
supersite are less effective against 
viruses with the glycan at 334 despite 
some promiscuity in recognition [49], a 
finding that may be important as the 332 
glycan is less common in subtype C 
founder viruses [50]. However, as a single 
antibody lineage could evolve to 
recognize both N332 and N334 variants 
(such as in the case of PGT128 and 
PGT130), inclusion of multiple 
immunotypes into vaccine design 
strategies may enhance coverage. 
The availability of a large number of new 
more potent and cross-reactive mAbs has 
also enhanced prospects for passive 
immunotherapy. Early studies 
demonstrated that bNAbs could protect 
against infection in nonhuman primates 
and humanized mice [51–56]. However, 
these first-generation bNAbs were only 
able to transiently reduce viral loads in 
infected subjects [57–59]. The latest 
mAbs (mostly in combinations) resulted in 
more durable control of viremia while the 
mAbs were present, and in some cases 
thereafter [60–62]. Passively infused 
bNAbs will probably be used in 
combination. Indeed, mAbs targeting four 
different sites in double, triple, and 
quadruple combinations showed 98–
100% coverage [63]. In addition to 
coverage, potency is likely to be 
important, with bNAbs engineered for 
greater in vitro potency associated with 
protection at lower plasma levels [64]. 
Lack of potency may be a particular 
concern for bNAbs with relatively low 
neutralization plateaus (incomplete 
neutralization even at high 
concentrations) such as 35O22, PGT151, 
and many V2-dependent antibodies. 
Ongoing human clinical trials will allow 
assessment of the dose of bNAb that is 
required (for protection and 
immunotherapy) and whether systemic 
infusion protects mucosal portals of 
infection. 
 
CONCLUSION 
The last year has brought significant 
advances in our understanding of the 
HIV-1 Env structure and its neutralization 
targets. New isolation technologies have 
allowed for less biased identification of 
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bNAbs targeting increasingly complex 
epitopes. These new antibodies have 
provided important insights, culminating 
in the near complete structural 
delineation of the HIV-1 Env spike. 
However, in many instances only a single 
mAb targeting a given site is available 
(e.g. PGT135, 2G12, 8ANC195, PGT151, 
and 35O22), and these often 
demonstrate some level of clade 
preference. Many more antibodies will 
need to be identified to properly 
characterize each of these new HIV-1 
vulnerabilities. Additional bNAb–trimer 
complex structures will be necessary to 
define ‘hotspots’ or supersites for 
neutralization. Using the structural data 
from multiple bNAb–antigen complexes 
for a single target site will facilitate 
rational approaches to display specific 
sites of vulnerability, as is currently being 
done for the CD4bs and MPER epitope 
scaffolds. However, the extensive overlap 
between bNAb targets suggests that 
immunogen design may benefit from 
efforts to include whole, stabilized, 
cleaved HIV-1 trimers – perhaps 
rationally designed to expose the entire 
continuum of bNAb vulnerabilities while 
minimizing antigenicity to the 
hypervariable structures. The number of 
new bNAb targets, and our understanding 
of their structure have provided novel 
opportunities for preventing and treating 
HIV-1. 
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Abstract 
 
A comprehensive understanding of the regions on HIV-1 envelope trimers targeted 
by broadly neutralizing antibodies may contribute to rational design of an HIV-1 
vaccine. We previously identified a participant in the CAPRISA cohort, CAP248, who 
developed trimer-specific antibodies capable of neutralizing 59% of heterologous 
viruses at three years post-infection. Here, we report the isolation by B cell culture 
of monoclonal antibody CAP248-2B, which targets a novel epitope in the gp120-
gp41 trimer interface. Despite low maximum inhibition plateaus, often below 50% 
inhibitory concentrations, the breadth of CAP248-2B significantly correlated with 
donor plasma. Site-directed mutagenesis, X-ray crystallography, and negative-stain 
electron microscopy 3D reconstructions revealed how CAP248-2B recognizes a 
cleavage-dependent epitope that includes the gp120 C terminus. While this epitope 
was distinct, it did overlap in parts of gp41 with the epitopes of broadly neutralizing 
antibodies PGT151, 35O22, and 3BC315. CAP248-2B has a conformationally 
variable paratope with an unusually long 19 amino acid light chain third 
complementarity determining region. Two phenylalanines at the loop apex were 
shown by docking and mutagenesis data to interact with the viral membrane. 
Neutralization by CAP248-2B is not dependent on any single glycan proximal to its 
epitope, and low neutralization plateaus could not be completely explained by N- or 
O-linked glycosylation pathway inhibitors, furin co-transfection, or pre-incubation 
with soluble CD4. Viral escape from CAP248-2B involved a cluster of rare mutations 
in the gp120-gp41 cleavage sites. Simultaneous introduction of these mutations into 
heterologous viruses abrogated neutralization by CAP248-2B, but enhanced 
neutralization sensitivity to 35O22, 4E10, and 10E8 by 10-100 fold. Altogether, this 
study expands the region of the HIV-1 gp120-gp41 quaternary interface that is a 
target for broadly neutralizing antibodies and identifies a set of mutations in the 
gp120 C terminus that exposes the membrane proximal external region of gp41, with 
potential utility in HIV vaccine design. 
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Author Summary 
 
Our understanding about which regions of the HIV-1 envelope are targets for broadly 
neutralizing antibodies (likely required for an HIV-1 vaccine) has expanded greatly in 
recent years, offering insights for vaccine design. For instance, much of solvent-
exposed gp41 is now known to be targeted by antibodies at the gp120-gp41 interface. 
In this study, we isolated the neutralizing monoclonal antibody CAP248-2B, and used 
structural biology to characterize its epitope which spanned both the gp120-gp41 and 
gp41-gp41 interfaces in a manner distinct from other antibodies. CAP248-2B extends 
the interface target to include the gp120 C terminus, effectively encircling the base of 
native pre-fusion trimers. While CAP248-2B recapitulated the donor’s plasma breadth, 
it had poor potency against some isolates as a consequence of low neutralization 
plateaus. Unlike many other broadly neutralizing antibodies, these plateaus did not 
appear to be a consequence of glycan heterogeneity, suggesting additional 
mechanisms that may contribute towards incomplete neutralization. Finally, we 
characterized viral escape pathways from CAP248-2B, and identified a cluster of 
unusual mutations in the gp160 cleavage sites that made HIV-1 viruses more sensitive 
to antibodies targeting highly conserved membrane-proximal epitopes. These 
mutations might improve the immunogenicity of gp41, and thereby inform HIV-1 
immunogen design. 
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Introduction  
The HIV-1 envelope glycoprotein trimer (Env) is the only known target for neutralizing 
antibodies and is thus a focus for vaccine design efforts. However, the development 
of an effective HIV-1 vaccine has been thwarted by the complex nature of Env, and 
the inability to produce soluble Env immunogens able to elicit broadly neutralizing 
antibodies (bNAbs) (1). Env is expressed as a single gp160 protomer that is 
extensively glycosylated and trimerized in the endoplasmic reticulum (2, 3). These 
gp160 oligomers are cleaved into gp120 (receptor binding subunit) and gp41 
(transmembrane subunit), resulting in a trimer of heterodimers that is then subjected 
to extensive glycan processing in the Golgi apparatus (3, 4). The cleaving of gp160 
occurs primarily through furin activity at position R511, but a fraction of Env is also 
cleaved at position R504 (4-6). During this process gp120 is often shed from non-
covalently associated gp120-gp41 trimers, and the entry-competent form of Env may 
comprise only a small portion of the total Env content on the viral membrane (3, 4, 7). 
The remainder often exists as gp41 “stumps”, and incorrectly processed or 
prematurely triggered monomers and oligomers. The abundance of these aberrant 
forms of Env on the viral surface, and the consequent exposure of immunodominant 
regions not normally present on entry competent trimers, misdirects the humoral 
immune response toward non-protective epitopes (8). In addition Env is highly 
sequence variable, particularly within the V1-V5 variable loop regions, and 
heterogeneously glycosylated (even at conserved NxS/T sequons) because the 
densely packed glycans afford each other varied protection from the different glycan 
processing enzymes. This combination of factors favours the formation of strain-
specific neutralizing antibodies (9-13).  
Nevertheless some individuals develop HIV-1 bNAbs after several years of infection 
that are able to target more conserved regions of Env, and thus neutralize diverse viral 
strains (14-17). In some instances these bNAbs can neutralize 50% - 99% of globally 
circulating strains, and have been shown to prevent infection in animal models (18-
24). HIV-1 bNAbs often display unusual characteristics such as high levels of somatic 
hypermutation, unusually long complementarity determining regions (CDRs), and 
insertions/deletions in both the CDRs and antibody framework regions (25-27). These 
features enable HIV-1 bNAbs to access epitopes that are often recessed or contain 
conserved glycan or membrane components. Interestingly, bNAbs that include 
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glycan(s) in their epitope frequently display incomplete neutralization, usually because 
they have evolved to recognise a specific glycoform not present on every trimer (28-
32). More recently, incomplete neutralization has also been described for HIV-1 bNAbs 
with epitopes that do not appear to depend on glycan, suggesting that additional 
factors may contribute to neutralization potency (33).  
To understand how these unusual bNAb specificities might be elicited by an HIV-1 
vaccine, there has been a concerted effort to isolate bNAbs from HIV-1 infected 
individuals and to define their targets and developmental pathways (29, 34-47). The 
identification of bnAb-mediated immune selection pressures on Env, coupled with 
mutagenesis and structural biology techniques have been instrumental in our 
understanding of the epitopes susceptible to broad neutralization (48). These include 
the CD4 binding site (CD4bs), a cluster of epitopes surrounding the N332 glycan, the 
membrane proximal external region of gp41 (MPER), and a number of quaternary 
structure specific epitopes in either the V2 trimer apex or the gp120-gp41 interface. 
The more recently discovered gp120-gp41 interface bNAbs 8ANC195, PGT151, 
35O22, and 3BC315  target distinct, usually glycan dependent epitopes, that overlap 
in gp41 (29, 43, 46, 47). For example, 8ANC195 requires glycans at positions N234 
and N276, but prefers the absence of a glycan at position N230, while PGT151 
requires glycan at positions N611 and N637 and 35O22 at positions N88 and N625. 
The identification of additional bNAbs that have epitopes within the gp120-gp41 
interface could further enhance our understanding of this new site of vulnerability.  
In a previous study we described CAP248, an HIV-1 subtype C infected participant in 
the CAPRISA 002 cohort who developed bNAbs to a trimer-specific epitope that could 
not be defined at the time (15). Here, we have isolated a monoclonal antibody (mAb) 
that was representative of the broadly neutralizing plasma response, but lacked 
potency due to low neutralization plateaus that could not be accounted for by glycan 
heterogeneity. Through the interrogation of autologous selection pressure in Env, 
together with X-ray crystallography and electron microscopy, we mapped the CAP248-
2B target to a glycan independent epitope in the gp120-gp41 interface that overlaps 
with previously identified gp120-gp41 interface bNAbs, but is distinct in its recognition 
of the gp160 cleavage motifs in the gp120 C terminus. Escape from this antibody 
conferred a viral phenotype that was exceptionally sensitive to neutralization by MPER 
directed antibodies, suggesting a role for the C terminus of gp120 in the exposure of 
important bNAb epitopes in gp41.  
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Results 
Isolation of antibody CAP248-2B, which recapitulates CAP248-plasma 
neutralization breadth 
CAP248 first developed cross-neutralizing antibodies after one year of infection 
(Figure 1A). By three years, the neutralization breadth of CAP248 plasma increased 
incrementally, from 7% to 59% when tested against a 44 pseudovirus panel (15). This 
neutralization was largely subtype C specific with CAP248 plasma neutralizing 89% of 
26 subtype C, 50% of 6 subtype A and 33% of 12 subtype B pseudoviruses (Figure 
1A). As mapping of polyclonal plasma may be complicated by the presence of multiple 
overlapping specificities (49, 50), we used a stored peripheral blood mononuclear cell 
(PBMC) sample from 3.5 years post-infection to isolate a monoclonal antibody. B cells 
were enriched by negative selection with immunomagnetic beads, and B cell culture 
supernatants were screened after 14 days for neutralization of CAP45, a tier-2 
pseudovirus sensitive to CAP248 plasma at ID50 titres of ~1:4,000. The isolated 
antibody, called CAP248-2B, was predicted to be derived from the IGHV4-31*05 and 
IGHJ3*01/02 heavy and IGLV2-14*01 and IGLJ1*01 lambda chain germline genes, 
and displayed modest levels of affinity maturation, with 13.5% and 9.7% nucleotide 
mutation in the heavy and light chains respectively (Supplementary Figure 1A). 
CAP248-2B potently neutralized CAP45 with an IC50 of 0.04 µg/mL (IC80 of 0.19 
µg/mL), but against the same 44 pseudovirus panel on which CAP248 plasma 
displayed 59% neutralization breadth at three years post-infection, CAP248-2B 
neutralized only 23% of viruses with IC50 titres (Figure 1B). Examination of the 
neutralization curves indicated that the poor breadth of CAP248-2B was due to 
incomplete neutralization, e.g. the maximum inhibition of CAP45, CNE52, CAP228, 
and ZM249 plateaued at 95%, 69%, 54%, and 32% respectively (Figure 1C). When 
IC20 values were examined, CAP248-2B neutralized a much larger fraction of the 
panel, showing 57% breadth, equivalent to the plasma breadth (Figures 1B and 1D). 
Overall there was significant concordance (p<0.00001) between pseudoviruses 
neutralized by the plasma at 3 years (measured as ID50) and those neutralized by the 
monoclonal antibody at IC20 (Figure 1D). This suggested that CAP248-2B was 
representative of the dominant bNAb specificity in CAP248 plasma, though more 
potent variants of this mAb lineage remain to be isolated.  
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Figure 1: Isolated antibody CAP248-2B exhibits low neutralization plateaus, but 
recapitulates the plasma neutralization breadth 
(A) Bar graph showing percentage neutralization breadth of CAP248 plasma at ID50 
titers of >1:100 (y-axis) on a 44 virus panel at one, two, and three years post-infection 
(x-axis). The total breadth at each time point is indicated above the bars. The 
proportion of subtype C, B, and A viruses neutralized by CAP248 plasma is indicated 
in red, blue, and green respectively. (B) Percentage neutralization breadth of 
monoclonal antibody CAP248-2B (y-axis) on the same 44 virus panel as in A, when 
measured at IC80, IC50, and IC20 (x-axis), colored and labelled as above. (C) 
Neutralization curves of CAP248-2B against four viral strains (CAP45, CNE52, 
CAP228, and ZM249) plotted as percentage inhibition (y-axis) versus antibody 
concentration (x-axis). Dotted lines indicate y-axis intersections for IC80, IC50, and IC20. 
The maximum inhibitory percentage achieved against each virus is listed to the right 
of each curve. (D) Comparison between the neutralization breadth of CAP248 plasma 
at three years, and CAP248-2B at IC20 and IC50. Titers are colored yellow, orange and 
red by potency. A strong inverse spearman correlation with a rho value of -0.802 (p-
value <0.00001) indicates good concordance between increasing plasma ID50 and 
decreasing antibody IC20.   
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Structural characterization of monoclonal antibody CAP248-2B  
CAP248-2B possessed an average length CDR-H3 of 15 amino acids, but had an 
unusually long CDR-L3 of 19 amino acids (Figure 2A). The typical length of a CDR-L3 
is 8-12 amino acids, and there are no antibodies with CDR-L3s of greater than 15 
amino acids in the Abysis database (http://www.bioinf.org.uk/abysis/index.html). In 
addition to the CDRs, there was also maturation away from germline in the framework 
region three (FR3) of the heavy chain (Figure 2A – blue). We determined two crystal 
structures of the unliganded CAP248-2B antigen binding fragment (Fab) to resolutions 
of 3.1 Å and 2.0 Å respectively (Figure 2B and Supplementary Figure 1). The CDR-
H3 and CDR-L3 loops of the 2.0 Å resolution structure were influenced slightly by 
crystal packing (Supplementary Figure 1B and 1C), and a comparison of the CDR-H3 
between the two structures revealed two distinct loop conformations that bent at 
residues Gly100D and Gly100E to flip the Asp100B and Asp100C anionic pair ~180° 
between CDR-L3 proximal and distal orientations (Figure 2B – top inset).  
In the 3.1 Å resolution structure, the 19 amino acid CDR-L3 formed a β-hairpin which 
was stabilized along its length by seven hydrogen bonds, and protruded ~15Å at a 
right angle relative to the other CDR’s. The tip of the CDR-L3 ended in hydrophobic 
residues Phe95C and Phe95D that were specifically angled by Pro95F and 
immediately flanked by residues Ser95B and Gly95E which may confer a degree of 
plasticity to this region. In all structures, the angle at which the CDR-L3 extended from 
the Fab was stabilized at its base by germline conserved hydrogen bonding 
interactions with CDR-L1, as well as a salt bridge formed between CDR-L3 residue 
Arg95I, and Asp50 in the CDR-H2. Ultimately, the CAP248-2B antigen binding site 
displayed substantial structural plasticity, an attribute that likely contributes to its mode 
of neutralization.  
Viral escape from CAP248-2B was mediated by unusual mutations in the gp160 
cleavage site 
Previously, we have shown that CAP248 plasma bNAbs could not be adsorbed using 
recombinant monomeric gp140 or MPER peptides, and were not sensitive to V2 
mutations at positions N160 and L165 (15). This suggested that CAP248 bNAbs 
targeted a quaternary epitope distinct from the V1V2 epitope. To identify potential 
escape mutations in response to CAP248 bNAbs, autologous gp160 sequences from 
nine weeks (study enrolment), as well as 1, 2, 3, and 3.5 years post-infection were 
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examined for accumulating mutations (indicative of selection pressure) in normally 
conserved regions of the envelope. Several autologous mutations were identified in, 
or proximal to, known bNAb epitopes within V2 (E164I/V, L165I/F), C1 (G87R/E) and 
C2 (D230N, N234T/S, T236K), V3 (D321E/G, N325D/K, E328K/D), and the MPER 
(N674G, K677N/Q, K683R) (Supplementary Figure 2A). However when these 
changes were made in the heterologous tier-2 virus CAP45, none affected CAP248-
2B neutralization (Supplementary Figure 2B).  
 
 
 
Figure 2: Crystal structure of CAP248-2B reveals an unusually long, protruding 
CDR-L3, with a hydrophobic tip 
(A) Sequence alignment of the CAP248-2B heavy and light chain with their predicted 
V- and J-gene precursors. The CDRs are shaded, labelled, and colored. The heavy 
chain FR3 is similarly indicated in blue. (B) Crystal structure of the CAP248-2B Fab. 
The light and heavy chains are colored olive and forest green respectively, while CDR 
loops and FR-H3 are colored according to A. Two views are shown around a ~45° axis 
to highlight the long CDR-L3 (yellow). Insets show the conformational differences 
between the CDR-H3 and CDR-L3 loops between Fab structure 1 (shown here) and 
Fab structure 2 (shown in supplementary figure 1). Two Fabs were present in both 
asymmetric units, so four loops are shown per inset, two for Fab1 CDR-H3 (red) or L3 
(yellow), and two for Fab2 CDR-H3 and L3 (both grey). Asp100B and Asp100C in the 
heavy chain and Phe95C and Phe95D in the light chain are shown with stick 
representations to highlight the conformational divergence between the two structures. 
Due to crystal packing all downstream analyses were based on the 3.1 Å structure.  
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To rule out these four epitopes as the target for CAP248-2B, we also assessed the 
effect of mutations known to confer resistance to bNAbs targeting these regions, but 
these mutations also failed to abrogate CAP248-2B neutralization (Supplementary 
Figure 2C). There were slight effects following the T303A and F672L/W673L 
mutations, but these are known to affect overall Env conformation (30, 51), and so 
may not form part of the CAP248-2B epitope. A cluster of unusual mutations were 
identified in the C terminus of gp120 at positions 500, 502, 505, 507, 508, and 509 
within the gp160 furin cleavage motifs that separate gp120 from gp41 (Figure 3A). 
This region has not previously been implicated in viral escape from neutralizing 
antibodies, but analysis of 2,558 sequences from the Los Alamos National Laboratory 
HIV-1 database showed that while sequence variation at position 500 is common, 
mutations at the other five sites are rare, particularly amongst clade C viruses (Figure 
3B). The simultaneous presence of these mutations in CAP248 viral sequences 
therefore suggested strong immune pressure on this region. When the six most 
common mutations at 3.5 years post-infection (E500K, R502Q, V505M, E507G, 
R508K, and E509G) were introduced individually into the heterologous virus CAP45, 
only the V505M mutation substantially reduced CAP248-2B neutralization (Figure 3C 
– blue line). However, the simultaneous introduction of all six mutations into CAP45, 
hereafter referred to as CAP45(CS-Mut), conferred complete resistance to CAP248-
2B neutralization, confirming their collective role in escape from CAP248 bNAbs 
(Figure 3C – red line).  
The gp120 C terminus is proximal to gp41, suggesting that the CAP248-2B epitope 
might be in the gp120-gp41 interface. To determine whether autologous gp41 
mutations might contribute towards escape from CAP248-2B, we examined CAP248 
gp41 ectodomain sequences over time. Of the thirteen changes identified (I515M, 
L519F, K588Q, N607T, Q619L, D621E, D624G, D632E, S636H, G640D, K644Q, 
N651I, and D659E), none drastically affected CAP248-2B neutralization when 
introduced into CAP45 (Figure 3D). Altogether, these data suggest that major escape 
mutations from the CAP248-2B lineage accumulated in the gp160 cleavage motifs, 
with the role of additional mutations accumulating in proximal regions of gp41 still to 
be defined.  
 
  
Chapter 3: Isolation of a Novel gp120-gp41 Interface Antibody     Wibmer et al., 2016 
3 78 
 
 
Figure 3: Escape mutations from CAP248-2B accumulate in the gp120 C 
terminus 
(A) Sequence alignment of the gp120 C terminus from CAP248 autologous viruses at 
nine weeks (study enrolment), 1, 2, 3 and 3.5 years post-infection. The primary 
(position 511) and secondary (position 504) gp160 cleavage sites are indicated with 
arrows. The total number of viruses with identical amino acid sequence within this 
region are indicated in brackets to the right. Residues undergoing significant selection 
pressure are indicated with the asterisks. (B) Sequence logograms showing variation 
within the gp120 C terminus for all strains, and clade C only, from the LANL HIV 
sequence database, as well as from CAP248-2B at 3.5 years post-infection, colored 
and labelled as in A. The global frequencies for each of the autologous mutations 
identified in CAP248 sequences were: 500 (E8.88%, K46.56%, G3.56%), 502 
(K79.35%, R18.73%, Q1.37%), 505 (V98.98%, A0.55%, M0.08%, L<0.01%), 507 
(E47.5%, G3.87%, A0.7%), 508 (R98.24%, K1.49%), 509 (E95.11%, G1.53%, 
A0.27%). (C) Neutralization by CAP248-2B of the heterologous strain CAP45, when 
compared to gp120 C-terminal mutant viruses with changes identified from autologous 
CAP248 Env sequences. Data was plotted as percent inhibition (y-axis) against 
antibody concentration (x-axis). The wild-type virus is shown in black. Dotted lines 
indicate y-axis intersections for IC80, IC50, and IC20. (D) Neutralization by CAP248-2B 
of CAP45 wild-type and mutant viruses with the gp41 changes identified from CAP248 
autologous sequences, plotted as in C.  
CAP248-2B targets a distinct membrane proximal epitope in the gp120-gp41 
interface 
To identify the binding site of CAP248-2B, we obtained structural information about 
the Fab bound to an Env trimer by electron microscopy (EM) (Figure 4 and 
Supplementary Figure 3). CAP248 plasma was unable to neutralize BG505, and 
CAP248-2B failed to bind recombinant BG505 SOSIP trimer in ELISA (Figure 4A – top 
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graph). Since it seemed likely that CAP248-2B targeted an epitope in the gp120-gp41 
interface, we engineered the CAP248-2B epitope into a SOSIP trimer by designing a 
BG505(gp120)-CAP45(gp41) chimera. BG505 and CAP45 differed in gp41 by only 
6.7% (23 amino acids), with most of these mutations not predicted to interact with 
gp120 in the pre-fusion structure. This chimeric SOSIP trimer was efficiently cleaved 
(data not shown), and bound well to trimer-specific bNAbs CAP256-VRC26.09 and 
CAP248-2B, but not to the non-neutralizing antibody F105, suggesting that it retained 
a native-like conformation (Figure 4A – bottom graph). Single particle negative stain 
EM reconstructions at ~20 Å showed a maximum stoichiometry of three CAP248-2B 
Fabs bound to the BG505(gp120)-CAP45(gp41) SOSIP trimer (Figure 4B – top view). 
Docking of the CAP248-2B Fab into the EM 3D reconstruction revealed a binding site 
that was extremely close to the viral membrane, similar to 35O22 and 3BC315 (43, 
47), but approaching from an angle that was proximal to the gp120 C terminus (Figure 
4B – side view). Since this is also the site of viral escape mutations, these data support 
the hypothesis that CAP248-2B binds to the C terminus of gp120, at the membrane 
proximal gp120-gp41 interface. In addition CAP248-2B appeared to interact with the 
α8 helix of one gp41 protomer and α9 helix of another gp41 protomer at the gp41-
gp41 interface (Supplementary Figure 3E).  
The CAP248-2B Fab structures could be docked into the EM reconstructions in two 
possible orientations. These placed the hydrophobic CDR-L3 tip in close proximity to 
either the viral membrane, or the fusion peptide (FP) of gp41, with approximately 1,100 
Å2 - 900 Å2 of surface area buried by the paratope in Env respectively (Figure 4C). In 
the latter FP binding model, protein clashes would require flexible fitting of the CDR-
L3 and/or FP, whereas in the lipid binding model Phe95C and Phe95D would insert 
into the core of the viral membrane, while Lys94 and Lys95 would be positioned to 
interact with the polar membrane lipid heads. To distinguish between these two 
binding orientations, we replaced the phenylalanine residues at the CAP248-2B CDR-
L3 tip with either tryptophan or alanine (Figure 4D). The bulky, hydrophobic tryptophan 
side chains should interfere with specific FP interactions, negatively impacting on 
neutralization, whereas these same mutations would be expected to enhance 
interactions with the viral lipids, improving neutralization. The Trp95C/Trp95D CDR-
L3 mutant was more potent against CAP45, CNE52, and CAP228, although 
neutralization plateaus were not improved. Similarly, mutating only one of the CDR-L3  
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Figure 4: Negative-stain EM describes a distinct membrane proximal epitope for 
CAP248-2B in the gp120 C terminus and parts of gp41 
(A) ELISA data comparing the binding of trimer-specific antibodies CAP256-VRC26.09 
and CAP248-2B, and the non-neutralizing, gp120 binding antibody F105 to purified 
wild-type BG505 (top panel), and chimeric BG505(gp120)-CAP45(gp41) (bottom 
panel) SOSIP trimers. Absorbance readings are plotted on the y-axis and antibody 
concentration on the x-axis. (B) Negative stain EM 3D reconstruction of the CAP248-
2B Fab bound trimers, shown in grey. The previously determined trimer structure with 
pdb ID: 4TVP was docked into the 3D reconstruction, and colored red for gp120 and 
cyan for gp41. Three CAP248-2B Fab structures were also docked, and colored forest 
and olive green for the heavy and light chains respectively. Two views are shown: As 
seen from the target cell (top view), and perpendicular to the viral membrane (side 
view). The approximate location of the viral membrane is indicated with dotted lines. 
(C) Two docking orientations for the CAP248-2B Fab are modelled and coloured as in 
B. In the two zoomed panel insets, the CDR-L3 (yellow) is shown in its predicted 
binding location with either the viral membrane (left panel inset) or interacting with the 
gp41 fusion peptide (right panel inset). The fusion peptide is colored purple and shown 
with surface representation. (D) Neutralization of three heterologous viruses by 
CAP248-2B and related CDR-L3 mutants. Percentage inhibition was plotted on the y-
axis versus antibody concentration on the x-axis. Dotted lines indicate y-axis 
intersections for IC80, IC50, and IC20.   
Chapter 3: Isolation of a Novel gp120-gp41 Interface Antibody     Wibmer et al., 2016 
3 81 
 
Phe residues to generate Trp95C/Phe95D, or Phe95C/Trp95D mutants, also resulted 
in enhanced neutralization, with Trp95C showing the greater effect. In contrast the 
CDR-L3 Ala95C/Phe95D mutant showed decreased neutralization potency, 
confirming the importance of the CDR-L3 tip in effective neutralization of HIV-1. 
Binding of CAP248-2B to soluble SOSIP trimers was unaffected by any of these CDR-
L3 substitutions (Supplementary Figure 3F). In contrast CDR-H1 mutations predicted 
to interfere with SOSIP binding in the membrane bound orientation, but not in the FP 
bound model, completely abrogated binding. Altogether, these data support a docking 
orientation where the CAP248-2B CDR-L3 makes critical hydrophobic interactions 
with the viral membrane.  
The CAP248-2B binding site overlaps with broadly neutralizing antibody 
epitopes in gp41 
Comparisons with previously determined structures showed CAP248-2B binding to be 
adjacent to the PGT151 epitope near N611/N637, the 35O22 epitope near to 
N88/N625, and overlap with the 3BC315 epitope at the gp41-gp41 interface 
(Supplementary Figure 4A and Figure 5A). To measure the extent to which these 
antibody epitopes overlapped, we assessed the ability of various bNAbs to block 
CAP248-2B binding to cell surface expressed CAP45 envelope trimers (Figure 5B). 
The gp120-gp41 interface antibodies PGT151 and 35O22 (but not 8ANC195) both 
competed for CAP248-2B binding, but 3BC315 only showed slight competition at the 
highest concentrations tested. In the reverse competition assay, CAP248-2B 
competed more substantially with 3BC315, consistent with the overlap observed by 
EM (Supplementary Figure 4B). Surprisingly, MPER bNAb 4E10 also competed for 
CAP248-2B binding to Env, while CAP248-2B binding did not affect 4E10 in the 
reverse assay (Figure 5B and Supplementary Figure 4B). Current trimer structures do 
not include the MPER, so it is not clear whether this region forms part of the CAP248-
2B epitope, but this one-directional competition suggests MPER antibodies prevent 
CAP248-2B binding indirectly. Altogether, these data highlight the importance of the 
gp120-gp41 pre-fusion interface as a target for broadly neutralizing antibodies with 
multiple overlapping epitopes often in close proximity to the MPER.  
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Figure 5: Broadly neutralizing antibodies that target gp41 compete with CAP248-
2B for binding to cell-surface Env 
(A) Surface view of the envelope trimer colored to show the core epitopes for bNAbs 
targeting the gp120-gp41 and gp41-gp41 interfaces. The approximate location of the 
MPER and the viral membrane are indicated. (B) Binding of labelled CAP248-2B to 
cell-surface anchored HIV-1 Env by flow cytometry, in the presence of increasing 
concentrations of unlabeled competitor antibody. Median fluorescence intensity (MFI) 
is shown on the y-axis, and increasing concentrations of each competitor antibody is 
plotted on the x-axis. Decreasing MFI signals correspond to increasing competition 
with CAP248-2B.  
 
CAP248-2B is not dependent on glycans proximal to the gp120-gp41 interface  
With the exception of 3BC315, all bNAbs targeting the gp120-gp41 interface identified 
to date depend on various highly conserved glycosylation sites for neutralization. 
Docking of the CAP248-2B Fab into the EM 3D reconstruction showed that CAP248-
2B does not use long CDRs to penetrate the glycan shield, but instead glycans 
proximal to the epitope (particularly N88 and N611) need to shift to facilitate CAP248-
2B binding (Figure 6A). The 35O22 bound orientation of the N88 glycan was 
incompatible with CAP248-2B binding, suggesting that similarly to 3BC315 (47), the 
N88 glycan must first be relocated. To assess whether glycans in gp120 or gp41 that 
were proximal to the CAP248 epitope were required for CAP248-2B neutralization, 
knock-out mutants were generated in CAP45 and tested for altered sensitivity to 
CAP248-2B, 8ANC195, 35O22, PGT151, and 3BC315 (Figure 6B and Supplementary 
Figure 5A). As expected from previous studies, 8ANC195 neutralization was 
abrogated by T236K and N276A mutations but enhanced by an N230A mutation, 
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35O22 neutralization was reduced by N88A, N230A, T236K, and N625A mutations, 
and PGT151 was negatively affected by N611D and N637A mutations (Supplementary 
Figure 5A) (29, 43, 52). However unlike these three bNAbs, but similar to 3BC315, 
CAP248-2B neutralization titres were not negatively affected by any of these glycan 
deleting mutations (Figure 6B).  
 N276D and N611D changes did result in slightly lower neutralization plateaus, but did 
not affect the CAP248-2B IC50. To test whether CAP248-2B neutralization was 
dependent on the N611 glycan, a S613A mutation (that also removes the N611 glycan) 
was introduced into CAP45. While similarly resistant to PGT151 (when compared to 
N611D), the S613A mutation had no effect on CAP248-2B neutralization, suggesting 
that unlike PGT151, CAP248-2B does not interact with the N611 glycan but rather with 
the amino acid side chain at position 611 (Figure 6B and Supplementary Figure 5A – 
dashed red line). In contrast, the N88A, N230A, and N625A glycan mutants did not 
affect neutralization plateaus, but were more potently neutralized by CAP248-2B at 
IC50 than the wild-type CAP45, supporting the observation that these glycans obscure 
the CAP248-2B epitope. The N88A glycan mutant was also more sensitive to 3BC315 
neutralization, consistent with published data showing that this glycan partially 
occludes the 3BC315 epitope (47). These data suggest that CAP248-2B was not 
critically dependent on any single glycan in the gp120-gp41 interface for effective 
neutralization.  
PGT151 is only partially affected by the individual N611D/S613A or N637A mutations, 
and simultaneous mutation at both N611 and N637 glycan sites is required to 
completely abrogate neutralization (29). To test whether the removal of an additional 
glycan, in conjunction with the N611D mutation, was similarly required to knock out 
CAP248-2B activity, each of the glycan mutants was also made in the N611D mutant 
backbone (Figure 6C and Supplementary Figure 5B). None of these double glycan 
mutant pseudoviruses showed increased resistance to CAP248-2B, though all 
showed partially elevated plateaus relative to the N611D mutant for CAP248-2B, with 
a T90A mutation (that removes the N88 glycan) having the greatest effect. Altogether 
these data suggest that CAP248-2B binds to a glycan-independent epitope, but that 
this binding must overcome steric occlusion by several glycans at positions N88, 
N230, N611, and N625.  
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Figure 6: The CAP248-2B epitope is proximal to Env glycans, but not affected 
by glycan heterogeneity 
(A) Schematic of CAP248-2B bound trimer (colored as in Figure 4 with gp120 shown 
in transparent surface grey scale) including modelled (NAG)2MAN3 basic glycans at 
epitope proximal N88, N611, N616, N625, and N637 residues (colored brown, yellow, 
pink, purple, and blue respectively). Two views are shown: Top view (left panel), and 
a side view zoom (right panel). Relocation of the N88 glycan between 35O22 and 
CAP248-2B bound states is indicated. (B) Neutralization of CAP45 by CAP248-2B 
when compared to epitope proximal glycan mutants. The S613A mutant that removed 
the glycan at N611 but maintains the amino acid side chain properties is shown with 
red dashed lines and open circles. Percentage inhibition was plotted on the y-axis 
versus CAP248-2B antibody concentration on the x-axis. (C) Neutralization of the 
CAP45 N611D single mutant, and various N611D including double glycan mutants, 
plotted as in B. (D) Neutralization of heterologous tier-2 strains CAP45, CNE52, 
CAP228, and ZM249 when grown normally (black lines), with co-transfected furin 
(dashed pink lines), or in the presence of kifunensine (blue lines), swainsonine (cyan 
lines), and an O-linked glycosylation inhibitor (dashed orange lines), or in a GnTI 
deficient cell line (grey lines). Neutralization was also assessed in the presence of 
sCD4 at predetermined IC40 concentrations for each virus (dashed green lines). 
Graphs are plotted as in B.   
Chapter 3: Isolation of a Novel gp120-gp41 Interface Antibody     Wibmer et al., 2016 
3 85 
CAP248-2B neutralization plateaus could not be explained by glycan 
heterogeneity, cleavage, or soluble CD4 
While CAP248-2B did not appear to be critically dependent on glycans surrounding 
the gp120-gp41 interface, incomplete inhibition by HIV-1 bNAbs is often attributed to 
heterogeneous glycosylation within or proximal to bNAb epitopes (33). To test whether 
CAP248-2B had a preference for particular N-linked glycoforms of Env, we evaluated 
CAP248-2B neutralization of pseudoviruses grown in the presence of N-glycosylation 
pathway inhibitors kifunensine or swainsonine, or grown in a GnTI deficient cell line 
(Figure 6D). Four sensitive strains representing different neutralization maxima (from 
Figure 1B) were used. Except for the slightly enhanced sensitivity of swainsonine-
grown CNE52 to CAP248-2B, there was no substantial change in the CAP248-2B 
neutralization plateaus when enriching for high mannose (kifunensine), medium-high 
mannose (GnTI (-/-)) or pre-complex only (swainsonine) glycans (Figure 6D). 
Therefore, the unusually low neutralization plateaus of CAP248-2B could not be 
completely explained by overall envelope N-linked glycan heterogeneity.  
Other factors for intra-strain heterogeneity could potentially include O-linked 
glycosylation of Env, inefficient gp160 cleavage, or an exclusive preference for a CD4 
activated form of envelope. While the potential role of O-linked glycosylation in 
envelope heterogeneity has not been extensively characterized, recombinant gp120 
expressed as a monomer can be O-glycosylated in the C terminus at position T499, 
and at least some forms of gp160 might be O-glycosylated at position T606 in gp41 
(53-57). Both of these sites were proximal to the CAP248-2B epitope, but manipulating 
Env O-linked glycosylation pathways by growing pseudoviruses in the presence of 
benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (a modulator of mucin-like O-
linked glycosylation pathways, preventing N-acetyl glucosamine addition) did not 
affect CAP248-2B maximum inhibition plateaus (Figure 6D – orange dashed curves). 
Similarly, increasing gp160 cleavage efficacy by co-transfecting pEnv and pFurin 
during pseudovirus production (Figure 6D – pink dashed curves), or increasing the 
sampling of a CD4-bound conformation during the neutralization assays by pre-
incubating pseudovirions with soluble CD4 at a previously determined IC40 value (data 
not shown) for 30 minutes, did not substantially affect CAP248-2B neutralization 
(Figure 6D – green dashed curves). These data suggest that gp160 cleavage, 
sampling of the CD4 bound conformation, or O-linked glycan processing also do not 
contribute to the low neutralization plateaus of CAP248-2B.  
Chapter 3: Isolation of a Novel gp120-gp41 Interface Antibody     Wibmer et al., 2016 
3 86 
 
 
 
 
Figure 7: Fine mapping of the CAP248-2B epitope  
(A) Cartoon of the CAP248-2B paratope (shown as a mirror image of the docked model 
in B, and colored as in Figure 2), showing amino acids that have affinity matured 
relative to the predicted germline genes with main chain Cα spheres. (B) A surface 
view schematic of gp41 (dark grey) and proximal regions in gp120 (light grey) showing 
predicted heavy chain (dark green) and light chain (olive green) binding footprints. The 
interface between two separate gp120-gp41 heterodimers is indicated with the dotted 
line. CDR loops and the heavy chain FR3 predicted to interact with envelope are 
shown in cartoon and colored as in A. (C) The envelope trimer is shown and colored 
as in B. Point mutants shown to significantly affect CAP248-2B neutralization are 
shown in dark blue, relative to the CAP248-2B predicted binding footprint. The 
autologous mutations in gp41 that were identified in Figure 4 are shown in cyan, with 
many in close proximity to the CAP248-2B predicted binding footprint. (D) Table 
showing neutralization IC50 titers for CAP248-2B, PGT151, 3BC315, 35O22, and 
8ANC195 against CAP45 and various mutants. The location of each mutant in either 
gp41 or the gp120 C terminus is shown on the left. Fold effects on IC50 are colored.   
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Fine mapping of the CAP248-2B epitope 
Most of the CAP248-2B affinity maturation occurred in the heavy chain CDRs and 
FR3, with limited maturation occurring in the CDR-L1 (Figure 2A and Figure 7A). In 
accordance with these data the CAP248-2B heavy and light chain footprint (based on 
the SOSIP bound EM analyses) was dominated by interactions with CDR-H1, H2, and 
H3, as well as the heavy chain (FR3), with limited predicted peptide interactions for 
the CDR-L1 or L3 (which interacts with viral lipids) (Figure 7B). To characterize the 
CAP248 epitope in finer detail, we made mutants in the gp120 C terminus (the location 
of escape mutations) and proximal regions of gp41 to compare neutralization of 
CAP248-2B to 8ANC195, PGT151, 35O22, and 3BC315 (Figure 7D). None of the 
mutations universally abrogated neutralization of all the bNAbs tested, suggesting that 
trimer conformation was not compromised, however the A501C mutation negatively 
affected the neutralization of PGT151, CAP248-2B, and 35O22. A mutation at position 
Q652 substantially affected CAP248-2B neutralization, while N656A completely 
abrogated its activity. These sites are close enough to interact with CDR-H1 residues 
Glu32/Asp33 that were shown above to be critical to the CAP248-2B interaction with 
SOSIP trimer (Supplementary Figure 3). Mutations between positions 640-660 in the 
α9-helix of gp41 affected PGT151 neutralization, and the N656A mutation also 
moderately affected 35O22 neutralization, though this residue does not form part of 
the 35O22 epitope. Three mutations, V506A, L661A, and L663A appeared to affect 
CAP248-2B maximum inhibition percentages, but did not affect CAP248-2B IC50 
values more than three-fold (within the error of the assay), suggesting that 
hydrophobic interactions play a role in modulating CAP248-2B neutralization plateaus. 
Mutations in the gp120 C terminus affected both CAP248-2B and PGT151 
neutralization, though the exact sites/effects differed between the two antibodies. 
Interestingly, although PGT151 does not appear to bind the gp120 C terminus directly 
(its access is occluded by gp41) the CAP45(CS-Mut) virus, that is completely resistant 
to CAP248-2B, was also resistant at IC50 to PGT151 (neutralization plateaus just 
under 50%). Conversely, 35O22 neutralization of CAP45(CS-Mut) was considerably 
more potent than the wild-type CAP45 virus. All of the mutations affecting CAP248-2B 
overlapped with the predicted antibody binding footprint, confirming their importance 
in the CAP248-2B epitope (Figure 7C – dark blue). In addition to these resistance 
mutations, we also examined the location of autologous mutations in gp41 identified 
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from longitudinal viral sequences. While these mutations were not implicated in 
CAP248-2B escape, half of them (N607T, Q619L, K644Q, N651I, and D659E) were 
proximal to the predicted CAP248-2B epitope, and may play a role in resistance to 
other members of the CAP248-2B lineage present in CAP248 plasma (Figure 7C – 
light blue).  
Escape from CAP248-2B exposes proximal epitopes for anti-gp41 broadly 
neutralizing antibodies 
The enhancement of 35O22 neutralization after the introduction of cleavage site 
mutations into CAP45 suggested a role for the gp120 C terminus in Env conformation. 
To investigate this, the neutralization of CAP45(CS-Mut) was compared to wild type 
CAP45 for bNAbs with diverse epitopes on HIV-1 Env (Figure 8A). CAP45(CS-Mut) 
neutralization by V2 and N332 antibodies remained unchanged relative to wildtype. 
The neutralization of CD4bs antibodies VRC01 and b12 was marginally enhanced, but 
neutralization of MPER bNAbs 4E10 and 10E8 was enhanced by 26- and 38-fold 
respectively. CAP45 is resistant to 2F5 and Z13e1, so these bNAbs were not tested. 
To determine whether this effect was specific to CAP45, the six CAP248 autologous 
escape mutations (CS-Mut) were simultaneously introduced into four additional 
heterologous pseudoviruses. Similar to CAP45, all four of these mutant pseudoviruses 
were between 10- and 100-fold more sensitive to 35O22, 4E10, and 10E8 
neutralization (Figure 8B). In some instances introduction of the CS-mutations 
conferred sensitivity to 35O22 or 4E10, where the wild-type virus was completely 
resistant at the concentrations tested. These data show that mutations in the C 
terminus of gp120 induce localised effects in trimer conformation that specifically 
enhance sensitivity to MPER bNAbs.  
Discussion 
The identification of HIV-1 bNAbs with overlapping epitopes in the gp120-gp41 
interface has greatly expanded our knowledge of the regions of the envelope trimer 
susceptible to neutralization (29, 43, 46, 47, 58-60). Here, we isolated a monoclonal 
antibody called CAP248-2B that targeted a membrane proximal epitope in the gp120-
gp41 and gp41-gp41 interfaces overlapping with, but distinct from the epitopes for 
bNAbs PGT151, 35O22, and 3BC315. Together with 8ANC195, these epitopes 
surround the base of the HIV-1 envelope trimer, forming a continuum of neutralization  
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Figure 8: Escape mutations from CAP248-2B enhance the neutralization of 
broadly neutralizing antibodies that bind to gp41 
(A) Neutralization of CAP45 and a mutant variant that includes the six gp120 C-
terminal mutations identified in CAP248 autologous sequences (CS-Mut), by broadly 
neutralizing antibodies with epitopes in V2, V3, the CD4bs, the MPER, and the gp120-
gp41 interface. Fold changes that were less than three were regarded as being within 
the error of the assay (no effect). Fold enhancement in neutralization sensitivity to 
CAP248-2B is indicated in orange (3 – 10 fold increased sensitivity) and red (> 10 fold 
increased sensitivity). Conferred resistance to the mutant virus at IC50 is shown by 
grey shading. (B) Neutralization of five paired WT (blue) and CS-Mut (red) viruses by 
35O22, 10E8, and 4E10.  
 
 
vulnerability (Figure 5A) (48). Unlike many other bNAbs, CAP248-2B neutralization 
plateaus could not be completely explained by glycan heterogeneity. Furthermore, 
rare mutations in the gp120 C terminus that mediated escape from CAP248-2B 
increased the sensitivity of HIV-1 viruses to MPER antibodies. Thus the identification 
of new antibodies targeting this supersite of vulnerability may provide important 
insights for vaccine design. 
CAP248-2B was isolated from a CAPRISA donor (CAP248) who showed plasma 
neutralization breadth of nearly 60% against a multi-subtype panel and 80% against 
subtype C viruses. While CAP248-2B did not recapitulate the donor’s plasma breadth 
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at IC50, the neutralization profile at IC20 strongly suggested that this lineage was 
responsible for CAP248 broad neutralization The CAP248-2B epitope was structurally 
proximal to glycans at N88, N230, N611, and N625, but CAP248-2B neutralization 
was not dependent on any single glycan, or any double glycan knock-outs that 
included N611D. These data would support recent evidence for the common 
occurrence of neutralization plateaus across all bNAb classes, including those that do 
not require glycan for effective neutralization (33). Potential confounders such as the 
rate of furin cleavage or random sampling of CD4-induced transition intermediates 
were also tested, but did not affect the low plateaus for CAP248-2B. It is possible that 
CAP248-2B neutralization plateaus were the result of a preference for different 
glycoforms at two or more N-linked glycan sites. This could explain why shifting the 
overall glycosylation profile of a viral strain in one direction (e.g. by growing a 
pseudovirus in the presence of a glycosylation pathway inhibitor) had no substantial 
effect on the neutralization plateau. Alternatively, our data suggest an additional 
contributor to envelope heterogeneity, which could be an important confounder for 
vaccine immunogen design.  
Structural analysis indicated that the CAP248-2B paratope was conformationally 
variable.  Divergent CDR-H3 conformations that were only seen because of crystal 
packing may represent a level of plasticity that could have evolved to better 
accommodate Env sequence variation. Many bNAb epitopes are composed of 
structurally dynamic components, such as lipid membranes or large glycan moieties. 
For instance, the N88 glycan is oriented towards the viral membrane when bound by 
35O22, but must shift into an orientation that would clash with 35O22 binding to allow 
for 3BC315 to access its epitope (47, 60). As a result, bNAb affinity maturation often 
rigidifies the paratope by hydrogen bonding and/or disulphide bonds within the CDRs. 
This optimization of the “lock-and-key” fit between antigen and antibody, can result in 
increased potency by reductions in binding entropy. Conversely the additional 
flexibility observed for CAP248-2B may contribute to its potency through low 
neutralization plateaus.  
The unusually long CDR-L3 of CAP248-2B was specifically angled towards the viral 
membrane but its tip retains a level of plasticity that may assist in interacting with 
dynamic viral lipids. In this way, the CAP248-2B light chain CDR-L3 performs a similar 
function to the heavy chain CDR-H3 of MPER targeting bNAbs 2F5, Z13e1, 4E10, and 
10E8 which all extend hydrophobic residues at the CDR-H3 loop tips to anchor the 
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antibody in the viral membrane. In addition to sharing a common mechanism of lipid 
recognition, CAP248-2B, 35O22, and MPER bNAbs all approach the HIV-1 trimer very 
close to the viral membrane. These antibodies may require the trimer to alter its 
orientation or position relative to the viral membrane for them to access their epitopes 
(43). As a consequence of this epitope occlusion, MPER bNAbs may not bind well to 
pre-fusion native trimers (61). From our EM docking analyses, it appears that CAP248-
2B recognizes the pre-fusion “closed” state of the HIV-1 envelope trimer. These data 
are supported by the observations that firstly, CAP248-2B binding to Env was not 
enhanced in the presence of sCD4, and secondly, that CAP248-2B could not compete 
with the MPER bNAb 4E10, which prefers recognition of the CD4-induced transition 
intermediate. It remains to be determined what structural rearrangements (if any) in 
the trimer are required for CAP248-2B to properly access its epitope.  
In accordance with its low angle of binding, escape from CAP248-2B occurred in both 
the gp160 cleavage motifs. Of the six identified mutations, only V505M individually 
affected CAP248-2B neutralization. In autologous viruses, mutations at positions 500, 
502, 507, 508, and 509 all occurred by two years post-infection, while variants at 
position 505 were only detectable after three years of infection. Based on these 
kinetics, it is likely that mutations at positions 500, 502, 507, 508, and 509 accumulated 
first in response to earlier members of the CAP248 bNAb lineage, with the eventual 
selection of extremely rare mutations at position 505 by later members of the antibody 
lineage. Similarly, we identified a cluster of autologous gp41 mutations that overlap 
the CAP248-2B epitope, and while these did not affect CAP248-2B neutralization they 
may have played a role in escaping earlier lineage members. Future experiments to 
isolate these early members of the lineage will help to understand how virus-antibody 
co-evolution led to the development of CAP248-2B. In addition, the isolation of more 
potent variants of CAP248-2B should help to explain the mechanisms of incomplete 
neutralization for this new interface targeting antibody.  
In addition to mediating escape from CAP248-2B, mutations in the gp120 C terminus 
conferred partial resistance to PGT151. Based on EM 3D reconstructions PGT151 
does not bind the gp120 C terminus (58), suggesting that these mutations have the 
ability to affect envelope conformation in a way that confers resistance to PGT151. 
Conversely, the gp120 C-terminal mutations also had the unexpected effect of 
dramatically enhancing the neutralization of 35O22 (targeting a membrane proximal 
epitope) and bNAbs targeting the MPER, suggesting that these conformational effects 
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may assist in raising gp41 relative to the membrane (43, 62-65), perhaps by increasing 
the frequency at which membrane associated Env trimers sample a CD4-induced 
conformation, without first having to engage the CD4 receptor. Importantly, this effect 
did not make viruses globally sensitive to HIV-1 antibodies, but was specific for bNAbs 
with membrane proximal epitopes. Incorporating these mutations into membrane 
bound HIV-1 trimer immunogens may therefore improve the antigenicity of bNAb 
epitopes in gp41.  
Overall these data expand the recently identified gp120-gp41 interface supersite to 
include the gp120 C terminus, highlighting the importance of this region as a vaccine 
target. Future experiments should aim to determine whether membrane-bound CS-
Mut trimers successfully engage MPER bNAb precursors, thus overcoming an 
important barrier to the induction of MPER bNAbs. Furthermore, defining additional 
glycan independent mechanisms of envelope heterogeneity will have implications for 
the use of bNAbs in both passive and active immunization strategies.  
Materials and Methods 
Ethics statement  
The CAPRISA Acute Infection study received ethical approval from the Universities of 
KwaZulu-Natal (E013/04), Cape Town (025/2004), and the Witwatersrand 
(MM040202). CAP248 provided written informed consent for study participation.  
CAPRISA 002 Acute Infection cohort 
The CAPRISA Acute Infection cohort is comprised of women at high risk of HIV-1 
infection in KwaZulu-Natal, South Africa (15). Blood samples collected at regular 
intervals from seroconversion through to the initiation of antiretroviral therapy were 
cryopreserved as individually processed PBMC, serum and plasma samples.  
B cell culture 
Cryopreserved CAP248 PBMC were thawed, washed and suspended in medium 
containing 10% foetal bovine serum (FBS) and antibiotics. B cells were enriched by 
negative selection with immunomagnetic beads (Miltenyi), and were cultured at 25 
cells per well in Iscove’s Modified Dulbecco’s Medium (IMDM) containing 10% FBS, 2 
µg/mL CpG2006, 100 units/mL rIL-2, rIL-21 (50 ng/mL) with 3T3msCD40L as feeder 
cells (a gift of Mark Connors) (44), plated at 2500 cells/well in multiple 96 well plates. 
rIL-2 was obtained from the NIH AIDS Reagent Program as provided by Maurice 
Gately (Hoffmann-La Roche). Fresh medium containing growth factors was added 
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after 7 days of culture and after each antibody screening procedure. B cell culture 
fluids were screened from day 14 for neutralizing activity against CAP45 pseudovirus 
in an adaptation of the single-cycle TZM-bl neutralization assay as previously 
described (66).  
Cloning and expression of human immunoglobulin genes 
B cells from wells testing positive for antibody were stored in RNAlater (Ambion). VH, 
Vκ, or Vλ genes were amplified in separate reactions from RNA using a one-step RT-
PCR (Invitrogen SuperScript III kit with Platinum Taq High Fidelity polymerase) with 
previously described primer mixes (67). For expression vector assembly, forward 
primers included a 25 nucleotide non-annealing 5’ tag sequence, which was 
homologous to the immunoglobulin leader sequence at the 3’ end of the CMV 
promoter fragment. Reverse primers were designed to overlap the 5’ end of the 
immunoglobulin constant region for each vector. Linear expression constructs were 
assembled by overlapping PCR between two DNA fragments containing the CMV 
promoter and immunoglobulin leader sequence or the constant region sequences for 
IgG1, kappa or lambda genes followed by a C-terminal BGH poly A sequence. These 
were co-transfected into 293T cells, and supernatant fluids were tested for 
neutralization activity. This step allowed rapid detection of pairs of VH and VL chain 
genes that functioned together to produce antibody. To produce monoclonal 
antibodies, the In-Fusion cloning system (Clontech) was used to insert re-amplified 
pairs of VH and VL gene fragments into pLM2 expression plasmids similar to 
previously described (68), but modified to contain the immunoglobulin leader 
sequence in the linear vectors. Expression plasmids were linearized by restriction 
enzymes acting on sites within the multiple cloning site of plasmid (EcoRI for IgG1 and 
lambda, BsiWI for kappa).  Linearized vectors were then PCR amplified with primer 
pairs designed to create terminal sequences that were homologous to 5’ and 3’ 
terminal sequences of the variable region insert fragments, allowing insertion of the 
VH and VL fragments into linearized plasmids by the activity of the In-Fusion enzyme 
as described (69). The resulting plasmids were transformed in E.coli JM109 cells. A 
previously described strategy was used to identify the correct pair of VH and VL clones 
responsible for antibody production (70). Subsequent sequencing of multiple clones 
showed that only one heavy and one light chain were capable of directing mAb 
synthesis.  
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Cell lines 
CD4+/CCR5+ TZM-bl HeLa cells were obtained from the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH (developed by Dr. John C. 
Kappes, and Dr. Xiaoyun Wu [79,80]). 293T cells were obtained from Dr George Shaw 
(University of Alabama, Birmingham, AL). Adherent cell lines were cultured at 37°C, 
5% CO2, in DMEM containing 10% heat-inactivated fetal bovine serum (Gibco BRL 
Life Technologies) and supplemented with 50 ug/ml gentamicin (Sigma). Cells were 
routinely disrupted at confluency with 0.25% trypsin in 1 mM EDTA (Sigma) every 48-
72 hours. 293F suspension cells were cultured in 293Freestlye media (Gibco BRL Life 
Technologies) at 37°C, 10% CO2, 125 RPM and diluted twice a week to between 0.2 
and 0.5 million cells/mL.  
Single genome amplification 
The single genome amplification of HIV Env has been previously described (71). 
Briefly, CAP248 viral RNA was isolated using the Viral RNA Extraction Kit (QIAGEN), 
to serve as a template for Superscript III Reverse Transcriptase (Invitrogen) in cDNA 
generation. Residual RNA was degraded with RNaseH (Invitrogen) and CAP248 
envelope genes were amplified by a nested PCR approach using Platinum Taq 
(Invitrogen). PCR products were cleaned up (QIAGEN) and sequenced with the ABI 
Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) 
on the ABI 3100 automated genetic analyser, assembled using Sequencher v.4.5 
(Genecodes), and compiled into working alignments in Bioedit v.7.0.5.3. 
Pseudovirus production and site-directed mutagenesis 
Plasmids expressing the HIV Env of interest were co-transfected with pSG3DEnv 
backbone expressing plasmids (obtained from the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH) into 293T cells using PEI-MAX 
40,000 (Polysciences). Cultures were incubated for 48 hours at 37°C, then filtered 
through 0.45 µm and frozen in DMEM, 20% FBS to yield Env-pseudotyped viruses 
capable of a single round of infection only. Mutant envelope genes were generated 
with the QuikChange Lightning Kit (Stratagene), confirmed by DNA sequencing, and 
transfected as above. For the glycan heterogeneity experiments, pseudoviruses were 
grown as above in the presence of 25 M glycosylation inhibitor, or in 293S GnTI(-/-) 
cells.  
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Neutralization assays 
Neutralization assays were performed in TZM-bl cells as previously described (12, 72). 
Neutralization is measured as a reduction in relative light units after a single round of 
pseudovirus infection in the presence of the monoclonal antibody or plasma sample 
of interest. Samples were serially diluted 1:3 and the ID50/IC50 calculated as the dilution 
at which the infection was reduced by 50%.  
Protein production 
For CAP248-2B antibody expression, plasmids separately encoding heavy and light 
chain genes were co-transfected into 293F cells with PEI-MAX 40,000 (Polysciences). 
To make CAP248-2B Fab, the HRV-3C protein cleavage site (GLEVLFQGP) was 
introduced into the heavy chain gene between Fab and Fc fragments by PCR. 
Expressed full length mAb was digested with HRV-3C enzyme (Merck Millipore) at 
25°C for four hours, and then the separated Fab fragments were purified by sequential 
negative selection over protein A, and positive selection by gel filtration using a 
superdex 200 (GE Healthcare). Cells were cultured for seven days in 293Freestyle 
media at 37°C, 10% CO2, then harvested supernatants were 0.22 µm filtered and 
purified using protein A. Trimers were expressed previously described (60), and 
purified from 0.22 µm filtered supernatants with an Ni-NTA column (30 mM Imidazole 
wash and 400 mM Imidazole elution buffers at pH 7), and then by CAP248-2B mAb 
bound to protein A. The Fab-trimer complexes were eluted by digestion with HRV-3C 
(which also removed the His6 tag from gp41), and further purified by gel filtration using 
a superdex 200 column (GE Healthcare).  
Enzyme-Linked Immunosorbent Assay (ELISA) 
HisTagged trimers were coated at 2 µg/mL in PBS onto nickel coated 96 well plates 
(Thermo) for one hour at 25°C. Plates were washed and then probed with serial 
dilutions of HIV-1 monoclonal antibody for one hour at 25°C. This process was 
repeated using an anti-Fc/HRP conjugate to detect trimer-bound antibodies. Antigen-
antibody complexes were detected by incubating with 100 µL of enzyme substrate for 
five minutes and then the reaction was stopped with 25 µL of 1 M HCl. Absorbance 
was read at 450 nm. 
Protein X-ray crystallography 
Concentrated aliquots were stored at 4°C. 576 crystallization conditions were 
screened in 96 well plates (Corning) using the Cartesian Honeybee crystallization 
robot by sitting drop vapour diffusion in 400 nL drops at 25°C containing 50% mother 
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liquor. Crystal hits were hand-optimised in 15 well hanging drop diffusion plates at 
25°C in 1 µL drops containing 50% mother liquor. All crystallographic diffraction data 
was collected at the Advanced Photon Source (Argonne National Laboratory) SER-
CAT ID-22 beamline, at a wavelength of 1.00 Å, 100 K, and processed with HKL2000. 
Model building and refinement was handled with COOT v0.8 and PHENIX v1.9-1692 
software packages respectively, using 5% of the data as an R-free cross validation 
test set, and hydrogens were refined to minimise clashes. The unliganded CAP248-
2B Fab was first crystallized in 10.25% PEG4000, 87.5 mM ammonium sulphate, and 
flash frozen in 25% PEG400 as a cryoprotectant. This crystal diffracted to a resolution 
of 2.0 Å and phasing by molecular replacement was done using PDB-IDs: 4QHK and 
3B2U as search models. We could not reliably build the constant domain for one of 
the two Fabs in the asymmetric unit, which appeared to have considerable mobility 
within the crystal lattice, resulting in poor RSRZ scores for regions of these chains. 
This first structure served as the search model for the second crystal structure 
obtained in 7.5% PEG4000, 12.5% isopropanol, 0.1 M sodium citrate (pH5.6), and 
flash frozen in 30% ethylene glycol as a cryoprotectant, which diffracted with I/αI >2 to 
a resolution of 3.1 Å, with data up to 2.8 Å (PDB-ID: 5F89). All structural images were 
generated in PyMOL Molecular Graphics System, Version 1.3r1edu, Schrödinger 
LLC., or UCSF Chimera (73). 
Negative stain Electron Microscopy (EM) 
BG505-CAP45 SOSIP trimers were incubated with a 6 molar excess of CAP248-2B 
Fab overnight at room temperature and the complexes were diluted to ~0.03 mg/mL 
in Tris-buffered saline prior to application onto a carbon-coated 400 Cu mesh grid 
(Electron Microscopy Sciences) that had been glow discharged at 20 mA for 30 
seconds. The grids were stained with 2% (w/v) NanoW (Nanoprobes) for 7 s, blotted, 
and stained for an additional 15 s. Samples were imaged on an FEI T12 electron 
microscope operating at 120 keV, with an electron dose of ~25 electrons/Å2 and a 
magnification of 52,000x that resulted in a pixel size of 2.05 Å at the specimen plane. 
Images were acquired with Leginon (74), using a Tietz TemCam F416 camera and a 
nominal defocus range of 1000-1500 nm. Stage tilts between -50° and 0° using 10° 
increments were performed to increase the amount of unique views to aid with 3D 
reconstruction. Automated particle picking, stack creation, and initial 2D classification 
were performed in the Appion software suite (75). Classes representing noisy 
alignments, neighboring particles, unbound Fab, or ligand-free trimers were discarded 
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and representative class averages with unique views of the SOSIP-CAP248-2B 
complex were used to generate an initial common-lines model using EMAN2 (76), 
followed by refinement against all 28,215 particles in Sparx (77), with C3-symmetry 
imposed. The resolution of the final reconstruction is ~20 Å based on a Fourier shell 
correlation of 0.5. Two-dimensional back projections of the final 3D models were 
generated using EMAN (76).  
Cell-surface binding assay 
The CAP45.2.00.G3J (Genbank: EF203960) env plasmid was codon optimised 
(GenScript) and truncated at the cytoplasmic tail to increase surface Env content (78). 
Following restriction digest cloning this plasmid was transiently transfected using 
TrueFect-MAX (United Biosystems) into HEK/293T cells. Two days after transfection, 
cells were labelled with Live/Dead Fixable Aqua Dead Cell Stain (Life Technologies) 
followed by biotinylated CAP248-2B and serially diluted unlabelled competitor 
antibodies (CAP248-2B, 3BC315, 35O22, PGT151. 8ANC195, 4E10, and control 
antibody Palivizumab). After incubation and three washes with 5% FBS in PBS, cells 
were stained with Streptavidin-PE (Life Technologies) at a 1:300 dilution. Reverse 
competition assays were also performed with biotinylated 3BC315, 35O22, PGT151, 
8ANC195 and 4E10 and serially diluted CAP248-2B or Palivizumab. Cells were 
analysed on a BD FACS Aria II (Becton Dickinson) and binding was measured as the 
median fluorescence intensity (MFI) for each sample minus the MFI of the cells stained 
with the detection antibody only.  
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Supplementary Figure 1: Conformational differences between unliganded 
structures of CAP248-2B explained by crystal packing   
(A) Predicted germline alleles, CDR3 lengths, and mutation frequencies for CAP248-
2B from the IMGT database (79). (B) Cartoon representation of neighboring 
asymmetric units from the 2 Å resolution dataset showing crystal packing in the 
antibody paratope. The heavy and light chains of Fab1 in the first unit are colored 
forest and olive green respectively, and in the second unit dark and light blue. The 
CDR-H3 (red), and CDR-L3 (yellow) are indicated. (C) Data collection and refinement 
statistics for the two unliganded CAP248-2B Fab crystal structures.  
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Supplementary Figure 2: Selection pressure in conserved bNAb epitopes does 
not contribute to escape from CAP248-2B 
(A) Alignments of five different regions in CAP248 autologous envelope sequences at 
nine weeks (study enrolment), 1, 2, 3 and 3.5 years post-infection, that overlap with 
previously described broadly neutralizing antibody epitopes in V2 (boxed in purple), 
C1/C2 (boxed in brown), V3 (boxed in orange), and the MPER (boxed in blue). N-
linked glycosylation sequons are shaded grey. (B) CAP248-2B neutralization of the 
heterologous strain CAP45, compared to mutants containing potential autologous 
escape mutations identified from CAP248 sequences. CAP45 already had the N230 
glycan, so the N230D reverse mutation was tested (grey dashed line). Percent 
inhibition (y-axis) is plotted against CAP248-2B concentration (x-axis). (C) CAP248-
2B neutralization of CAP45 and mutants with known resistance mutations to common 
bNAbs (not identified in CAP248 sequences), plotted as in B.  
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Supplementary Figure 3: Negative stain EM data, and approximation of the 
CAP248-2B epitope.  
(A) Reference-free 2D class averages (B) 2D back-projections of the final model (C) 
3D reconstructions (top and side views) (D) Fourier Shell Correlation (FSC) curves 
with estimated resolution using an FSC cut-off of 0.5. Samples were stained with 
NanoW. (E) Elements of gp120 and gp41 within 5 Å of CAP248-2B, based on EM 
docking. Different gp41 protomers are labelled as A and B superscript (F) ELISA 
binding of CAP248-2B and related CDR-L3/H1 mutants to chimeric BG505gp120-
CAP45gp41 SOSIP trimer. Positive and negative controls CAP256-VRC26.09 and 
F105 are shown. The wild-type amino acids are indicated in the legend for both CDR-
L3 and CDR-H1. 
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Supplementary Figure 4: CAP248-2B blocks the binding of 35O22, 3BC315, and 
PGT151 to cell surface envelope trimers 
(A) Comparisons of gp120-gp41 interface bNAbs bound to SOSIP trimers by EM. The 
CAP248-2B bound trimers are shown in solid grey surface, while 35O22, PGT151, 
8ANC195, and 3BC315 bound trimers are shown with mesh representation colored as 
in Figure 5. Both top views and side views are shown. (B) Binding of labelled HIV-1 
bNAbs 35O22, 3BC315, PGT151, 8ANC195, and 4E10 to cell-surface anchored HIV-
1 trimers by flow cytometry, in the presence of increasing concentration of unlabeled 
CAP248-2B. Median fluorescence intensity (MFI) is shown on the y-axis, and 
increasing concentrations of CAP248-2B or palivizumab are plotted on the x-axis. 
Decreasing MFI signals correspond to increasing competition by CAP248-2B. 
  
Chapter 3: Isolation of a Novel gp120-gp41 Interface Antibody     Wibmer et al., 2016 
3 108 
 
 
 
 
 
 
 
Supplementary Figure 5: Glycan dependence of known gp120-gp41 interface 
targeting bNAbs.  
(A) Neutralization of CAP45 by broadly neutralizing antibodies that target the gp120-
gp41 interface, when compared to CAP248-2B epitope proximal glycan mutants. The 
S613A mutant that removed the glycan at N611 but maintains the amino acid side 
chain properties is shown with red dashed lines and open circles. Percentage inhibition 
is plotted on the y-axis versus CAP248-2B antibody concentration on the x-axis. (B) 
Neutralization of the CAP45 N611D single mutant, and various N611D including 
double glycan mutants, plotted as in A. 
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 Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased 
Plasma Neutralization Breadth through Sequential Recognition of 
Multiple Epitopes and Immunotypes 
Constantinos Kurt Wibmer1,2, Jinal N. Bhiman1,2, Elin S. Gray1¤, Nancy Tumba1, Salim  
S. Abdool Karim3, Carolyn Williamson4, Lynn Morris1,2, Penny L. Moore1,2* 
Abstract 
Identifying the targets of broadly neutralizing antibodies to HIV-1 and understanding how these 
antibodies develop remain important goals in the quest to rationally develop an HIV-1 vaccine. We 
previously identified a participant in the CAPRISA Acute Infection Cohort (CAP257) whose plasma 
neutralized 84% of heterologous viruses. In this study we showed that breadth in CAP257 was 
largely due to the sequential, transient appearance of three distinct broadly neutralizing antibody 
specificities spanning the first 4.5 years of infection. The first specificity targeted an epitope in the 
V2 region of gp120 that was also recognized by strain-specific antibodies 7 weeks earlier. Specificity 
for the autologous virus was determined largely by a rare N167 antigenic variant of V2, with viral 
escape to the more common D167 immunotype coinciding with the development of the first wave 
of broadly neutralizing antibodies. Escape from these broadly neutralizing V2 antibodies through 
deletion of the glycan at N160 was associated with exposure of an epitope in the CD4 binding site 
that became the target for a second wave of broadly neutralizing antibodies. Neutralization by these 
CD4 binding site antibodies was almost entirely dependent on the glycan at position N276. Early 
viral escape mutations in the CD4 binding site drove an increase in wave two neutralization breadth, 
as this second wave of heterologous neutralization matured to recognize multiple immunotypes 
within this site. The third wave targeted a quaternary epitope that did not overlap any of the four 
known sites of vulnerability on the HIV-1 envelope and remains undefined. Altogether this study 
showed that the human immune system is capable of generating multiple broadly neutralizing 
antibodies in response to a constantly evolving viral population that exposes new targets as a 
consequence of escape from earlier neutralizing antibodies. 
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Introduction 
 
Neutralizing antibodies are the principal 
correlate of protection for most 
preventative vaccines. Designing suitable 
vaccine immunogens to elicit these types 
of antibodies has been relatively simple 
for conserved pathogens such as 
smallpox and other DNA viruses. For 
more diverse pathogens like HIV-1, the 
neutralizing antibodies elicited by 
vaccination or during natural infection are 
largely strain-specific and therefore would 
not be protective against globally 
circulating viral variants [1–5]. The HIV-1 
envelope glycoprotein spikes mediate 
viral entry and are the sole targets for 
neutralizing antibodies. The spikes are 
trimeric, made up of three non-covalently 
associated gp41-gp120 heterodimers, 
each with a conserved core that mediates 
infection of CD4+ T cells. Functionally 
conserved sites are protected by 
extensive glycosylation, and large solvent 
exposed hypervariable structures (the 
V1–V5 loops, and the a2-helix in C3) [6]. 
All HIV-1 infected individuals develop 
strain-specific neutralizing antibodies 
which target these sequence variable 
regions, but only a quarter develop 
broadly neutralizing antibodies [7–11], 
which will likely be needed for a 
preventative HIV-1 vaccine.  
Author Summary 
Four sites of vulnerability for broadly 
neutralizing antibodies to HIV-1 have 
been identified thus far. How these 
broadly reactive antibodies arise, and 
the host-pathogen interactions that drive 
the affinity maturation necessary for 
neutralization breadth are poorly 
understood. This study details the 
sequential development of three distinct 
broadly neutralizing antibody responses 
within a single HIV-1 infected individual 
over 4.5 years of infection. We show 
how escape from the first wave of 
antibodies targeting V2 exposed a 
second site that was the stimulus for a 
new wave of glycan dependent broadly 
neutralizing antibodies against the CD4 
binding site. These data highlight how 
antibody evolution in response to viral 
escape mutations served to broaden the 
host immune response to these two 
epitopes. Finally, we document a third 
wave of neutralization that targets an 
undefined epitope that did not appear to 
overlap with the four known sites of 
vulnerability on the HIV-1 envelope. 
These data support the design of 
templates for sequential immunization 
strategies aimed at increasing 
neutralization breadth through the 
recognition of multiple epitopes and their 
immunotypes. 
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To engineer an envelope immunogen that 
can specifically elicit these antibodies, the 
HIV-1 vaccine research field has adopted 
a strategy based largely on rational 
design: identifying the targets for these 
broadly cross-reactive antibodies, and 
elucidating the pathways that promoted 
their development.  
Plasma mapping strategies and the 
isolation of monoclonal antibodies have 
defined four major targets for broadly 
neutralizing antibodies on the HIV-1 
glycoprotein [7–10,12–20]. The CD4 
binding site (CD4bs) of gp120 and the 
membrane proximal external region 
(MPER) of gp41 are glycan independent 
epitopes, while the V1/V2 sub-domain 
and the co-receptor/V3 site on gp120 are 
sites of vulnerability for glycan binding 
antibodies (predominantly at positions 
N156/N160 and N301/N332 respectively) 
[14–16]. Both CD4bs antibodies and co-
receptor/V3 antibodies bind well to 
monomeric gp120, while MPER 
antibodies bind to a linear peptide in 
gp41. This makes it possible to adsorb out 
their neutralization activity from plasma 
with various recombinant proteins. In 
contrast the epitope for V2 antibodies 
(such as PG9/16) consists of two anti-
parallel b-sheets (B- and C- strands) of a 
Greek key motif, and the glycans therein, 
that is preferentially formed on the native 
trimer. This region is critically important 
for the gp120-gp120 interactions that 
stabilize the envelope glycoprotein spike 
in its unliganded conformation, and 
therefore cannot be readily adsorbed 
[16,21]. Various sub-epitopes within each 
of these four major sites of vulnerability 
have also been identified through subtle 
differences in the mechanism of 
neutralization [22]. For instance 
antibodies targeting the CD4bs can be 
sub-divided into two groups: those that 
are sensitive to the D368A and/or E370A 
mutations in the CD4 binding loop a3 
(such as VRC01); and those that are 
dependent on amino acids D474, M475, 
and/or R476 in a5 termed CD4bs/DMR 
(such as HJ16) [23–26]. Despite this 
detailed knowledge, epitope mapping 
strategies have failed to identify the 
neutralization targets in a subset of 
plasma samples [7– 9,17,19,27,28]. The 
antibodies mediating breadth in these 
samples could target sub-epitopes within 
one of the four sites of vulnerability or they 
may target entirely novel epitopes. 
In the CAPRISA 002 Acute Infection 
Cohort, we previously identified seven 
individuals with broadly neutralizing 
antibodies. In five cases we were able to 
map the plasma antibody specificities to 
known epitopes (two targeted N332, two 
the V2 epitope, and one the MPER) [7]. In 
this study we have focused on one of the 
individuals (CAP257) for which the target 
Chapter 4: HIV-1 Viral Evolution Drives Neutralizing Breadth Wibmer et al., 2013 
October 2013 | Volume 9 | Issue 10 | e1003738 114 
was undefined. Heterologous and 
autologous neutralization data as well as 
viral sequences from longitudinal 
samples were used to identify the 
epitopes for CAP257 broadly neutralizing 
antibodies. We showed that heterologous 
neutralization in CAP257 was conferred 
by three distinct, sequentially occurring 
antibody waves, two of which were 
mapped to epitopes in V2 and the CD4bs 
respectively. While individuals with more 
than one broadly neutralizing antibody 
specificity have been previously identified 
[29–31], there is little information on how 
the dynamic relationship between host 
and pathogen contributed to the 
development of antibodies targeting 
multiple epitopes. We have shown 
previously that escape from strain-
specific neutralizing antibodies can drive 
the formation of epitopes for broadly 
neutralizing antibodies [32]. Here we 
found that viral escape from broadly 
neutralizing antibodies targeting V2 
promoted the development of a second 
broadly neutralizing antibody response 
targeting a glycan dependent epitope in 
the CD4bs. We also identified early 
escape mutations from both the V2 and 
CD4bs antibodies that drove an increase 
in the neutralization breadth of CAP257 
plasma. These findings have implications 
for the design of HIV-1 vaccine antigens 
and sequential immunization strategies. 
Results  
 
The broadly neutralizing activity of 
CAP257 develops in three distinct 
waves 
We have previously described the 
development of neutralization breadth in 
CAP257 using longitudinal plasma 
samples from HIV1 seroconversion to 
three years post-infection (p.i.) [7]. Here, 
we extended this analysis until the start of 
anti-retroviral therapy at four and a half 
years p.i. (Figure 1A). Longitudinal 
plasma was tested against the 
autologous CAP257 virus amplified from 
the earliest available time point (7 weeks 
p.i.), the subtype C consensus sequence 
(ConC) [33], 4 Tier 1b viruses, and 39 Tier 
2 viruses [34]. Autologous neutralizing 
antibodies appeared by 14 weeks of 
infection with a peak titer at two years of 
1:6,754. This was followed by the 
neutralization of heterologous viruses 30 
weeks after infection. CAP257 
neutralized 84% of the heterologous 
viruses at three years (174 weeks) with 
neutralization breadth of 100% against 
subtype A (6/6 viruses), 96% against 
subtype C (25/26 viruses, including 
ConC), and 50% against subtype B (6/12 
viruses). The titers of these broadly 
neutralizing antibodies peaked and 
waned in three separate waves. 
The first wave of neutralization breadth 
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(typified by CAP63) peaked at 67 weeks 
p.i. with a maximum titer of 1:1,493 and 
exclusively neutralized subtype C viruses 
(Figures 1A and 1B – red curves). Wave 
1 titers dropped to as low as 1:145 by 149 
weeks of infection. As this early 
heterologous neutralization began to 
wane, CAP257 plasma gained the 
capacity to neutralize additional subtype 
C viruses as well as several subtype A 
and B viruses (Figures 1A and 1B – blue 
and green curves). This second wave 
(typified by Q842) peaked at 122 weeks 
p.i. with titers as high as 1:8,565 against 
RHPA that dropped to 1:1,254 by 213 
weeks of infection. Finally, a third wave of 
heterologous neutralization (represented 
by Du156) appeared by 149 weeks p.i. 
and peaked at 213 weeks p.i. (Figure 1B 
– brown curve). This third wave was also 
largely subtype C specific. These data 
suggested that the neutralization breadth 
of CAP257 plasma was mediated by at 
least three distinct antibody specificities. 
To identify the targets of each of the three 
broadly neutralizing antibody specificities 
in CAP257 plasma we first assessed 
whether they targeted epitopes in 
monomeric gp120 (such as the CD4bs or 
N301/N332 glycans). We adsorbed out 
the gp120 binding antibodies in plasma 
samples from the peak neutralizing 
activity of each wave using recombinant 
ConC gp120 coupled to tosyl-activated 
magnetic beads (Figure 1C). The 
adsorbed plasma was compared with 
untreated plasma for activity against a 
heterologous virus neutralized by each 
wave. Neutralization by wave 1 (67 weeks 
p.i.) and wave 3 (213 weeks p.i.) was not 
affected by adsorption with monomeric 
gp120 (Figure 1C – red and brown 
curves), however neutralization by wave 
2 antibodies (122 weeks p.i.) could be 
partially adsorbed with the ConC gp120 
protein (Figure 1C – blue curve). The 
neutralizing activity of wave 2 could also 
be equally adsorbed with a core gp120 
lacking the hypervariable loops V1/V2 
and V3 (Figure 1C – green curve). These 
data supported our hypothesis that 
CAP257 heterologous neutralization was 
mediated by more than one neutralizing 
antibody specificity, two of which were 
largely subtype C specific and targeted an 
epitope not present on monomeric gp120, 
and a third whose epitope in gp120 was 
more conserved across clades and did 
not require the hypervariable loops V1/V2 
or V3.  
Wave 1 broadly neutralizing 
antibodies target V2 
The inability of gp120 to adsorb out wave 
1 neutralization suggested these 
antibodies might recognize the trimer 
specific epitope in V1/V2 defined by  
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PG9/16 [16]. Therefore, we performed 
mapping studies using ConC, which was 
neutralized by all three waves of 
neutralizing antibodies (Figure 2A – red 
curve). Seven mutations in the V2 region 
(F159A, N160A, R166A, K168A, K169E, 
K171A, and I181A) each abrogated wave 
1 neutralization, but did not significantly 
affect the titers of waves 2 or 3 (Figure 2A 
– purple curves). In contrast, a D167N 
mutation resulted in enhanced 
neutralization by wave 1 antibodies, but 
did not significantly affect the titers of 
waves 2 or 3 (Figure 2A – orange curve). 
 
 
Figure 1. CAP257 broadly neutralizing antibodies develop sequentially in three 
distinct waves.  
A) Longitudinal neutralization of the autologous CAP257 virus (black) and 37 heterologous viruses 
neutralized by CAP257 plasma at titers .1:100. The ID50 titers (y-axis) are shown versus weeks p.i. 
(x-axis). Three peaks in heterologous neutralization titers at 67, 122, and 213 weeks p.i. are 
indicated with dotted lines. Heterologous viruses are colored according to subtype (A = green, B = 
blue, C = red). B) A summary of the three waves of heterologous neutralization defined by a 
representative virus, superimposed over the neutralization kinetics shown in Figure 1A. Wave 1 
was subtype C specific and is colored red. Wave 2 neutralized viruses from all three clades and is 
colored green. Wave 3 is colored brown. C) Adsorption of heterologous neutralization at the peak 
of each of the three waves. Percentage inhibition (y-axis) is shown versus plasma dilution (x-axis). 
Untreated plasma is shown in black, blank beads in grey and beads coated with recombinant 
proteins are shown in red (wave 1), blue/green (wave 2) or brown (wave 3). 
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A second mutation (L165A) also resulted 
in significant neutralization enhancement 
at all the time points tested, including 
those preceding breadth (Figure 2A – 
grey curve), suggesting that this mutation 
resulted in general neutralization 
sensitivity. Overall, these data indicated 
that wave 1 antibodies (but not waves 2 
or 3) targeted residues in the V2 region. 
To define whether the V2 epitope 
recognized by CAP257 plasma 
antibodies overlapped with that of known 
broadly neutralizing antibodies to this site, 
we tested the sensitivity of PG9/16, 
CH01-04, and PGT145 to the same ConC 
V2 mutations described above and 
compared them to CAP257 neutralizing 
antibodies at the peak of wave 1 activity, 
67 weeks p.i. (Figure 2B). Of the seven 
mutations that abrogated CAP257 
neutralization only two (N160A and 
K169E) resulted in complete resistance to 
all the antibodies tested, consistent with 
previous data [35,36]. Neither the 
monoclonal antibodies nor CAP257 wave 
1 antibodies were sensitive to deletion of 
the N156 glycan (through the S158A 
mutation) in ConC. Lastly, mutations at 
two hydrophobic amino acids in V2 
(F159A and I181A) that do not form part 
of the PG9 epitope as defined by the 
crystal structure [37], had a significant 
effect on the neutralization of monoclonal 
antibodies targeting V2, and CAP257 
wave 1 antibodies.  
Immunotype switching within V2 
precedes the development of wave 1 
antibodies 
To define escape from wave 1 
neutralizing antibodies, we examined 
sequences from the V2 region of CAP257 
over time. Using single genome 
amplification (SGA) we obtained 125 full 
envelope sequences from twelve time 
points between 7 and 213 weeks p.i., and 
focused on the N160 glycan and the 
cationic C-strand in V2 that are the targets 
of wave 1 antibodies (Figure 3A). 
Interestingly, the earliest virus (7 weeks 
p.i.) had an asparagine at position 167. 
This N167 residue is rare, occurring in 
only 5.6% (196 of 3,478) of sequences in 
the Los Alamos National Laboratory 
(LANL) HIV sequence database. By the 
time of the earliest detectable 
heterologous neutralization (30 weeks 
p.i., maximum titer of 1:49) mutations in 
sites forming part of the wave 1 V2 
epitope were already apparent in 6/14 
autologous sequences at positions R166, 
K169, and Q170 (Figure 3A). Of the 
remaining eight sequences, six exhibited 
other mutations either in the N160 
glycosylation sequon or the V1/V2 C- 
strand. This rapid selection pressure in 
the C-strand of V1/V2 was sometimes an 
N167D mutation (4/14 autologous 
sequences) that was unlikely to be 
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Figure 2. The first wave of broadly neutralizing antibodies targets residues in 
the V2 region.  
A) Longitudinal neutralization of ConC V2 mutants. ConC wild-type (wt) is shown in red. V2 mutants 
F159A, N160A, R166A, K168A, K169E, K171A, and I181A that abrogated wave 1 neutralization 
are shown in purple. The D167N mutation that enhanced wave 1 neutralization is shown in orange, 
while the L165A mutation that resulted in universal neutralization sensitivity is shown in grey. The 
timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized above as 
horizontal lines, while the peak titers at each wave are indicated with dotted lines. ID50 titers (y-
axis) are shown versus weeks p.i. (x-axis). B) The dependence of CAP257 wave 1 neutralizing 
antibodies (at 67 weeks p.i.) on V2 residues in ConC, compared to monoclonal antibodies PGT145, 
CH01-04, and PG9/16. Complete abrogation of neutralization is colored red, 2–10 fold reductions 
in IC50 are colored yellow, and >10 fold reductions in IC50 are coloured orange.  
 
selected for by wave 1 broadly 
neutralizing antibodies, as all the 
heterologous viruses neutralized by wave 
1 had a D167 residue. Since the V1/V2 
region is a common target of strain-
specific neutralizing responses [38–41], 
these data suggested the possibility of an 
earlier neutralizing response targeting 
N167 in V2 that preceded the 
development of broadly neutralizing 
antibodies. Wave 1 mapping data (Figure 
2A) further supported this possibility 
because the reverse D167N mutation 
enhanced the neutralization of ConC by 
wave 1 antibodies only, and resulted in 
earlier neutralization kinetics (Figure 2A – 
orange curve).To test this we selected an 
envelope from 174 weeks p.i. (CAP257 3 
yr) that was completely resistant to 
CAP257 neutralizing antibodies 
(consistent with ongoing neutralization 
escape), and back-mutated the V1/V2 
region to match the earliest sequence 
from 7 weeks p.i. (Figure 3B). The 
neutralization sensitivity of the back-
mutated virus, CAP257 3 yr(V1/V2s), was 
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then compared to the parental CAP257 3 
yr virus using longitudinal plasma 
samples. In contrast with the resistant 
CAP257 3 yr virus, the back-mutated 
V1/V2 virus (CAP257 3 yr(V1/V2s)) 
became sensitive to neutralization at 23 
weeks p.i. (Figure 3B – black curve). This 
suggested the emergence of a strain-
specific V1/V2 response 7 weeks prior to 
the development of wave 1 broadly 
neutralizing antibodies at 30 weeks p.i. 
To establish whether these strain-specific 
V1/V2 neutralizing antibodies targeted 
the same epitope as wave 1 broadly 
neutralizing antibodies, we introduced 
selected escape mutations (N167D, 
N160D/ S and K169E) into the sensitive 
CAP257 3 yr(V1/V2s) back-mutated 
envelope. Introduction of the N167D 
mutation (Figure 3B – orange curve), a 
common V2 change at 30 weeks p.i., 
shifted the timing of autologous V1/V2 
neutralization to overlap with the 
emergence of wave 1 broad 
neutralization. The introduction of 
N160D/S mutations that deleted the N160 
glycan (Figure 3B – purple curves), 
further shifted autologous neutralization 
to overlap with the emergence of wave 2 
neutralizing antibodies. Finally, when the 
K169E mutation was introduced (Figure 
3B – pink curve), autologous V1/V2 
neutralization titers were completely 
abrogated. As the N160A and K169E 
mutations in ConC also completely 
abrogated neutralization by CAP257 
wave 1 broadly neutralizing antibodies 
(Figure 2B) these data suggest that the 
strain-specific V2 neutralizing antibodies 
in CAP257 plasma targeted the same site 
of vulnerability that was later targeted by 
wave 1 broadly neutralizing antibodies. 
However the strain-specific V2 antibodies 
recognized the rare N167 immunotype of 
V2 present in the CAP257 infecting virus. 
Following an early N167D escape 
mutation at this site, V1/V2 neutralization 
became N167 independent, allowing 
recognition of the more common D167 
immunotype. This switch in the fine 
specificity of CAP257 V2 antibodies 
correlated with the emergence of broadly 
neutralizing wave 1 antibodies.  
Escape from wave 1 antibodies 
exposed the epitope for wave 2 
neutralization 
Wave 1 broadly neutralizing antibodies 
were completely dependent on the glycan 
at N160 (Figure 2A). Viral escape from 
wave 1 neutralizing antibodies by deletion 
of this glycan first occurred at 54 weeks 
p.i. (in 37.5% of the sequences), 
immediately prior to the development of 
wave 2 neutralizing antibodies (Figure 3A 
– pie charts). This escape pathway 
persisted at 93 weeks p.i. (in 30% of 
sequences), but by 122 weeks p.i., at the 
peak of wave 2 activity, alternative  
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Figure 3. Escape from V2 neutralizing antibodies drives the formation/exposure 
of broadly neutralizing antibody epitopes in the CD4bs.  
A) Amino acid sequence alignment of the CAP257 B- and C- strands in the V1/V2 sub-domain of 
gp120, from twelve time points. The number of envelopes per unique V2 sequence is shown on 
the right. The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is 
summarized to the left with vertical lines. Potential N-linked glycans are shaded grey, and the 
presence (grey slices) or absence (red slices) of the N160 glycan within the population at each 
time point is shown with pie charts to the right. B) CAP257 develops a strain-specific V2 response 
prior to wave 1 broadly neutralizing antibodies. Neutralization of an autologous virus amplified from 
174 weeks p.i. (CAP257 3 yr), is shown in grey. The V1/V2 region of this virus was back-mutated 
to the earliest known sequence (CAP257 3 yr(V1/V2s)) shown in black. Longitudinal neutralization 
of the N167D, N160D/S, and K169E mutants is shown in orange, purple, and pink respectively. 
The timing of wave 1 (red), wave 2 (green), and preceding strain-specific V2 (black) neutralization 
is summarized above with horizontal lines. ID50 titers (y-axis) are shown versus weeks p.i. (x-
axis). C) Wave 2 neutralization of Q842 (green) or RHPA (blue) wild-type (wt) viruses, and their 
N160K mutants (purple). The timing of wave 1 (red), wave 2 (green), and wave 3 (brown) 
neutralization is summarized above as in Figure 1B. ID50 titers (y-axis) are shown versus weeks 
p.i. (x-axis).  
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escape pathways existed, and all 
sequences contained the N160 glycan. 
The transient nature of this highly 
effective escape pathway suggested that 
deletion of the N160 glycan had a 
deleterious effect on the virus. 
A potential mechanism for this came from 
the observation that deleting the N160 
glycan (critical to wave 1 neutralization) in 
the CAP257 3 yr(V1V2s) virus conferred 
slight neutralization sensitivity coinciding 
temporally with wave 2 (Figure 3B – 
purple curves). These data suggested 
that mutations at N160 exposed the wave 
2 epitope. To examine whether loss of the 
N160 glycan enhanced CAP257 wave 2 
neutralization we selected two viruses, 
Q842 and RHPA, which were neutralized 
at high titer by wave 2 but resistant to 
wave 1, and deleted the N160 glycan in 
each. The effect of these N160K 
mutations was assessed longitudinally 
using CAP257 plasma. While the timing of 
RHPA N160K and Q842 N160K 
neutralization by CAP257 was not altered 
compared to the wild-type viruses, these 
mutant viruses were neutralized 2–8 fold 
more potently by wave 2 antibodies 
(Figure 3C – purple curves). A similar 2 
fold increase in titer was shown at the 
peak of wave 2 activity when the N160 
glycan was deleted in ConC (Figure 2A – 
purple closed circles). As deletion of the 
N160 glycan in the autologous virus 
occurred prior to the development of wave 
2 neutralizing antibodies, these data 
suggest that this particular escape 
pathway from wave 1 neutralizing 
antibodies may have contributed to the 
development of wave 2 antibodies, 
possibly by better exposing the epitope. 
Therefore, after the development of wave 
2, the K169E mutation that also allowed 
escape from wave 1 broadly neutralizing 
antibodies, but did not enhance wave 2 
neutralization, was preferentially selected 
over deletion of the N160 glycan (Figure 
3A). 
Wave 2 neutralizing antibodies target 
the CD4bs 
The V1/V2 sub-domain of gp120 plays an 
important role in shielding the envelope 
from neutralization. More specifically, 
several modifications in V1/V2 
(particularly at N-glycosylation sites) have 
been implicated in either shielding or 
exposing the CD4bs to neutralizing 
antibodies [42–51]. As escape from wave 
1 at N160 enhanced neutralization by 
wave 2, these data suggested the CD4bs 
as the target for wave 2 antibodies. This 
was supported by the adsorption data 
(Figure 1C), showing that wave 2 
neutralizing antibodies bound the core 
gp120 protein. Therefore we examined 
envelope sequences from 191 weeks p.i. 
for selection pressure in the conserved 
CD4bs (Figure 4). Three mutations in the 
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D-loop (N276D/S, T278A/K and N279D) 
and one at the base of V5 in the b23 sheet 
of C4 (R456W) dominated the viral 
population at this time point. Both the D-
loop and V5 have been previously 
implicated in resistance to CD4bs 
antibodies [52–54]. To assess whether 
these CD4bs mutations mediated 
resistance to wave 2 neutralization, we 
introduced the three most common 
mutations (T278A, N279D and R456W) 
simultaneously into two heterologous 
viruses (Q842 and RHPA) neutralized by 
wave 2 but not by wave 1 (Figure 1A), and 
tested them against plasma from the peak 
of wave 2 activity (122 weeks p.i.). The 
mutants were at least 20 fold more 
resistant to neutralization at this time point 
than the wild-type viruses, confirming the 
role of CD4bs mutations in escape from 
wave 2 antibodies (Figure 5A). 
To further characterize the epitope 
targeted by wave 2 antibodies, we 
assessed the dependence of wave 2 
binding on the D368 residue in a3 (critical 
for VRC01-like antibodies), and residues 
474/475/476 in a5 (critical for HJ16-like 
antibodies) by adsorption studies. The 
D368R or D474A / M475A / R476A 
mutations were separately introduced into 
ConC gp120, and compared to the wild-
type protein for their ability to adsorb out 
the neutralizing activity against Q842 and 
RHPA at peak wave 2 titers. Both mutant 
gp120s (Figure 5B – yellow and brown 
bars) adsorbed out a significant fraction of 
the neutralizing activity against Q842 and 
RHPA, equivalent to that adsorbed by 
wild-type gp120 (Figure 5B – white bars). 
These data suggested that CAP257 
antibody binding was not dependent on 
these residues in the a3 and a5 helices. 
CAP257 neutralization could not be 
adsorbed with the RSC3 protein used to 
isolate VRC01, which binds weakly to the 
HJ16 class of CD4bs antibodies [55].  
CAP257 wave 2 antibodies recognize 
a glycan dependent epitope in the 
CD4bs, also recognized by the 
monoclonal antibody HJ16 
Of the three changes identified above as 
mediating escape from wave 2 
antibodies, N279 and R456 make contact 
with CD4, while T278 forms part of an 
adjacent glycosylation sequon [6]. This 
glycosylation sequon is conserved in 96% 
(n=3,475) of envelope sequences in the 
LANL HIV sequence database. Its 
deletion via N276D/S or T278A/K 
mutations in later viruses (Figure 4) for 
wave 2 escape was therefore striking, and 
suggested a possible role for glycan 
recognition by CAP257 wave 2 
antibodies. To examine wave 2 glycan 
binding, we expressed an RHPA core 
gp120 in GnTI(-/-) 293S cells, which 
allowed for deglycosylation of the protein 
using Endo-H, and assessed the ability of  
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Figure 4. Accumulating escape mutations from wave 2 broadly neutralizing 
antibodies occur in the CD4 binding site.  
Amino acid sequence alignment of the CAP257 D loop and b23 regions of gp120 from seven time 
points. The number of envelopes per unique sequence is shown on the right. The timing of wave 
1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized to the left with vertical 
lines. Amino acids contacting CD4 (as described in [57]) are indicated above the sequence 
alignment, with ○ denoting backbone only contacts, ☼ denoting side chain contacts, and ● denoting 
main chain and side chain contacts. Potential N-linked glycans are shaded grey. The frequency of 
escape mutations at position 279 (orange slices), in the N276/T278 glycosylation sequon (purple 
slices), or at position 456 (pink slices) for each time point is shown with pie charts. 
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both glycosylated and deglycosylated 
proteins to adsorb out wave 2 
neutralization activity. While neutralizing 
activity against RHPA was efficiently 
adsorbed with the glycosylated RHPA 
gp120 core (Figure 5C – white bars), the 
deglycosylated protein only adsorbed out 
a fraction of that activity (Figure 5C – 
purple bars) confirming the importance of 
glycans in wave 2 antibody binding. 
Similarly HJ16 was not adsorbed by the 
deglycosylated protein suggesting glycan 
dependence. In contrast, VRC01 was 
adsorbed equally effectively by both 
proteins. 
To assess in more detail the role of the 
N276 glycan in wave 2 neutralization, we 
generated four mutants in RHPA, 
comparing the effects of two conservative 
mutations (N276Q, T278S) with the 
effects of two alanine substitutions 
(N276A, T278A) in the N276 glycosylation 
sequon (Figure 5D – boxed in purple). 
Both alanine mutations significantly 
affected wave 2 peak titers by 18- and 30-
fold respectively. The N276Q mutation 
which deleted the glycan but retained the 
amino acid properties at position 276 also 
affected wave 2 neutralization by 21-fold 
(a similar effect to the N276A mutation), 
while the T278S mutation that retained 
the N276 glycan had no effect on 
neutralization. These data suggested that 
sensitivity to wave 2 neutralization was 
largely dependent on the glycan at 
position 276, rather than the N276 amino 
acid side chain. We also assessed the 
effect of the remaining two autologous 
mutations in the CD4bs (N279D and 
R456W) identified above (Figure 5D). The 
N279D mutation alone had a relatively 
small 2 fold effect on neutralization, 
suggesting only a minor role in escape 
from wave 2. When an alanine was 
substituted at position 279 instead, wave 
2 neutralization was enhanced. The 
R456W mutation had a more significant 
10-fold effect on CAP257 neutralization, 
but was still less effective than the glycan 
deleting mutations at positions 276/278 
which were the major escape mutations. 
We next compared the epitope for 
CAP257 wave 2 neutralizing antibodies 
with that of HJ16 (CD4bs/DMR) and 
VRC01 (CD4bs). Both monoclonal 
antibodies were profoundly affected by 
the R456W mutation (514- and 30-fold 
respectively). Like CAP257, HJ16 
neutralization was significantly dependent 
on the glycan at position 276 with glycan 
deleting mutations (N276Q/A and T278A) 
resulting in a 74–106 fold increase in IC50 
(Figure 5D). This dependence on the 
N276 glycan distinguished both CAP257 
and HJ16 from VRC01, for which 
neutralization was slightly enhanced (2–3 
fold) when the glycan was removed. This 
effect on VRC01 is consistent with  
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Figure 5. CAP257 broadly neutralizing antibodies bind a glycan-dependent 
epitope in the CD4bs, also targeted by mAb HJ16.  
A) Effect of escape mutations T278A, N279D, and R456W in the CD4bs on wave 2 neutralization. 
ID50 titers at 122 weeks p.i. (y-axis) are shown for Q842 and RHPA (black bars), or the 
corresponding triple mutants (red bars). B) Adsorption of peak wave 2 titers (122 weeks p.i.) with 
wild-type or mutant gp120 proteins. The residual neutralizing activity in the adsorbed plasma 
samples is shown as ID50 titers (y-axis) for the heterologous viruses Q842 and RHPA. Untreated 
plasma is shown in black, plasma adsorbed with blank beads in grey, plasma adsorbed with ConC 
gp120 in white, plasma adsorbed with D368R mutant gp120 in yellow, plasma adsorbed with 
D474A/M475A/R476A triple mutant gp120 in brown, and plasma adsorbed with RSC3 protein in 
orange. C) Effect of glycosylation on the CAP257 wave 2 epitope in RHPA. The fold reduction in 
titer (y-axis) of adsorbed samples from 122 weeks p.i. are shown for CAP257 wave 2, HJ16, and 
VRC01. Plasma adsorbed with blank beads is shown in grey, gp120 core in white, and 
deglycosylated gp120 core in purple. D) The dependence of CAP257 wave 2 neutralizing 
antibodies (at 122 weeks p.i.) on D-loop and b23 residues/ glycans in RHPA, compared to the 
monoclonal antibodies HJ16, VRC01, and 10E8. The effect of N276 glycan mutations on CAP257 
plasma is boxed in purple, and the presence or absence of a glycan at N276 for each mutation is 
indicated. Fold effects between 2–10 are yellow, 10–100 colored orange, and .100 colored red. 
Triple* is the triple mutant described in A. E) Effect of glycosylation on the HJ16 epitope. The 
ELISA OD at 450 nm is shown (yaxis) versus antibody concentration (x-axis). Binding to 
glycosylated or deglycosylated gp120 core is shown with solid or open circles respectively. The 
monoclonal antibodies tested were VRC01 (green), b12 (yellow), HJ16 (purple), 2G12 (blue), and 
CAP88-3468L (grey). 
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previous studies showing that deleting the 
N276 glycan exposes the CD4 binding 
site to neutralization by VRC01 or b12 
[52,56]. Introducing all three CAP257 
escape mutations identified above 
therefore had a compensatory effect on 
VRC01 resistance (8-fold compared to 
30-fold effect for R456W alone), but 
completely abrogated HJ16 
neutralization, confirming the similarities 
between HJ16 and CAP257 plasma. 
Despite these overall similarities, some 
differences were apparent between 
CAP257 wave 2 antibodies and HJ16, 
such as the preference of HJ16 for the 
threonine at position 278 and the 
asparagine at position 279. Unlike 
CAP257, the N279A mutation did not 
enhance HJ16 neutralization but rather 
resulted in a 4-fold reduction in titer. 
These data may suggest minor contacts 
between HJ16 and the amino acid side 
chain at position 279. The N279A 
mutation also significantly affected 
VRC01 neutralization (76-fold), 
consistent with either asparagine or 
aspartic acid residues at position 279 
being directly contacted by W100B in the 
CDR3-H3 of VRC01 [52,57]. 
To clarify the role of glycan binding we 
tested three CD4bs neutralizing 
antibodies (VRC01, b12, and HJ16) in 
ELISA for binding to either the 
glycosylated or deglycosylated RHPA 
gp120 core proteins (Figure 5E). The 
neutralizing antibody 2G12 has a well-
defined glycan epitope and was used as 
a positive control [58– 62], while CAP88-
3468L (a V3 binding antibody) served as 
a negative control [63]. Deglycosylation 
significantly affected the binding of both 
2G12 and HJ16 (Figure 5E – blue and 
purple curves), but did not significantly 
affect binding of either VRC01 or b12 
(Figure 5E – green and yellow curves) to 
the RHPA gp120 core. These data 
confirmed the glycan binding properties of 
HJ16, and suggest that both CAP257 
wave 2 neutralizing antibodies and HJ16 
have a glycan dependent mechanism of 
neutralization at the CD4bs.  
Early wave 2 escape mutations drive 
an increase in neutralization breadth 
While the simultaneous introduction of 
T278A, N279D, and R456W mutations 
into heterologous viruses Q842 and 
RHPA made them resistant to wave 2 
neutralization at 122 weeks p.i. (Figure 
5A), when each mutation was introduced 
individually into RHPA the results were 
varied (2–30-fold reductions in titer) with 
no single mutation resulting in complete 
escape (Figure 5D). These data 
suggested that escape from wave 2 
required a combination of all three 
mutations. Longitudinal sequence 
analysis showed that the N279D mutation 
emerged first at 93 weeks in 5% of the 
Chapter 4: HIV-1 Viral Evolution Drives Neutralizing Breadth Wibmer et al., 2013 
October 2013 | Volume 9 | Issue 10 | e1003738 127 
population, followed by N276D/S glycan 
deleting mutations at 122 weeks in 36% 
of the population, and then by substitution 
of the R456 residue with a bulky amino 
acid side chain (H, Y, or W) at 161 weeks 
p.i. in 17% of the population (Figure 4).  
To better characterize their contributions 
to escape from wave 2 antibodies, each 
mutation (T278A, N279D, and R456W) 
was introduced separately into Q842 and 
RHPA and compared to the wild-type 
viruses. The N279D mutation (Figure 6 – 
orange curves) had a significant effect 
only at the beginning of wave 2 activity 
against Q842, shifting the earliest 
heterologous neutralization of Q842 from 
80 weeks to 93 weeks p.i. (with a 5-fold 
effect on titers at 107 weeks p.i.). The 
mutation also affected the titers against 
RHPA by 2–3 fold. This suggested an 
initial dependence on N279, with later 
wave 2 antibodies being less vulnerable 
to mutations at this residue. This reduced 
dependence on N279 coincided with the 
emergence of the N279D mutation at 93 
weeks p.i. (Figure 6 – orange dotted lines) 
providing a mechanism for maturation of 
the antibody response. The T278A 
mutation (Figure 6 – purple curves) that 
deleted the N276 glycan conferred almost 
complete resistance in Q842, and shifted 
the earliest neutralization of RHPA from 
67 to 122 weeks p.i. The R456W mutation 
(Figure 6 – pink curves) did not result in a 
further right shift in the neutralization 
curves for RHPA relative to the T278A 
mutation, but did affect the neutralization 
kinetics of Q842 relative to the wild-type 
or N279D mutant viruses. As with the 
N279D mutation, these changes in the 
fine specificity of the maturing antibody 
response reflected the emergence of 
either T278A or R456W mutations in 
longitudinal autologous sequences 
(Figure 6 – purple and pink dotted lines 
respectively). 
These data are consistent with 
accumulating resistance to wave 2, and 
suggest that after each successive round 
of escape, new antibody variants 
emerged that were able to neutralize first 
the N279D mutant, and then later 
autologous viruses with additional 
polymorphisms at positions 276, 278, or 
456. We wished to determine whether the 
ability to neutralize escaped viral variants 
correlated with increased wave 2 
neutralization breadth. Heterologous 
viruses neutralized by wave 2 were 
divided into two groups, those neutralized 
at 67 weeks p.i. (early wave 2 
neutralization), and those first neutralized 
at 93 weeks p.i. (late wave 2 
neutralization) after the emergence of 
initial wave 2 escape mutations (Figure 
7A). Viruses also neutralized by wave 1 
were omitted as the overlapping titers 
confounded this analysis.  
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Figure 6. Changes in the fine specificity of CAP257 CD4bs antibodies in 
response to autologous escape mutations.  
The longitudinal neutralization of Q842 (green) or RHPA (blue) wild-type (wt) viruses was 
compared to the neutralization of N279D (orange), T278A (purple), and R456W (pink) mutant 
viruses. The triple mutant (T278A/N279D/R456W) from Figure 5A is also shown in red. ID50 titers 
(y-axis) are shown versus weeks p.i. (x-axis). Dotted lines indicate the time points at which each 
mutation (D=N279D, A=T278A, W=R456W) first appears in the autologous sequences (colored as 
above). 
 
Inspection of the envelope sequences 
(particularly in the D-loop) showed that all 
of the viruses neutralized by early wave 2 
antibodies had the N279 immunotype 
(Figure 7B – boxed in orange). In contrast 
44% of viruses neutralized by later wave 
2 antibodies had the D279 immunotype. 
Furthermore, of the viruses neutralized by 
later wave 2 antibodies, one (Q259) 
lacked the N276 glycan and four others 
also had additional non-conservative 
mutations at positions 273–275 in the N-
terminus of the D-loop. (Figure 7B – 
boxed in blue) that may also affect early 
wave 2 neutralization. These data 
suggest that wave 2 escape mutations 
guided maturation of the CD4bs 
response, enabling later wave 2 
antibodies to neutralize additional 
heterologous viruses and ultimately 
resulting in the increased neutralization 
breadth of CAP257 plasma.  
The wave 3 neutralizing antibody 
target is distinct but undefined 
Like wave 1, wave 3 neutralization could 
not be adsorbed with monomeric gp120, 
suggesting that these antibodies targeted 
a quaternary epitope, or an epitope in 
gp41. To assess whether wave 3 was a 
distinct antibody specificity, or a re-
emergence of wave 1 antibodies, we 
selected a virus (Du156) that was 
sensitive to waves 1 and 3, and less 
sensitive to wave 2 (Figure 8A – red 
curve). Resistance to wave 1 (V2) and 
wave 2 (CD4bs) neutralizing antibodies 
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was established by introducing the N160K 
and T278A mutations identified above.  
The resulting virus (Du156 N160K/ 
T278A) remained sensitive to wave 3 
neutralization only (Figure 8A – brown 
curve), suggesting that wave 3 differed 
from wave 1 (which was completely 
abrogated by the N160K mutation). To 
confirm this, we introduced additional V2 
mutations (R166A, K168A, K169E, 
K171A) known to abolish wave 1 
neutralization, into the Du156 double 
mutant. None of these mutations 
significantly affected the titers of wave 3 
neutralizing antibodies (Figure 8A – 
yellow curves), confirming that the 
epitope for wave 3 antibodies did not 
overlap with the wave 1 V2 epitope. An 
N332A mutation was also introduced to 
confirm that wave 3 antibodies did not 
target this glycan.  
 
 
 
Figure 7. Maturation of the wave 2 CD4bs response results in the increased 
neutralization breadth of CAP257 plasma. 
A) Summary of early (green) and late (blue) heterologous neutralization by wave 2 antibodies 
superimposed over the individual virus neutralization kinetics (grey). Viruses neutralized by V2 
antibodies in wave 1 have been excluded. ID50 titers (y-axis) are shown versus weeks p.i. (x-axis). 
B) Amino acid sequence alignment of heterologous viruses depicted in (A). The timing of early or 
late heterologous neutralization is shown on the left with horizontal lines. The N276 glycan is 
shaded grey, and position 279 is boxed in orange. The frequency of the N279D mutation or 
disrupted N276 glycosylation within the two groups is shown with orange or purple pie slices 
respectively. The N-terminal region of the D loop is boxed in blue. 
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To test whether CAP257 wave 3 
neutralizing antibodies targeted the 
MPER region of gp41, we coupled MPER 
peptides to magnetic beads and used 
them to adsorb out MPER specific binding 
antibodies in CAP257 plasma. The 
adsorption of MPER binding antibodies 
(Figure 8B) did not affect neutralization of 
Du156 or the double mutant Du156 
N160K/T278A (with wave 1 and 2 
resistance mutations) when compared to 
untreated plasma (Figure 8C). Thus, 
while we cannot exclude the possibility 
that wave 3 antibodies target V2 or gp41, 
these neutralizing antibodies appear to 
target an epitope distinct from any of the 
four known sites of vulnerability in the 
HIV-1 envelope. 
 
 
 
 
Figure 8. Wave 3 neutralizing antibodies target a novel epitope.  
A) Neutralization of Du156 wild-type (wt) virus by longitudinal CAP257 serum is shown in red. The 
timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized above as 
horizontal lines, with peak titers of each wave indicated with dotted lines. The Du156 N160K/T278A 
double mutant is shown in brown. Du156 triple mutants N160K/ T278A/(R166A, K168A, K169E, 
K171A, or N332A) are shown in yellow. ID50 titers (y-axis) are shown versus weeks p.i. (x-axis). B) 
Adsorption of MPER binding antibodies. OD (450 nm) against the MPER peptide is shown (y-axis) 
versus plasma dilution (x-axis). Untreated plasma is shown in black, and MPER adsorbed plasma 
in brown. C) Adsorption of wave 3 neutralization by MPER (colored as above). ID50 neutralization 
titers at 213 weeks p.i. (yaxis) are shown for Du156 and Du156 N160K/T278A. 
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CAP257 viruses develop resistance to 
known broadly neutralizing 
antibodies  
We hypothesized that the selection 
pressure exerted by these broadly 
neutralizing antibodies would impact on 
the overall neutralization phenotype of 
CAP257 viruses over time. Therefore we 
tested the sensitivity of envelopes from 7, 
30, 54, 93, and 174 weeks p.i. to broadly 
neutralizing monoclonal antibodies 
targeting the four major epitopes (Figure 
9). The 7 week clone from CAP257 was 
sensitive to neutralization by anti-V2 
antibodies, but following the development 
of wave 1 V2 neutralizing antibodies, 
CAP257 viruses became more resistant 
to PG9 and PGT145 neutralization. The 7 
week clone was also highly sensitive to 
HJ16 (0.02 mg/mL) and VRC01 (1.79 
mg/mL), however clones isolated after the 
emergence of wave 2 neutralization were 
increasingly resistant to neutralization by 
antibodies targeting the CD4bs. CAP257 
viruses from all the time points selected 
were sensitive to neutralization by 
antibodies targeting the MPER or 
N301/N332, neither of which was targeted 
by broadly neutralizing antibodies in 
CAP257 plasma. These data confirm that 
CAP257 developed broadly neutralizing 
antibodies targeting the CD4bs and V2. 
Furthermore, the finding that CAP257 
viruses remained sensitive to 
neutralization by antibodies targeting 
N301/N332 and the MPER supports our 
hypothesis that wave 3 antibodies target 
a novel epitope on the HIV-1 envelope.  
Discussion 
 
A preventative HIV-1 vaccine remains the 
most likely way to end the HIV pandemic, 
but current envelope immunogens have 
so far failed to elicit broadly neutralizing 
antibodies. Nonetheless, the 
development of cross-reactive antibodies 
in approximately a quarter of HIV-1 
infected individuals has confirmed that the 
human immune system can make such 
antibodies. Much emphasis has been 
placed on mapping the targets for these 
broadly neutralizing antibodies in an 
attempt to define viral vulnerabilities for 
immunogen design. Here we analyzed 
CAP257 heterologous neutralization over 
a 4.5 year period, describing the 
sequential evolution of three distinct 
broadly neutralizing antibody specificities 
within a single HIV-1 subtype C infected 
individual. We further showed how early 
viral evolution in the context of broadly 
reactive antibodies may profoundly shape 
the maturing antibody response towards 
enhanced neutralization breadth, in a 
process that may inform immunogen 
design.
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Figure 9. Accumulating resistance of CAP257 clones to broadly neutralizing 
monoclonal antibodies targeting V2 and the CD4bs.  
The sensitivity of nine CAP257 clones from 7, 30, 54, 93, and 174 weeks p.i. to broadly neutralizing 
antibodies targeting the four known sites of vulnerability was measured in a TZM-bl assay. The 
timing of wave 1 (red), wave 2 (green), and wave 3 (brown) neutralization is summarized above 
with arrows. Increases in IC50 relative to the 7 week clone are colored as follows: 5–10-fold (yellow), 
.10-fold (orange), and complete neutralization resistance (red). 
 
These data have been summarized in 
Figure 10. The CAP257 autologous virus 
efficiently escaped all three specificities. 
As a consequence the antigenic stimulus 
for these broadly neutralizing antibodies 
declined, and antibody titers dropped at 
least ten fold within a three year period. 
The waxing and waning of the broadly 
neutralizing specificities in CAP257 
confounded our previous attempts to map 
the targets at 174 weeks p.i. [7], when the 
titers of the three waves overlapped 
significantly. As most mapping studies 
are cross-sectional, the number of 
individuals who mount multiple broadly 
neutralizing antibody responses may 
therefore be underestimated, and may 
make up a significant proportion of those 
plasma samples that remain undefined. 
Nonetheless we were able to finely map 2 
of the 3 specificities in this study and 
showed that they targeted known sites of 
vulnerability on the HIV-1 envelope. 
Wave 1 antibodies targeted the site 
defined by PG9/16 and were completely 
dependent on N160 and K169, consistent 
with previous data describing PG9/16 
dependence on the N160 glycan and the 
positively charged amino acids in the C-
strand of V1/V2 [16,37]. In general the 
epitope for wave 1 antibodies showed a 
larger footprint in V2 when compared to 
the epitopes of other monoclonal 
antibodies targeting this site, but behaved 
most similarly to PGT145.
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Figure 10. Summary of the role of CAP257 viral evolution in shaping broadly 
neutralizing antibody responses.  
The schema depicts the evolution of plasma neutralizing antibodies and viral escape mutations 
over 240 weeks. Each of the three waves of CAP257 broadly neutralizing antibodies is shown. 
Text boxes highlight the key events described herein. Env trimers (EMD-5447) were drawn in 
UCSF-Chimera, and spheres were used to approximate the location of escape mutations. 1) 
Strain-specific antibodies (dotted orange line) developed at 23 weeks, targeting a V2 epitope 
overlapping with known V2 antibodies (eg: PG9). 2) Strain-specific V2 antibodies were escaped 
by an N167D mutation (D being the global consensus at this site). 3) Broadly neutralizing 
antibodies targeting V2 (wave 1 – red curve) developed at 30 weeks. 4) Escape from wave 1 
antibodies through deletion of the N160 glycan was associated with exposure of an epitope in the 
CD4bs. 5) At 67 weeks broadly neutralizing antibodies targeting the CD4bs (wave 2 – green curve) 
develop. Neutralization was N276 glycan dependent and sensitive to an N279D mutation. 6) The 
N279D change emerges at 93 weeks, significantly affecting wave 2 neutralization at this time point. 
7) Wave 2 neutralization becomes independent of position 279, which was associated with 
increased neutralization breadth. 8) Mutations that delete the N276 glycan (as well as an R456W 
change) escape wave 2 antibodies. 9) CAP257 develops a third broadly neutralizing antibody 
specificity that could not be mapped to any of the four known antibody targets. 
 
However none of the antibodies or 
plasma tested was sensitive to removal of 
the N156 glycan. While the crystal 
structure of PG9 with V2 showed 
interactions with the N156 glycan [37], the 
effect of deleting the N156 glycan is 
variable [16,35,36]. This effect might be 
explained by recent data suggesting that 
PG9 recognizes two N160 glycans (from 
two adjacent gp120 monomers) but only 
one N156 glycan [64]. The requirement 
for a lysine at position 169 explains the 
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subtype C specificity of CAP257 wave 1 
antibodies, as this residue is less 
common in subtypes A and B [35]. Wave 
2 antibodies targeted a known site of 
vulnerability, the CD4bs, but these 
antibodies had an unusual glycan 
dependent mechanism of neutralization. 
CAP257 wave 2 and HJ16 neutralization 
were both highly dependent on 
interactions with the N276 glycan. N276 is 
also the recently described target of the 
broadly neutralizing antibody 8ANC195, 
but this antibody does not appear to 
interact with the CD4bs [65]. While glycan 
dependence for neutralization has not 
previously been described for CD4bs 
antibodies, including HJ16, Balla-
Jhagjhoorsingh et al. reported that 
resistance to HJ16 involved an N276D 
mutation (deleting the glycan) with a 
hundred-fold drop in titer [66], providing 
support for our observations. The glycan 
dependence of both HJ16 and CAP257 
wave 2 antibodies suggests that they 
target a similar sub-epitope of the CD4bs 
that may be better defined as an N276 
glycan dependent class of neutralizing 
antibodies, which is distinct from the 
VRC01 class. Recently it was shown that 
related variants of VRC01 do bind the 
glycan at N276 [67], however this glycan 
is not a major determinant of 
neutralization sensitivity to VRC01 
[52,56,57,68]. Rather, N276 has been 
described as a protective shield for the 
CD4bs, and deleting this glycan 
enhances the neutralization of CD4bs 
antibodies VRC01 and b12 [52,56]. 
Removing N276 from gp120 also enabled 
binding to the predicted germline antibody 
for VRC01, which otherwise did not bind 
to gp120, and has been suggested as a 
modification for candidate vaccine 
immunogens [69,70]. However, the 
glycan shield is increasingly recognized 
as a major site of vulnerability on the HIV-
1 envelope [15,16], and as with the 
glycans at N156/N160 and N301/N332, 
conservation of the N276 glycan 
bordering the CD4bs may make it a 
promising target for vaccine design. 
Characterization of viral escape from 
CAP257 CD4bs antibodies indicated that 
deletion of the N276 glycan alone did not 
confer complete resistance. Escape 
required accumulating mutations in the 
CD4bs site, consistent with the functional 
conservation of this epitope. In addition to 
deletion of the N276 glycan, CAP257 
escape occurred through a R456W 
mutation that also significantly affected 
neutralization by VRC01 (30 fold) and 
HJ16 (514-fold). This mutation likely 
contributed towards the evolution of 
VRC01 resistant virus by 174 weeks. 
W456 is extremely rare, occurring in only 
0.78% (27 of 3,481) of sequences in the 
LANL HIV-1 sequence database. A 
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crystal complex for HJ16 is not available, 
however the structure of VRC01 bound to 
its epitope showed that this antibody does 
not make significant contact with the 
R456 side chain in gp120, but rather 
hydrogen bonds with the R456 backbone 
carbonyl group. This suggests that the 
R456W mutation provides an indirect 
mechanism for resistance. The highly 
conserved R456 side chain can make 
hydrogen bonds with backbone carbonyl 
groups of amino acids at position 277 and 
278 in the D-loop, as well as hydrogen 
bonds with E466 side chain in b24, C-
terminal to V5 (Figure 11). Loss of these 
bonds and localized conformational 
changes to accommodate a bulky 
tryptophan residue may destabilize this 
critical component of the CD4bs epitope 
[52,56,71]. This study adds to data 
showing that the immune system can 
target multiple conserved epitopes [29–
31]. It is striking that in three of these four 
studies, antibodies targeted both V2 and 
the CD4bs (donors CH219, AC053, and 
CAP257), suggesting an association 
between these two epitopes. Indeed, 
there is a well-documented relationship 
between V1/V2 and the CD4bs. The 
V1/V2 region protects the receptor 
binding sites from neutralization [42–51], 
and also interacts with V3 at the 
trimerization domain to hold the CD4bs in 
its pre-liganded conformation [21]. The 
crystal structures of monoclonal 
antibodies PG9, CH58, and CH59 bound 
to their epitopes in V2 show that the 
conformation of the V1/V2 sub-domain 
may vary significantly, but the factors that 
govern these conformational states are 
not known [37,72]. In CAP257, deletion of 
the N160 glycan increased exposure of 
the CD4bs. It is possible that certain 
immunotypes of the V1/V2 epitope, such 
as the rare mutations at N160 or D167 
described here, shifted the equilibrium of 
V1/V2 toward conformations that better 
exposed the CD4bs to neutralizing 
antibodies. This is supported by previous 
observations that introduction of the 
N160K and D167N mutations 
simultaneously into JR-FL resulted in a 
50-fold increase in neutralization 
sensitivity to CD4bs antibodies [73]. 
CAP257 was infected with the less 
common N167 variant, and therefore 
following escape from V2 wave 1 
antibodies a similar conformational state 
(D/S160, N167) would have been 
presented to the immune system. Our 
data suggest that this escape pattern 
further exposed the glycan dependent 
CD4bs sub-epitope. Although vaccination 
with the K160 and/or N167 immunotype 
may improve antibody responses to the 
CD4bs site, antibodies induced to the V2 
epitope would be relatively strain-specific, 
like monoclonal antibody 2909 that  
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Figure 11. The R456 side chain stabilizes the CD4bs epitope through hydrogen bonding.  
A diagram of the 93TH057 gp120 crystal structure (pdb file 4JKP) shown in an orientation similar 
to the angle of approach for CD4. The crystalized part of the N276 attached glycan (GlcNAc2Man4) 
is shown with purple spheres. The D-loop is shown in green, the V5 loop is shown in cyan, and the 
R456 residue is shown in pink. Oxygen atoms are colored red, and nitrogen atoms blue. The inset 
shows a magnified view of the interaction between R456 and residues in the Dloop or the b24 
strand. Putative hydrogen bonds are shown with dotted orange lines. The image was created using 
The PyMOL Molecular Graphics System, Version 1.3r1edu, Schrodinger LLC 
 
recognizes the K160 immunotype and is 
therefore specific for SF162 [74]. In 
CAP257, switching from N167 to the more 
common D167 residue resulted in escape 
from the strain-specific response to V2, 
and this coincided with the development 
of a much broader response targeting the 
same epitope. Sequential immunization 
may be a useful strategy to promote the 
broadening of the B-cell response. 
Recently Murphy et al. showed that two 
light chain variants paired with a single 
heavy chain of a strain-specific 
neutralizing antibody differentially 
neutralized early autologous envelopes 
[75]. While evolution of that strain-specific 
epitope did not affect the development of 
broadly neutralizing antibodies in this 
individual, the data supports the 
possibility that viral evolution might 
facilitate the neutralization of amino acid 
variants within a given epitope. Similarly, 
we have previously shown in an individual 
who developed broadly neutralizing 
antibodies to the V2 region that viral 
escape drove a maturation of the antibody 
response towards recognizing multiple V2 
variants [35]. Here we show that 
emergence of an aspartic acid at position 
279 preceded a broadening of the B-cell 
response to the CD4bs. The N279 and 
D279 amino acid variants of the CD4bs 
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are equally common among sequences in 
the LANL HIV-1 database (50% and 48% 
respectively, n=3,479), and preferential 
neutralization of either immunotype would 
halve the neutralization breadth of an 
antibody. CAP257 wave 2 neutralizing 
antibodies and HJ16 were somewhat 
sensitive to the N279D change. However 
the resistance of D279 containing viruses 
to CAP257 antibodies was rapidly lost 
after the emergence of the N279D escape 
mutation. Therefore, like the N167D 
mutation in V2 described for wave 1, this 
change in the fine specificity of CAP257 
antibodies coincided with an increase in 
the neutralization breadth of the CD4bs 
response. We hypothesize that position 
N279 was non-critical for antibody 
binding, and despite temporarily 
facilitating neutralization escape, the 
N279D mutation then promoted affinity 
maturation by reducing the dependence 
of CAP257 antibodies on this amino acid. 
This adds to recent data suggesting a 
major role for viral evolution in the 
development of neutralization breadth to 
the CD4bs [76]. These data support the 
possibility that a sequential immunization 
strategy would enhance neutralization 
breadth by systematically presenting 
common variants in a given epitope. Such 
residues would have to be noncritical to 
antibody binding allowing for the evolution 
of higher affinity variants that would in turn 
recognize multiple immunotypes. Overall 
these data highlight how interactions 
between the host immune system and 
viral escape mutations shaped the 
development of broadly neutralizing 
antibodies. The escape pathways 
identified here that led to the increased 
breadth of neutralization for both V2 and 
CD4bs antibodies provide potential 
pathways for generating broadly 
neutralizing antibodies. Further defining 
these pathways through the isolation of 
monoclonal antibodies will provide 
valuable insight into how these types of 
antibodies could be elicited using 
sequential immunization in a vaccine 
setting. 
 
Materials and Methods 
 
Ethics statement  
The CAPRISA Acute Infection study 
received ethical approval from the 
Universities of KwaZulu-Natal (E013/04), 
Cape Town (025/2004), and the 
Witwatersrand (MM040202). CAP257 
provided written informed consent for 
study participation. 
CAPRISA 002 Acute Infection cohort 
participant  
The CAPRISA Acute Infection cohort is 
comprised of women at high risk of HIV-1 
infection in KwaZulu-Natal, South Africa 
[77]. Here we studied one individual 
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(CAP257) from seven weeks p.i. through 
four and a half years of infection, until she 
started anti-retroviral therapy. During this 
time she had an average viral load of 
60,784 copies/mL and an average CD4 
count of 498 cells/ mL. Plasma samples 
collected at 30 time points were used in 
this study. 
Single genome amplification  
The amplification of envelope genes from 
single HIV-1 RNA genomes has been 
previously described [78]. Viral RNA was 
isolated from CAP257 plasma using a 
Viral RNA Extraction Kit (QIAGEN), and 
cDNA was synthesized with Superscript 
III Reverse Transcriptase (Invitrogen). 
The reaction product was treated with 
RNase H (Invitrogen) and envelope 
genes were amplified by nested PCR with 
Platinum Taq (Invitrogen). Amplicons 
were purified with a PCR Clean-up Kit 
(QIAGEN) and single genome 
amplification confirmed by DNA 
sequencing using the ABI PRISM Big Dye 
Terminator Cycle Sequencing Ready 
Reaction kit (Applied Biosystems) and an 
ABI 3100 automated genetic analyzer. 
The full-length env sequences were 
assembled and edited using Sequencher 
v.4.5 (Genecodes) and Bioedit v.7.0.5.3. 
Cell lines  
The TZM-bl cell line engineered from 
CXCR4-positive HeLa cells to express 
CD4, CCR5, and a firefly luciferase 
reporter gene (under control of the HIV-1 
LTR) was obtained from the NIH AIDS 
Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH 
(developed by Dr. John C. Kappes, and 
Dr. Xiaoyun Wu [79,80]). The 293T cell 
line was obtained from Dr George Shaw 
(University of Alabama, Birmingham, AL). 
Cells were cultured at 37°C, 5% CO2 in 
DMEM containing 10% heatinactivated 
fetal bovine serum (Gibco BRL Life 
Technologies) with 50 ug/ml gentamicin 
(Sigma) and disrupted at confluency by 
treatment with 0.25% trypsin in 1 mM 
EDTA (Sigma). 
Pseudovirus production  
Selected envelope sequences were re-
amplified from first round nested PCR 
products (described above) with PfuUltra 
II (Stratagene), purified by a Gel 
Extraction Kit (QIAGEN) and cloned into 
pcDNA3.1 (Invitrogen). The envelope 
plasmids were co-transfected into 293T 
cells using FuGENE 6 (Roche) with the 
pSG3DEnv backbone (obtained from the 
NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, 
NIAID, NIH). Cultures were incubated for 
48 hours to produce Envpseudotyped 
viral stocks that were filtered through 0.45 
mm and frozen in DMEM supplemented 
with 20% FBS. Mutant envelopes were 
generated with the QuikChange Lightning 
Kit (Stratagene) and confirmed by DNA 
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sequencing (as above). 
Neutralization assay  
The TZM-bl neutralization assay has 
been described previously [4,81]. It 
measures a reduction in relative light units 
generated by a single round of infection in 
TZM-bl cells with Env-pseudotyped 
viruses after pre-incubation with 
monoclonal antibodies or a plasma 
sample of interest. Samples were serially 
diluted 1:3 and the ID50 calculated as the 
dilution at which the infection was 
reduced by 50%. 
Protein expression and adsorptions  
Plasmids encoding Histidine tagged 
recombinant envelope proteins were 
transfected into 293T cells using 
polyethylenimine 25 kDa (Polysciences). 
Recombinant proteins were expressed 
and purified as previously described [9]. 
Aliquots of 400 mg each were coupled to 
MyOne Tosyl-activated magnetic 
Dynabeads (Invitrogen) at 37°C pH 9.5 
overnight, and then blocked with 0.5% 
BSA in 0.05% Tween20 PBS overnight at 
37uC. Protein coupled beads were 
incubated with 200 mL of plasma (diluted 
1:20) for two hours at 37°C, then the 
beads were removed magnetically and 
the remaining plasma assessed for 
binding and neutralizing antibodies using 
ELISA and neutralization assays 
respectively. 
Enzyme Linked Immunosorbent Assay 
(ELISA)  
Protein antigens were coated at 4 mg/mL 
onto high binding 96 well ELISA plates 
(Corning) overnight at 4°C. All 
subsequent steps were carried out in 5% 
fat-free milk, 0.05% Tween20 in PBS for 
1 hour at 37°C. The plates were blocked 
and then probed with serial dilutions of the 
adsorbed plasma or specific monoclonal 
antibodies, biotinylated goat anti-human 
polyclonal antibodies (KPL), and an anti-
biotin monoclonal conjugated to HRP 
(Calbiochem). Antigen-antibody 
complexes were detected by incubating 
with 100 mL 1-Step Ultra TMB-ELISA 
(Thermoscientific) for five minutes and 
then the reaction was stopped with 25 mL 
1 M H2SO4. Absorbance was read at 450 
nm on a VERSAmax tunable microplate 
reader (Molecular devices). 
Protein deglycosylation  
Plasmid encoding the RHPA gp120 core 
was transfected with polyethylenimine-
MAX 40 kDa (Polysciences) into GnTI(-/-
) 293S cells and purified using two step 
lectin chromatography and Ni-NTA affinity 
chromatography. Protein was assessed 
for purity and conformation by SDS-
PAGE and ELISA. 1 mg of the RHPA core 
gp120 was deglycosylated overnight at 
37°C in 500 mM sodium chloride, 100 mM 
sodium acetate pH 5.5 with 0.5 U of Endo-
H. Glycans were removed through buffer 
exchange into PBS using Vivaspin 20 mL 
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concentrators (Sartorius stedim). 
Deglycosylation was confirmed by SDS-
PAGE and sandwich ELISA (described 
above) using lectins as a capture protein. 
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Abstract 
All HIV-1 infected individuals develop strain-specific neutralizing antibodies to their 
infecting virus, which in some cases mature into broadly neutralizing antibodies. 
Defining the epitopes of strain-specific antibodies that overlap with conserved sites of 
vulnerability might provide mechanistic insights into how broadly neutralizing 
antibodies arise. We have previously described an HIV-1 clade C infected donor, 
CAP257, who developed broadly neutralizing plasma antibodies targeting an N276 
glycan-dependent epitope in the CD4 binding site. The initial CD4 binding site 
response potently neutralized the heterologous tier-2 clade B viral strain RHPA, which 
was used to design resurfaced gp120 antigens for single B cell sorting. We report the 
isolation and structural characterization of CAP257-RH1, an N276 glycan-dependent 
CD4 binding site antibody, representative of the early CD4 binding site plasma 
response in CAP257. A cocrystal structure of CAP257-RH1 bound to RHPA gp120 
revealed critical interactions with the N276 glycan, loop D, and V5, but not with aspartic 
acid 368, similar to HJ16 and 179NC75. This antibody was derived from IGHV3-33 
and IGLV3-10 genes, and neutralized RHPA but not the CAP257 transmitted/founder 
virus. Its narrow neutralization breadth was attributed to a binding angle that was 
incompatible with glycosylated V5 loops, present in almost all HIV-1 strains including 
the CAP257 transmitted/founder virus. Deep sequencing of autologous CAP257 
viruses however, revealed minority variants early in infection that lacked V5 glycans. 
These glycan-free V5 loops likely resulted in unusual holes in the glycan shield that 
may have been necessary for initiating this N276 glycan-dependent CD4 binding site 
B cell lineage. 
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Importance 
The conserved CD4 binding site on gp120 is a major target for HIV-1 vaccine design, 
but key events in the elicitation and maturation of different antibody lineages to this 
site remain elusive. Studies have shown that strain-specific antibodies can evolve into 
broadly neutralizing antibodies, or in some cases act as helper lineages. Therefore 
characterizing the epitopes of strain-specific antibodies will help to inform the design 
of HIV-1 immunogens to elicit broadly neutralizing antibodies. In this study we isolate 
a narrowly neutralizing N276 glycan-dependent antibody, and use x-ray 
crystallography and viral deep sequencing to describe how gp120 lacking glycans in 
V5 might have elicited these early glycan-dependent CD4 binding site antibodies. 
These data highlight the importance of glycan holes in the elicitation of B cell lineages 
targeting the CD4 binding site.  
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Introduction 
Neutralizing antibodies to the HIV-1 envelope (Env) glycoprotein generally appear in 
all individuals within months of infection (1-4). These antibodies target highly sequence 
variable epitopes that are fully accessible on pre-fusion Env trimers, such as the 
immunodominant, solvent exposed, hypervariable regions V1 to V5 (2, 3, 5-8). As a 
result, these early neutralizing antibodies are strain-specific for the 
transmitted/founder virus, and rapidly select for escape mutants that drive Env 
diversification (6). Broadly neutralizing antibodies (bNAbs) that are able to cross-
neutralize diverse HIV-1 strains by targeting structurally/functionally conserved 
regions of Env develop in some individuals later in infection (9-14). Animal studies 
have shown that bNAbs have the capacity to prevent infection, and are likely the types 
of antibodies that will need to be elicited by an HIV-1 vaccine (15, 16). Significant effort 
has therefore gone into designing bNAb-initiating immunogens, and understanding 
how bNAb precursors become broadly neutralizing. Studies defining the ontogeny of 
bNAbs have shown that they can develop from strain-specific precursors through 
affinity maturation, suggesting that in addition to recognising hypervariable loop 
regions, strain-specific neutralizing antibodies might also overlap the conserved 
epitopes recognised by bNAbs (17-20). Furthermore, strain-specific or narrowly 
neutralizing antibodies have the potential to cooperate with other lineages in driving 
overall viral diversity, which in turn creates stimuli for the diversification of bNAbs (21, 
22). Thus studies of strain-specific antibodies are providing important insights for 
understanding how antibody lineages acquire neutralization breadth.  
A large number of bNAbs targeting the CD4 binding site (CD4bs) have been isolated 
from HIV-1 infected individuals (18, 23-28). These antibodies can be adsorbed out of 
complex polyclonal sera by gp120 monomers, making them ideal candidates for 
isolation by flow cytometry. High resolution crystal structures in complex with Env 
antigens have made this the most well characterized site of vulnerability on the HIV-1 
envelope (25, 26, 29). Two classes of CD4bs bNAbs have been described: the VH-
gene-restricted class, and the CDR-H3-dominated class. VH-gene-restricted bNAbs 
all develop from the germline-encoded immunoglobulin heavy chain variable genes 
IGHV1-2 or IGHV1-46, and were defined by prototypical antibodies VRC01 and 
8ANC131 (25, 26, 29, 30). This class has a germline-encoded arginine residue at 
position 71 in the heavy chain complementarity determining region two (CDR-H2) that 
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mimics an arginine at position 59 in CD4 by interacting with aspartic acid 368 in the 
CD4 binding loop of gp120. Over half of the VRC01 interaction with gp120 is mediated 
by the CDR-H2 (30). As a result, VH-gene-restricted CD4bs bNAbs are all similarly 
oriented with respect to Env. This angle of approach positions the light chains of 
IGVH1-2/46 derived CD4bs antibodies proximal to loop D in gp120, causing steric 
clashes with loop D and/or the glycan at position N276, which is thought to severely 
hamper the initiation of VH-gene-restricted CD4bs bNAb lineages (31, 32). In contrast, 
the CDR-H3 dominated class of CD4bs antibodies are derived from a wider variety of 
IGHV genes, and bind to Env with diverse angles of approach that are not impeded 
by the N276 glycan (26). Antibodies VRC13 (IGVH1-69), VRC16 (IGVH3-23), and 
CH103 (IGVH4-59) all form important interactions with D368 that develop through 
affinity maturation or germline V-D-J recombination, similar to VH1-2/46 class 
antibodies. A sub-group of the CDR-H3 dominated class, that includes HJ16 (IGVH3-
30) and the more recently described 179NC75 (IGVH3-21), have a different mode of 
recognition where neutralization is independent of interactions with D368, but critically 
dependent on the N276 glycan (the same glycan that obstructs VH1-2/46 binding) (28, 
33). Recombinant Env-derived proteins with a glycan deletion at position N276 are 
able to engage the germline reverted antibodies of many IGVH1-2/46 derived CD4bs 
bNAbs, and have been proposed as HIV-1 vaccine immunogens (34, 35). Additional 
glycan deletions in V5 enable even better binding to VH-gene-restricted bNAb 
precursors (32). These glycan deletions create large holes in the glycan shield, but 
their effects on Env antigenicity, and the immunogenicity of the CD4bs, remain to be 
determined  
We have previously characterized the bNAb responses in the plasma of CAP257, a 
participant of the CAPRISA cohort (36). CAP257 developed three distinct waves of 
bNAbs that appeared sequentially in the plasma, first targeting the V2 epitope, then 
the CD4bs, and finally a third as yet undefined epitope. The CAP257 CD4bs bNAbs 
appeared between 50 and 60 weeks post-infection, peaking in titre at 122 weeks post-
infection and declining thereafter. They were critically dependent on the N276 glycan, 
and unlike most previously described CD4bs bNAbs could be readily adsorbed with 
D368R mutant gp120s. This CD4bs plasma bNAb response could be further divided 
into early and late CD4bs antibodies based on sensitivity to an N279D escape 
mutation that arose in the viral quasispecies at 93 weeks post-infection. Early CD4bs 
antibodies potently neutralized the tier-2 clade B strain RHPA, but had very narrow 
Chapter 5: A Strain-specific Glycan-dependent CD4bs Antibody  Wibmer et al., 2016 
5 152 
neutralization breadth and were abrogated by the D279 immunotype. Late CD4bs 
antibodies were tolerant of the D279 immunotype, and this coincided with the 
acquisition of greater neutralization breadth. These broader antibodies were escaped 
first by mutations that removed the N276 glycan at 122 weeks post-infection, and then 
by bulky aromatic side chain substitutions at position R456 in the base of V5 by 163 
weeks post-infection.  
Here, we designed RHPA-derived sorting antigens to isolate an early member of the 
CD4bs neutralizing antibody response, called CAP257-RH1, from CAP257 memory B 
cells. A cocrystal structure of CAP257-RH1 in complex with an RHPA gp120 that 
included the N276 glycan revealed a CDR-H3-dominated interface that overlapped 
significantly with the epitopes of CD4bs bNAbs. CAP257-RH1 neutralized one virus, 
RHPA, out of a large multi-clade panel, and this heterologous strain-specificity was 
explained by a binding angle that was incompatible with the V5 glycans present in 
most HIV-1 strains. Analysis of CAP257 autologous viruses by deep sequencing 
revealed a minority population with glycan-free V5 loops similar to RHPA, which may 
have initiated this lineage, or provided the antigenic stimuli that allowed it to mature. 
These findings provide a mechanism for the strain-specificity of early CD4bs 
neutralizing antibodies in CAP257, which target a rare glycan hole in V5, and have 
implications for the use of HIV-1 immunogens that are aimed at activating CD4bs 
bNAb precursors by removing key glycans loop D and/or the V5 loop. 
Materials and Methods 
Ethics statement  
The CAPRISA 002 Acute Infection cohort is comprised of women at high risk of HIV-
1 infection in KwaZulu-Natal, South Africa. The CAPRISA Acute Infection study 
received ethical approval from the Universities of KwaZulu-Natal (E013/04), Cape 
Town (025/2004), and the Witwatersrand (MM040202). Donor CAP257 provided 
written informed consent for study participation. Blood samples were collected at 
regular intervals from seroconversion through to the initiation of antiretroviral therapy, 
processed, and cryopreserved individually. 
Cell culture and pseudovirus preparation 
293F suspension cells were cultured in 293Freestyle media (Gibco BRL Life 
Technologies) at 37°C, 10% CO2, 125RPM. 293S (GntI-/-) cells were cultured in 
suspension as above, but supplemented with 2% heat-inactivated fetal bovine serum 
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(FBS). Adherent CD4+/CCR5+ TZM-bl HeLa and HEK293T cells were grown to 
confluency in DMEM supplemented with 10% FBS, 22.7 mM HEPES (Gibco BRL Life 
Technologies), and 50 ug/ml gentamicin (Sigma) at 37°C, 5% CO2. Monolayers were 
disrupted with 0.25% trypsin in 1 mM EDTA (Sigma). For pseudoviruses, 293T cells 
were seeded in 10 mL at 2x106 cells/mL in 10 cm2 dishes. 24 hours later plasmids 
expressing the Env of interest and the pSG3ΔEnv backbone (obtained from the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH) were 
co-transfected using a 3:1 ratio of PEI-MAX 40,000 (Polysicences). Cultures were 
incubated for 48 hours at 37°C, filtered through 0.45 µm, and frozen in 20% FBS. 
Mutant Env plasmids were made with the QuikChange Lightning Kit (Stratagene).  
ELISA 
Recombinant gp120 was coated onto high-binding ELISA plates at 2 µg/mL in 
Carb/Bicarb buffer at 4°C, pH 10 overnight. Plates were washed between each 
subsequent step four times with PBS containing 0.05% Tween20. Blocking was done 
with 5% skim milk powder in PBS for 1 hour at 37°C. Serial dilutions of HIV-1 
monoclonal antibodies in 5% skim milk powder in PBS were added for 1 hour at 37°C, 
and complexes were detected with an anti-Fc/HRP conjugate. ELISA reactions were 
propagated in 100 µL of enzyme substrate for five minutes and stopped with 25 µL of 
1 M HCl. Absorbance was read at 450 nm.  
Neutralization Assays 
Neutralization assays (as previously described (3, 37)) measured the reduction in 
relative light units after a single round of pseudovirus infection in the presence of a 
monoclonal antibody or plasma sample. Samples were serially diluted 1:3 and the 
ID50/IC50 calculated as the dilution at which the infection was reduced by 50%.  
Adsorption Assays 
Protein aliquots of 400 µg each were coupled to MyOne Tosyl-activated magnetic 
Dynabeads (Invitrogen) at 37°C, pH 9.5 overnight, and then blocked with 0.5% BSA 
in 0.0 5% Tween20 PBS overnight at 37°C. Protein conjugated beads were incubated 
with 200 µL of plasma (diluted 1:20) for two hours at 37°C, then the beads were 
removed magnetically and the remaining plasma assessed for binding and neutralizing 
antibodies using ELISA and neutralization assays respectively.  
B-cell Sorting 
The RHPA-RC positive and RHPA-ADW negative gp120 antigens were engineered 
with a C-terminal AviTag, and the proteins were biotinylated post-expression using 
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bulk BirA biotinylation kit (Avidity). Biotinylated sorting antigens were conjugated to 
streptavidin labelled with Alexafluor (AF647) or brilliant violet (BV420) and titrated for 
flow cytometry. Thawed PBMCs were stained with sorting probes as well as viability 
marker Aqua vital (Invitrogen, Carlsbad, CA), CD3 phycoerythrin (PE), CD14 PE, 
CD16 PE, IgD Fluorescein isothiocyanate (FITC), and CD19 allophycocyanin (APC)-
Cy7 (BD Biosciences). Single sorted cells were frozen in RNase-free buffer. Flow 
cytometric data were acquired on a BD Aria 2 ﬂuorescence-activate cell sorter (FACS), 
and the data were analyzed using FlowJo software (Tree Star). 
Immunoglobulin Gene Amplification 
Single B-cell heavy and light chain mRNA transcripts were reverse transcribed using 
random hexamers, and amplified by nested PCR in five different primer pools (three 
distinct sets for groups of variable heavy chain genes) as previously described (38, 
39). Second round PCR reactions introduced restriction sites that were used to clone 
the antibodies into mammalian expression vectors for IgG expression.  
X-ray Protein Crystallography 
CAP257-RH1 monoclonal antibody containing the HRV3C site was bound to protein 
A, and used to purify an RHPA gp120 core that had already been enriched for by Ni-
NTA chromatography (30 mM Imidazole wash and 400 mM Imidazole elution buffers 
at pH 7). The Fab-gp120 complexes were eluted with HRV3C, and further purified by 
gel filtration using a superdex 200 column (GE Healthcare). Complexes were 
concentrated to ~8 mg/mL, aliquoted, and flash frozen in the presence of Endo H at 
~200 U/mL. Aliquots were thawed immediately before setting up crystallization drops. 
400 nL crystallization screens (containing 50% mother liquor) were set-up over 576 
conditions in 96 well sitting drop vapour diffusion plates (Corning) at 25°C, using the 
Cartesian Honeybee and TTP Labtech Mosquito crystallization robots. A single crystal 
hit was hand-optimised in 15 well hanging drop diffusion plates using 1 µL drops at 
25°C. The final crystallization conditions were 0.1 M HEPES (pH 7.5), 8% PEG4000, 
10% isopropanol, and crystals were flash frozen in 15% 2R3R or 25% MPD as a 
cryoprotectant. Once mounted onto the goniometer only 5% of the crystals yielded 
measurable x-ray diffraction, and this was considerably improved after these crystals 
were annealed in situ by diverting the cryostream for three seconds. Two of the 
crystals diffracted to a final resolution of 3.2 Å. Diffraction data were collected at the 
Advanced Photon Source (Argonne National Laboratory) SER-CAT ID-22 beamline, 
at a wavelength of 1.00 Å, 100K, and processed with HKL2000. The structure was 
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solved by molecular replacement using the PHENIX v1.9-1692 software package and 
search models 4JZZ, 1NL0, 4HPY. Models were refined with hydrogens to minimise 
clashes in COOT v0.8 using 5% of the data as an R-free cross validation test set. All 
structural images were generated in PyMOL Molecular Graphics System, Version 
1.3r1edu, Schrodinger LLC.  
Next-generation sequencing library preparation. 
RNA extraction, cDNA synthesis and subsequent amplification were carried out as 
described previously (40), with the following modifications: A minimum of 5,000 HIV-1 
RNA copies were isolated from longitudinal plasma samples spanning ~3.5 years of 
infection, using the QIAamp Viral RNA kit (Qiagen). The cDNA synthesis primer was 
designed to bind to the C5 region of the HIV-1 envelope gene (HXB2 gp160 DNA 
position 1,408–1,431) and included a randomly assigned 9-mer tag (Primer ID 
method) to uniquely label each cDNA molecule, followed by a universal primer binding 
site to allow out-nested PCR amplification of cDNA templates. First-round amplification 
primers were designed to bind to the end of the V3 loop (HXB2 gp160 DNA position 
890-911) and contained a template-specific binding region, followed by a variable-
length spacer of 0–3 randomly assigned bases to increase sample complexity. In 
addition, PCR primers contained 5′ overhangs, introducing binding sites for the 
Nextera XT indexing primers (Illumina). This allowed the amplification of the C3 to V5 
region of the envelope spanning HXB2 gp160 positions 911 to 1408. Nested PCR 
reactions were carried out using the Nextera XT indexing kit. After indexing, samples 
were purified using SPIRselect magnetic beads (Beckman Coulter) with a sample 
volume to bead ratio of 1:0.65, for the removal of <300bp fragments. Samples were 
quantified using the Qubit dsDNA HS assay (ThermoFisher) and pooled in equimolar 
concentrations. The pooled amplicons were gel extracted using the QIAquick gel 
purification kit (Qiagen) to ensure primer removal before the final library was submitted 
for sequencing on an Illumina MiSeq, using 2 × 300 paired-end chemistry. 
Next-generation sequencing data processing and analysis. 
Raw reads were processed using a custom pipeline housed within the University of 
Cape Town High-Performance Computing core. Read quality was assessed using 
fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Short reads (<150 
bp) were filtered out using Trimmomatic (41), and reads with an average quality of 
>Q20 were removed using a custom python script. A low Q-score cut off was used, as 
the Primer-ID method removes sequencing and PCR error during the consensus 
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sequence generation step. The overlapping forward and reverse reads were merged 
using PEAR (42), and the forward primer sequence was stripped out of all reads using 
a custom python script. Reads where the forward primer could not be found were 
discarded. An in-house program, developed in R, was used to bin all reads containing 
an identical Primer ID tag, align the reads within each bin using MAFFT (43), and to 
produce a consensus sequence based on a majority rule. Consensus sequences from 
bin of sizes > n (where n is proportional to the size of the largest bin, and had a mean 
value of 15 for this dataset) were filtered out using the cut-off model previously 
described in (44). Consensus sequences containing degenerate bases, frame shift 
mutations, or stop codons were also removed. Custom python scripts were used to 
calculate and plot the number and frequency of glycosylation sites in the V5 loop.  
Results 
Design of a resurfaced gp120 core sorting antigen based on the tier-2 strain 
RHPA 
We have previously shown that the CD4bs neutralizing antibodies in CAP257 plasma 
were similar to HJ16 (36), and could not be adsorbed with the Resurfaced Stabilised 
gp120 Core (RSC3) sorting antigen used to isolate VRC01. Therefore a new sorting 
antigen was engineered for CAP257 B-cell isolation based on the tier-2 strain RHPA, 
which was highly sensitive (ID50 titer of ~1:8,000) to the CAP257 CD4bs antibodies. 
Similar to RSC3, the RHPA gp120 sorting antigens were truncated in the V1-V3 loops 
as well as the N and C termini, and resurfaced with 47 rare mutations in surface 
exposed, but normally conserved residues outside the CD4bs (Figure 1A and 
Supplementary Figure 1A) (24). Hypervariable regions are unlikely to be reactive with 
heterologous antibodies, and were not resurfaced. The RSC3 cavity filling mutations 
(M95W, T257S, S375W, A433M) and cystine bonds near loop D (W96C/V275C) that 
were previously designed to stabilize gp120 in the CD4-bound conformation were 
avoided, because it was not known how these might affect the CAP257 epitope which 
differed from VRC01-like antibodies (36). This resurfaced core gp120, called RHPA-
RC, bound to the conformation sensitive neutralizing antibodies VRC01 and 2G12, 
confirming that resurfacing mutations did not compromise protein folding 
(Supplementary Figure 1B). To enhance the specificity for CAP257 CD4bs antibodies, 
we also created a negative sorting antigen, called RHPA-ADW, which included three 
mutations in the gp120 loop D and the base of V5 (T278A, N279D, and R456W) that  
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we have previously shown to contribute to escape from the CD4bs neutralizing 
antibodies in CAP257 plasma (Figure 1A, green) (36). The negative antigen RHPA-
ADW did not bind strongly to the CD4bs antibody VRC01 as expected, but still bound 
well to 2G12, confirming the antigens conformational integrity and ability to select for 
CD4bs antibody responses (Supplementary Figure 1C).  
The ability of CAP257 CD4bs antibodies to bind to either the RHPA-RC positive 
antigen or RHPA-ADW negative antigen was assessed by ELISA and adsorption 
assays. Remarkably, the longitudinal kinetics of CAP257 plasma antibody binding to 
the positive antigen RHPA-RC tracked with the neutralization of the RHPA parent 
strain, increasing or decreasing in titre at similar time points throughout infection 
(Figure 1B). Similarly, CAP257 plasma antibodies did not bind well to the negative 
antigen RHPA-ADW, although they did show weak binding between 161 and 174 
weeks post-infection that tracked with the neutralization of the more resistant RHPA-
ADW mutant virus (Figure 1B). Adsorption experiments using CAP257 plasma from 
122 weeks post-infection, when the CD4bs antibody titres had peaked, showed that 
the positive antigen RHPA-RC could efficiently adsorb out the CD4bs neutralizing 
antibodies against RHPA (a clade B virus), Q23 and Q842 (clade A) and CAP61 (clade 
C) respectively, while the negative antigen RHPA-ADW could not (Figure 1C). 
Altogether these data suggested highly specific selection for CAP257 CD4bs 
neutralizing antibodies by the RHPA-RC positive, RHPA-ADW negative sorting probe 
combination.  
Isolation of an N276 glycan-dependent CD4bs B-cell lineage 
A PBMC sample from 107 weeks post-infection, when the CD4bs lineage was likely 
to be expanding, was selected for B-cell isolation. Single memory B-cells were isolated 
as CD3-, CD14-, CD16-, IgD-, RHPA-ADW-, CD19+, RHPA-RC+ by flow cytometry 
(Figure 2A). At least one antibody heavy or light chain could be recovered from 65% 
of the 94 sorted cells, and DNA sequencing revealed that RHPA-RC selected for three 
antibody lineages. The first of these was a family of five IGHV4-59/61 heavy chains 
that were 16%-18% mutated from germline, and shared the same heavy chain family 
as the CD4bs antibody CH103 (Supplementary Figure 2A). However, the paired light 
chains for this antibody family could not be recovered. Similarly, a family of six 
unpaired IGKV1-NL1 light chains that were between 5%-16% mutated were also 
isolated but could not be functionally assessed without complementary heavy chain 
sequences (Supplementary Figure 2B). The third family was derived from IGHV3-33 
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heavy and IGLV3-10 light chains, and is referred to hereafter as the CAP257-RH 
lineage (Figure 2B and Supplementary Figure 2C). CAP257-RH heavy and light chain 
genes were 8-11% and 4-13% mutated respectively, and had relatively normal CDR-
H3 and CDR-L3 lengths of eleven amino acids each (Kabat numbering). One of these 
antibodies, CAP257-RH1, bound well to the wild-type RHPA gp120 core by ELISA, 
and weakly to the positive sorting antigen RHPA-RC (similar to the bNAb HJ16), but 
did not bind to the negative sorting antigen RHPA-ADW (Figure 2C), confirming the 
specific selection of CAP257-RH lineage antibodies.  
CAP257-RH1 displays strain-specific heterologous neutralization and gp120 
binding 
We have previously shown that escape from CAP257 CD4bs antibodies was due to 
the sequential appearance of the three mutations at positions 279, 276/278, and 456. 
The N279D immunotype switch appeared first, and preceded the acquisition of 
breadth. Mutations that deleted the glycosylation sequon at position N276 (e.g. T278A) 
appeared next, while the R456W substitution was the last major escape mutation (36). 
These CD4bs mutants were used to compare the neutralization of monoclonal 
antibody (mAb) CAP257-RH1 to contemporaneous plasma from 107 weeks post-
infection (Figure 2D). The plasma from 107 weeks post-infection neutralized RHPA at 
ID50 titres exceeding 1:1,000, and by this time had already adapted to tolerate the early 
D279 escape mutation, but were still dependent on N276 and R456 for effective 
neutralization (Figure 2D – left panel). CAP257-RH1 potently neutralized RHPA with 
an IC50 of 0.11 µg/mL (Figure 2D – right panel). This neutralization was completely 
abrogated by N276Q and T278A mutations that removed the N276 glycan, confirming 
that CAP257-RH1 was a component of the CAP257 CD4bs plasma neutralizing 
response (Figure 2D). However, unlike CAP257 plasma, CAP257-RH1 neutralization 
was substantially reduced (100-fold) by the early N279D mutation, and unaffected by 
the late R456W change. These data suggest that CAP257-RH1 appeared very early 
in the CAP257 CD4bs neutralizing response, before the emergence of CD4bs-specific 
neutralization breadth.  
The cross-reactivity and breadth of mAb CAP257-RH1 was further examined by ELISA 
and neutralization assays respectively (Figure 2E and 2F). CAP257-RH1 showed 
binding to RHPA gp120, but was unable to bind any of the 11 heterologous clade C 
gp120 monomers tested, all of which were bound by a pooled HIV+ immunoglobulin 
control (HIV-Ig) (Figure 2E). Similarly, CAP257-RH1 displayed strain-specific  
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Figure 2: Isolation of an early N276 glycan-dependent CD4bs neutralizing 
antibody 
A) Sort plot showing the percentage of memory B cells identified that were able to bind 
the RHPA-RC positive sorting antigen (fluorescence plotted on the y-axis) but not to 
the RHPA-ADW negative sorting antigen (fluorescence plotted on the x-axis). B) 
Properties of the CAP257-RH lineage members, defined by IMGT and numbered by 
Kabat. C) Comparison of the binding of CAP257-RH1 (blue) or HJ16 (green) to a wild 
type RHPA core gp120 (squares), as well as to the positive gp120 sorting antigen 
RHPA-RC (triangles) or the negative gp120 sorting antigen RHPA-ADW (circles and 
dashed lines) by ELISA. Absorbance is plotted on the y-axis versus antibody 
concentration on the x-axis. D) Neutralization of RHPA and select mutants with varied 
resistance to CAP257 CD4bs plasma antibodies, by either CAP257 plasma from 107 
weeks post-infection, or the CAP257-RH1 monoclonal antibody isolated from the 
same time point. Percentage inhibition is plotted on the y-axis and dilution on the x-
axis. E) ELISA binding of an anti-HIV immunoglobulin pool (positive control) or 
monoclonal antibody CAP257-RH1 to 11 clade C gp120 proteins. F) Neutralization of 
seven heterologous viruses sensitive to early CAP257 CD4bs antibodies, by either 
CAP257 plasma from 107 weeks post-infection, or the monoclonal antibody CAP257-
RH1. Increasing potency is indicated by warmer colours.  
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heterologous neutralization of only RHPA among the 196 virus multi-clade panel 
tested, including other viruses neutralized by early CAP257 CD4bs neutralizing 
antibodies (Figure 2F and Supplementary Table 1). CAP257-RH1 did not display 
incomplete neutralization maxima, as seen with a number of recently isolated glycan-
dependent HIV-1 bNAbs (45).  
Structural classification of CAP257-RH1 as a CDR-H3-dominated class CD4bs 
antibody 
A cocrystal structure of the CAP257-RH1 Fab region bound to the RHPA core gp120, 
was determined to 3.2Å resolution (Table 1 and Figure 3A). The structure included a 
NAG2MAN5 glycan at position N276 bound in the paratope (shown in light green), and 
confirmed the CD4bs as the target for CAP257-RH1 neutralization. The crystallization 
conditions included Endo H to facilitate slow, in-drop deglycosylation of gp120, since 
pre-incubation with Endo H disrupted the Fab-gp120 complexes, however the enzyme 
was at a very low concentration and did not contribute to the asymmetric unit. The 
CAP257-RH1 angle of approach was compatible with Env oligomerization, and did not 
clash with the V1V2 domain (Figure 3B) as has been seen for other narrowly 
neutralizing CD4bs antibodies (46, 47). The interface between CAP257-RH1 and 
RHPAgp120 buries a total surface area of ~1,046 Å2, to which the heavy chain 
contributes ~584 Å2 and the light chain ~462 Å2 respectively (Figure 3C and 
Supplementary Tables 2, 3, and 4). Unlike other CD4bs antibodies, CAP257-RH1 
does not extend its CDRs deep into the cavity bound by CD4, but instead interacts 
with more peripheral regions of the CD4bs including loop D, V5, and the CD4 binding 
loop (Figure 3C, 3D, and Supplementary Figure 3). Accordingly protein-protein 
interactions with gp120 account for ~642 Å2 of the total buried surface area. More than 
one third of the total interface (~404 Å2) involves interactions with the N276 glycan, 
which fits snugly at the heavy-light chain interface where each chain contributes ~196 
Å2 and ~208 Å2 of bound surface area respectively. This is similar to the 300 Å2 to 400 
Å2 buried by N276 in the interfaces of some VRC01 relatives which are not glycan-
dependent, but is only half as large as the interface with N276 made by 8ANC195 (48-
50). The gp120 used for these crystallization experiments was grown in HEK293S 
GntI(-/-) cells to facilitate deglycosylation at pH 7. As a result, the cocrystal structure 
includes a low mannose glycan bound in the CAP257-RH1 paratope. Previously, the 
N276 glycan has been characterized on monomeric gp120 as mostly complex in 
composition (51-53), but a more recent analysis of native pre-fusion trimers suggests  
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Figure 3: Crystal structure of CAP257-RH1 bound to the N276 glycan in RHPA 
gp120 
A) An overview of the CAP257-RH1 Fab and RHPA core gp120 cocrystal structure 
shown in cartoon view. The CAP257-RH1 heavy and light chains are shown in dark 
and light blue respectively. RHPA gp120 is coloured grey, truncated N/C termini as 
well as the V3 loop stem are labelled, and loop D and V5 are shown in purple and red 
respectively. Glycans are shown in stick view, with green semi-transparent surfaces. 
The N276 glycan is indicated by its lighter shade. B) A surface view of the HIV-1 Env 
trimer (pdb 4TVP) is shown in grey, with the monoclonal antibody CAP257-RH1 shown 
in blue docked into its epitope (by superimposition). The CD4bs is coloured yellow, 
and the location of the viral membrane is indicated. C) Surface view of RHPA gp120 
in grey, coloured in dark or light blue to show the CAP257-RH1 heavy and light chain 
footprints respectively. Loop D and V5 are indicated with purple or red mesh 
respectively, and the N276 glycan (shown in stick and surface view) is outlined in 
green. D) Surface view of RHPA gp120, with the CD4 binding footprint coloured 
yellow. Loop D, V5, and the N276 glycan are indicated as in C. The CAP257-RH1 
CDRs are shown as thick cartoon loops.   
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that this glycan is mostly oligomannose in composition, and varies from Man5 to Man8 
(54). Additional mannose residues could be modelled at the termini of each glycan 
arm in the CAP257-RH1 bound structure, suggesting that this antibodies binding was 
compatible with both NAG2MAN5 low and NAG2MAN8/9 high mannose glycans at 
position N276 (Figure 4A). In both CAP257-RH1 and 8ANC195 bound structures, the 
N276 glycan adopts a similar orientation that differs substantially from the reoriented 
glycan conformation bound by VRC01-like antibodies (Figure 4B). Similarly, the 
CAP257-RH1 bound orientation of the N276 glycan was compatible with an HJ16 
bound gp120 (by superimposing the gp120 molecules from both structures) and 
packed closely against the HJ16 light chain in the model (Figure 4C), indicative of a 
common N276 glycan conformation bound by these neutralizing antibodies. Thus, this 
structure of the N276 glycan may represent a commonly occupied orientation of the 
N276 glycan when bound by bNAbs. 
The CAP257-RH1 paratope is centred on its eleven amino acid long CDR-H3, which 
accounts for ~53% of the heavy chain interface (Figure 3D). The remaining heavy 
chain CDR loops were positioned to interact with the conserved CD4bs, while the light 
chain CDRs were more distal, in close proximity to V5. In concordance with plasma 
mapping, CAP257-RH1 does not interact productively with D368 in gp120, despite a 
CDR-H2 that extended toward the CD4 binding loop (similar to VRC01) where H56HC 
forms a hydrogen bond with the S365gp120 backbone carbonyl oxygen (Figure 5A – 1st 
panel). The CDR-H1 and CDR-H3 loops are both in close proximity to gp120 loop D, 
where E31HC and D100AHC makes hydrogen bonds with N279gp120 and N280gp120 
respectively (Figure 5A – 2nd panel). The interaction between E31HC and N279gp120 
explains the antibody’s preference for an N279 immunotype, as a negatively charged 
aspartic acid immunotype at position 279 would clash electrostatically with the 
glutamic acid in the CDR-H1. The CDR-H3 also makes contact with the peptide 
backbone of loop D and V5 through K99HC, and with the D2 arm of the N276 glycan 
through D101HC, while K32HC in the CDR-H1 is positioned to make weak contact with 
the first NAG moiety. CAP257-RH1 also contacts the D1 arm of the N276 glycan via 
its heavy chain N terminal residue (Figure 5A 3rd panel). In addition to these heavy 
chain interactions, the CDR-L2 of the light chain also contributes to N276 glycan 
interactions by inserting F55LC in between the second NAG moiety and the D2 arm of 
the glycan, as well as a hydrogen bond with the backbone carbonyl of S56LC (Figure 
5A 3rd panel).  
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Figure 4: Analysis of the N276 glycan when bound by neutralizing antibodies 
A) CAP257-RH1 is shown in cartoon view, coloured as in figure 3, interacting with the 
N276 glycan (shown with green sticks). The 2Fo – Fc electron density map (contoured 
at 1σ) of the N276 glycan is shown with black mesh. Additional mannose moieties 
added to the glycan termini are shown in lime green, and the glycan arms are labelled. 
A schematic of the glycan is also shown below, and sugars with either visible density 
or those modelled onto the structure, are labelled. B) A comparison of the N276 glycan 
orientations when bound by 8ANC195 (glycan shown in yellow, Fab heavy and light 
chains shown in peach and red respectively), CAP257-RH1 (glycan shown in light 
green, Fab heavy and light chain shown in blue and cyan respectively), or VRC01-like 
antibodies (glycan shown in dark green, Fab heavy and light chains shown in purple 
and pink respectively). The Fab bound glycan complexes (PDB codes 4P9H and 
4JKP) were superimposed onto the HIV-1 Env trimer structure 4TVP shown in light 
(gp120) and dark (gp41) grey surface view. B) A surface view of the N276 glycan 
(green) bound by CAP257-RH1 (coloured as in A) is shown in the left panel. In the 
right panel, the HJ16 cocrystal structure (PDB code 4YE4) was superimposed onto 
the CAP257-RH1 bound gp120, showing compatibility with this N276 glycan 
orientation. HJ16 heavy and light chains are coloured light and dark green 
respectively.  
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To evaluate the relative contribution for each of the contacts identified above, alanine 
scanning mutants of the CAP257-RH1 paratope were made in the heavy chain (Figure 
5B) or light chain (Figure 5C), and assessed for their ability to neutralize RHPA. Heavy 
chain mutations at positions K32HC in the CDR-H1 and H56HC in the CDR-H2 
marginally affected CAP257-RH1 neutralization, while the E31AHC mutation had a 
much more substantial effect (Figure 5B). The reduction in potency of the E31AHC 
mutant against RHPA was equivalent to that of the wild type antibody against the 
N279Dgp120 mutant virus, consistent with the observed interaction between these two 
residues (Figure 2D compared to Figure 5B). In contrast to the CDR-H1/H2 
contributions, all of the CDR-H3 mutants failed to neutralize RHPA, highlighting the 
important role of this region in mediating neutralization. These data support the 
classification of CAP257-RH1 as having a CDR-H3-dominated paratope, despite a 
CDR-H3 loop length much shorter than other HIV-1 CD4bs antibodies of this class.  
The CDR-L2 F55ALC mutant, which disrupts interactions with the N276 glycan, was 
also unable to neutralize RHPA (Figure 5C). Two additional light chain contacts in the 
CDR-L1 at positions K31LC and W32LC also had a substantial contribution to CAP257-
RH1 neutralization, but alanine mutations at these sites did not completely abrogate 
the antibody’s activity (Figure 5C). While interactions with the conserved CD4bs (loop 
D and the CD4 binding loop) are mediated exclusively by the CAP257-RH1 heavy 
chain, the light chain is positioned close to V5, with its CDR-L1 binding perpendicularly 
over the V5 loop apex (Figure 5D). Light chain interactions with V5 account for ~259 
Å2 of buried surface area, and include extensive hydrogen bonding with the V5 peptide 
backbone, and notable van der Waals contributions by the W32LC side chain which 
inserts behind V5 to contact the backbone carbonyl of D461gp120. This displaces the 
D461gp120 side chain into the CAP257-RH1 paratope where it interacts with K31LC 
(Figure 5D). However, mutating D461gp120 to alanine in the RHPA V5 loop affected 
IC50 but was not critical for neutralization, while mutating V460gp120 actually enhanced 
CAP257-RH1 neutralization (Figure 5E). When taken altogether, both heavy and light 
chain interactions with the N276 glycan (D101HC and F55LC, but not K32HC), loop D 
(E31HC and D100AHC), or the base of V5 (K99HC) were critical to CAP257-RH1 
neutralization, while specific contacts with the hypervariable V5 loop apex (K31LC and 
W32LC) were not essential to neutralization and thus not the primary determinant of 
CAP257-RH1 strain-specificity.  
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Figure 5: Atomic details of the CAP257-RH1 interaction with RHPA core gp120 
A) Polar contacts between CAP257-RH1 the CD4bs/N276 glycan. The CAP257-RH1 
CDRs are shown in various shades of blue, while the CD4b binding loop, loop D, and 
the N276 glycan are coloured grey, purple, and green respectively. Potential hydrogen 
bonds are shown with the black dotted lines. B) Paratope mapping of the CAP257-
RH1 heavy chain by alanine scanning mutagenesis. Mutations are grouped by CDR 
loop using different shades of blue. Percentage inhibition is plotted on the y-axis and 
antibody concentration on the x-axis. C) Paratope mapping of the CAP257-RH1 light 
chain, labelled as in B. D) Atomic details of the interaction between the CAP257-RH1 
CDR-L1 (cyan), and the V5 loop of RHPA (red). Polar interactions are indicated as in 
A. E) Neutralization of various RHPA alanine mutants, plotted as in B.  
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CAP257-RH1 neutralization was incompatible with glycosylated V5 loops 
To better understand the strain specificity of CAP257-RH1, the cocrystal structures of 
other CD4bs antibodies were superimposed onto the cocrystal structure of CAP257-
RH1 bound to RHPA gp120 (Figure 6). Both N276 glycan-dependent antibodies 
CAP257-RH1 and HJ16 infiltrated less substantially into the CD4bs when compared 
to the other CD4bs neutralizing antibodies (Figure 6A). The VH-gene-restricted bNAbs 
VRC01 and CH235.12 were predicted to clash significantly with the CAP257-RH1 
bound orientation of the glycan at position N276, but the placement of this glycan was 
compatible with all of the CDR-H3-dominated class antibodies. These data are 
consistent with published observations that VH-gene-restricted bNAbs bind better to 
N276 glycan-deficient Env (31, 32, 55). Another striking difference between the CD4bs 
antibodies was their binding orientations relative to V5. While VH-gene-restricted 
CD4bs antibodies completely avoided the V5 loop apex, the binding of CDR-H3 
dominated antibodies often placed their light chains in close proximity to V5 (Figure 
6B). Overall, less penetration into the recessed CD4bs and greater overlap with the 
V5 loop apex correlated with reduced neutralization breadth. This was particularly 
prominent amongst the N276 glycan-dependent CD4bs antibodies HJ16 and CAP257-
RH1, which both increased their interacting surfaces with V5 through a bulky 
tryptophan residue from the CDR-L3 or CDR-L1 loops respectively (shown in Figure 
6B). The extent of this overlap suggested that the binding angles for these two 
antibodies were less tolerant of longer or more glycosylated V5 loops than other 
CD4bs antibodies such as VRC01.  
The RHPA V5 loop is relatively short (five amino acids between position 460 and 464) 
and unusually glycan-free (Figure 6C). Indeed, glycan-free V5 loops make up only 6% 
of the ~5000 HIV-1 group M Env sequences in the LANL database. To test whether 
this lack of glycan contributed towards CAP257-RH1 strain-specificity, V5-
glycosylated sequence variants of RHPA were made and tested for their sensitivity to 
CAP257-RH1, HJ16, and VRC01 (Figure 6D). These V5 mutants were all more 
resistant to the three CD4bs antibodies tested, though the effect varied depending on 
the location of the introduced glycosylation sequon. All the mutants were marginally 
less sensitive to neutralization by VRC01, and this effect was more pronounced for V5 
N-terminal glycan substitutions. In contrast HJ16 neutralization was knocked out by a 
glycan site at position 460gp120 and substantially affected by a glycan site at position 
462gp120, while CAP257-RH1 neutralization was completely abrogated by introducing  
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glycosylation sequons at positions 460gp120, 461gp120, and 462gp120, and significantly 
affected by a glycan site at position 464gp120. A glycosylation sequon at position 
463gp120 could not be tested because mutation of E465gp120 resulted in non-functional 
virions. These data are consistent with the level of V5 overlap displayed by each of 
these antibodies, and supports the hypothesis that CAP257-RH1 neutralization 
breadth is substantially limited by V5 glycosylation. 
A minority population of CAP257 autologous viruses lack glycans in V5  
Donor CAP257 was infected with a clade C tier-2 virus, which from the earliest 
autologous V5 loop consensus (7 weeks post infection) was glycosylated at position 
461gp120, and consequently resistant to CAP257-RH1 neutralization (Supplementary 
Tables 1 and 5). To identify potential autologous glycan-free V5 loops, a panel of ~150 
CAP257 Env sequences isolated by SGA from 16 time points throughout CAP257 
infection were examined, but all were glycosylated making it unclear which virus 
stimulated the CAP257-RH lineage (Supplementary Figure 5). The autologous 
CAP257 viral sequences were further probed by deep sequencing of the V3 to V5 
region of Env from 25 individual time points, between 7 weeks (study enrolment) and 
202 weeks post-infection, resulting in 19,761 consensus V5 sequences (Figure 7A). 
The CAP257-RH lineage was isolated from 107 weeks post-infection, where the major 
viral population had two glycans per V5 loop. However, at time points between 7 weeks 
and 67 weeks post-infection, a minor population of CAP257 viruses were detected 
with completely glycan-free V5 loops that were dominated by a D461 immunotype 
(Figure 7A – red spheres). These sequences peaked in frequency (at 4.9% of total 
sequences) at 16 weeks post infection (Figure 7B), when the viral load was ~32,000 
copies/mL (equating to ~1,568 RNA copies encoding glycan-free V5 Env sequences 
per mL of blood), but occurred less frequently after the detection of CAP257 CD4bs 
neutralizing plasma antibodies at 54 weeks post-infection (Figure 7C). A population of 
glycan-free V5 loops was consistently detectable at very low levels (<1% of total 
sequences) thereafter, alongside the evolving CAP257 CD4bs neutralizing antibody 
response, but appeared to be spontaneously generated and were unrelated to the 
initial glycan-free V5 loops detected prior to the development of CD4bs antibodies.  
To evaluate the potential effect of these glycan-free V5 loops on the Env glycan shield, 
we modelled the surface coverage of NAG2Man9 glycans on the Env trimer. 
Accessibility to the underlying protein surface was evaluated using probe radii of either 
1.4Å (the radius of a water molecule), or 10Å (the approximate radius of a single Fab  
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domain) (Figure 7D). This analysis revealed an unprotected region of the Env protein 
surface, showing how a glycan hole in V5 exposes epitopes for the induction of 
autologous neutralizing antibodies, such as CAP257-RH1.  
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Figure 7: Rare glycan-free V5 sequences from CAP257 reveal a hole in the 
glycan shield 
A) Deep sequencing of autologous V5 loop sequences in donor CAP257, with number 
of glycans on the y-axis and weeks post-infection on the x-axis. The relative 
frequencies for the number of glycans in V5 at a particular time point is represented 
by the size of the spheres, where larger spheres indicate a greater relative number of 
sequences at that particular time point that have the listed number of glycosylation 
sequons in V5. Populations of V5 sequences with one or more glycans are shown with 
blue spheres, while glycan-free V5 sequence populations are shown in red. A dotted 
vertical line is used to indicate the time point from which CAP257-RH1 was isolated. 
B) The relative number of glycan-free autologous V5 loops is plotted as a percentage 
of the total sequences (y-axis) over time (x-axis). C) The neutralization titres (plotted 
on the y-axis) of the second wave of broadly neutralizing antibodies from CAP257 
plasma (as described in (36)), which target the CD4bs, are shown over time (x-axis). 
D) The HIV-1 Env trimer is shown as the solvent-accessible surface representation 
(grey), with Loop D, V5, and the CD4bs coloured purple, red, and yellow respectively. 
The location of the viral membrane is indicated. The glycan shield is modelled and 
displayed as the solvent-accessible surface of NAG2Man9 glycan coverage (green) 
based on two probe sizes of 1.4 Å (solvent radius, top) and 10.0 Å (the estimated steric 
footprint of an antibody combining region, bottom), using 4TVP with an additional 
glycosylation site modeled at residue 241. The solvent-accessible protein surface of 
V5 comprises a largely exposed region upon deletion of the commonly glycosylated 
site at residue at 462 (right).  
 
Discussion 
The CD4bs on the HIV-1 envelope is the most extensively studied site of vulnerability 
to antibody neutralization, but not much is known about how these antibodies arise in 
natural infection, or how they might be induced by vaccination. Here, we isolate and 
characterise a CD4bs antibody called CAP257-RH1, which recognizes an N276 
glycan-dependent epitope targeted by early members of the CD4bs plasma bNAb 
response that developed in donor CAP257. A cocrystal structure that included the 
N276 glycan revealed extensive contacts between the CAP257-RH1 heavy chain and 
conserved elements of the CD4bs. Narrow neutralization breadth was attributed to a 
light chain binding angle that was incompatible with glycosylated V5 loops present in 
almost all HIV-1 strains. Rare autologous sequences from early in donor CAP257 
infection were found to have glycan-free V5 loops that may have been responsible for 
engaging the naive B cell that produced this CD4bs antibody lineage. Thus, vaccine 
immunogens that lack glycans in V5 may provide better exposure for the epitopes 
targeted by N276 glycan-dependent CD4bs antibodies.  
Although the CAP257-RH1 monoclonal antibody is strain-specific for the heterologous 
virus RHPA, it targets the same N276 glycan-dependent CD4bs epitope as CAP257 
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plasma bNAbs. In addition, CAP257-RH1 was very sensitive to the N279D mutation 
that in the plasma only affected the earliest of CAP257 CD4bs neutralizing antibodies, 
and coincided with the emergence of the later broadly neutralizing CD4bs response. 
Thus, CAP257-RH1 likely represents an early member of the neutralizing response to 
the CD4bs in this individual. Three studies detailing the ontogeny of bNAbs have 
shown that they arose from strain-specific precursors (17, 18, 20). While strain-specific 
neutralizing antibodies have long been known to target the hypervariable regions of 
Env (2, 3, 5-8), it has become apparent that the epitopes for strain-specific antibodies 
may also overlap substantially with the epitopes for bNAbs (56, 57). For instance, 2909 
is strain-specific for the heterologous virus SF162, and targets an epitope in V2 (58), 
but the isolation of PG9 and PG16 showed that this epitope was also vulnerable to 
bNAbs (59). The limited neutralization breadth of 2909 could be explained by the 
requirement for a lysine at position 160 (normally glycosylated) creating a hole in the 
Env glycan shield (50, 57). CAP257-RH1 specificity was similarly constrained by the 
requirement for a glycan-free V5 loop and a slight preference for the D461 
immunotype. However CAP257-RH1 still neutralized V5 alanine mutants of RHPA, 
and could conceivably mature to recognise more diverse V5 loop sequences. 
Alternatively, these antibodies may have helped drive viral diversity in the CD4bs, in 
turn promoting the development of plasma neutralization breadth, similar to the 
cooperative evolution of the CH103 and CH235 lineages in donor CH505 (21). It is not 
known whether the CAP257-RH lineage also went on to develop broadly neutralizing 
activity, and the isolation of CD4bs bNAbs from CAP257 would help to address this 
question.  
CAP257-RH1, together with HJ16 and 179NC75, form a sub-class of the CDR-H3 
dominated CD4bs antibodies (26, 28), that are critically dependent on the N276 
glycan, but not D368 (28, 36, 60). CAP257-RH1 binds the N276 glycan in a recess 
created by the antibody heavy-light chain interface, and recognises the glycan with a 
similar orientation to bNAb 8ANC195 that targets the gp120-gp41 interface (49, 61). 
This glycan orientation could also be accommodated by glycan-dependent CD4bs 
antibody HJ16 in our modelling analysis, but not by the VH-gene-restricted antibodies 
which clash sterically with N276, consistent with published crystal structures showing 
relocation of this glycan by VRC01 and related antibodies (48, 50). The degree of 
similarity in N276 glycan recognition is comparable to the N332 glycan supersite, 
which is oriented in the same conformation by antibodies with very different epitopes 
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and angles of approach (62). Together with more recent insights into the structure of 
the glycan shield (50, 54), these data help to define the role of N276 in bNAb 
development. HJ16 and other CDR-H3-dominated class bNAbs increase interactions 
with the CD4 binding pocket through long CDR-H3 loops. CAP257-RH1 binds to the 
periphery of the CD4bs, but does not extend deep into the conformationally occluded 
CD4 binding pocket, and its deviation from the previously described CD4bs of 
vulnerability results in a narrow neutralization breadth profile.  
CAP257-RH1 was unable to neutralize viruses with glycosylated V5 loops, including 
the CAP257 transmitted/founder virus. We speculate that the CAP257-RH lineage was 
elicited by low frequency autologous variants that had glycan-free V5 loops. These 
viruses never came to dominate the viral population, possibly due to selection 
pressures imposed by the CAP257-RH lineage. Alternatively, it is also possible that 
rare glycan skipping events in V5 (where glycosylation sequons are missed by 
oligosaccharyltransferase in the Golgi) stimulated the lineage. Interestingly, in another 
individual (CAP256) who developed broad and potent V2-reactive antibodies from a 
strain-specific precursor (17, 63), the bNAb-initiating Env was also found to be 
relatively rare compared to the dominantly circulating viral variant (64). Similar to the 
CAP257-RH1 epitope, several other studies have also identified strain-specific 
neutralizing antibody targets created by unusual holes in the glycan shield (22, 58, 65, 
66). These include vaccine induced antibodies such as the strain-specific macaque 
antibody DH427, which targets a large glycan hole in both V5 and loop E, allowing an 
angle of approach that does not include the CD4bs, and therefore is unlikely to mature 
towards neutralization breadth (67). In donor 45, from which VRC01 was isolated, 
proviral sequences with a rare hole in the glycan shield at position N276 have been 
identified (68, 69), which may represent rare bNAb-initiating Envs that set off the 
VRC01-like lineages in this donor. Thus, glycan holes may elicit highly strain-specific 
responses unable to further mature towards neutralization breadth, but may also 
represent key features of HIV-1 immunogens that engage the appropriate precursors 
of HIV-1 bNAbs. While these holes may recruit the appropriate naïve B cells, driving 
the process towards breadth will likely require the addition of fully glycosylated native 
trimeric immunogens that select for mutations able to accommodate the Env glycan 
shield (34, 35).  
Immunogens designed to activate VRC01-class VH-gene-restricted CD4bs bNAb 
precursors have so far shown promising results in animal studies. These antigens not 
Chapter 5: A Strain-specific Glycan-dependent CD4bs Antibody  Wibmer et al., 2016 
5 175 
only lack the N276 glycan, but have also been modified to bind with higher affinity to 
the VH1-2 germline gene (31, 32). Germline gene knock-in mice immunized with these 
constructs produced antibodies with neutralization compatible mouse light chains (34, 
35), and germline targeting antigens preferentially select for VH-gene-restricted 
precursors in healthy individuals (70). In addition to N276 mutants, Env immunogens 
that also lack glycans in V5 bind even better to the VH-gene-restricted CD4bs bNAb 
precursors (32). In this study, we show that viruses lacking glycans in V5 are also 
considerably better neutralized by N276 glycan-dependent antibodies. This sub-class 
of CD4bs antibodies would not be elicited by the N276-deficient Env immunogens 
designed to elicit VH-gene-restricted antibodies. Based on the CAP257-RH1 cocrystal 
structure, a glycan-free V5 may have been expressly required for activating the 
CAP257-RH lineage, and immunogens incorporating this feature may also improve 
binding to the precursors of other N276 glycan-dependent antibodies.  
Altogether, these data provide insights into the N276 glycan as a target for HIV-1 
neutralizing CD4bs antibodies, and the types of immunogens that might be required 
to activate their naïve B cell precursors. Further isolation and characterization of N276 
glycan-dependent bNAbs will be important for understanding how CD4bs 
immunogens might better capture the entire repertoire of bNAb precursors by 
immunization. Future studies will aim at assessing the role of glycan holes in priming 
B cell responses that might mature to acquire broadly neutralizing activity.  
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Supplement 
 
 
Supplementary Figure 1: Design of a resurfaced antigen based on RSC3 to 
isolate early CD4bs antibodies from donor CAP257 
A) A sequence alignment of RHPA gp120, and the two newly designed sorting 
antigens RHPA-RC and RHPA-ADW. Truncations or resurfacing mutations are 
coloured red, potential N-linked glycosylation sequons are shaded grey, the 
hypervariable regions, loop D, and the CD4 binding loop are highlighted cyan, purple, 
and light grey respectively, and the CD4bs is indicated with yellow asterisks. The 
CAP257 escape mutations incorporated into the negative sorting antigen RHPA-ADW 
are coloured green. B) ELISA binding of VRC01 (orange) and 2G12 (black) to the 
RHPA-RC resurfaced gp120 positive sorting probe. Absorbance readings are plotted 
on the left y-axis, and monoclonal antibody concentration on the x-axis. C) ELISA 
binding of VRC01 and 2G12 to the RHPA-ADW resurfaced gp120 negative sorting 
probe, plotted as in B.  
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Supplementary Figure 2: Potentially related immunoglobulin clusters isolated 
from donor CAP257 at 107 weeks post-infection 
Sequence alignments of the three potentially related immunoglobulin clusters isolated 
as RHPA-RC+, RHPA-ADW- by flow cytometry from CAP257 PBMC memory B cells, 
numbered according to Kabat. A) Heavy chain alignment of the IGHV4-59 genes. B) 
Kappa chain alignment of the IGKV1-NL1 genes. C) Heavy and light chain alignments 
of the IGHV3-33 and IGLV3-10 genes.  
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Supplementary Figure 3: Residue-by-residue contacts between RHPA gp120 
and CAP257-RH1 
A) The RHPA gp120 sequence is shown, and numbered according to the HxB2 
convention. Potential N-linked glycosylation sequons are shaded grey, disordered 
regions are indicated in italics, and loop D or V5 are indicate with purple and red 
underlines respectively. Contacts for the cocrystal complex are shown in blue, while 
previously determined interactions between CD4 and gp120 are shown in gold. Open 
circles (○) indicate main chain contacts only, ray circles (☼) indicate side chain 
contacts only, closed circles (●) indicate both main chain and side chain contacts, and 
the ¥ symbol is used to specify glycan interactions. B) The heavy and light chain 
sequences for CAP257-RH1 are shown, the CDR loops are underlined, and contacts 
in the cocrystal complex are labelled as in A.  
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Supplementary Figure 5: Autologous CAP257 V5 sequences 
A) An alignment of CAP257 Env V5 (and flanking regions) sequences identified by 
SGA from 7 weeks to 240 weeks post-infection. Potential N-linked glycosylation 
sequons are shaded grey, and the number of identical sequences are listed on the 
right of the figure.  
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Supplementary Table 1: Heterologous neutralization mediated by CAP257-RH1 
Neutralization IC50 values of CAP257-RH1 tested on a multi-clade 196 virus panel. 
Titres <50 µg/mL are highlighted in red.  
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Supplementary Table 2: CAP257-RH1 interacting residues 
 CDR/ 
FWRr 
Interfacial 
residue 
Bond 
type* 
Accessible 
Surface 
Area (Å2) 
Buried 
Surface 
Area (Å2) 
Buried 
Area 
(%) 
 ΔiG 
 FW1 Gln   1  192.96  98.79  51|||||| -1.11 
 FW1 Val   2   48.63  13.62  28|||  0.20 
 H1 Glu  31 HS 113.78  66.67  59|||||| -0.21 
 H1 Lys  32   56.94  22.25  39|||| -0.78 
 H2 Trp  52   32.72  15.31  47|||||  0.24 
 H2 Tyr  53   73.91  24.99  34||||  0.15 
 H2 Ile  56  115.67  41.72  36||||  0.67 
Heavy  H2 His  57   87.94  40.64  46|||||  0.15 
chain H3 Gly 101   13.90  10.22  74||||||||  0.16 
 H3 Gly 102 HS  14.19  14.19 100|||||||||| -0.03 
 H3 Lys 103 HS 113.24  99.92  88||||||||| -1.03 
 H3 Tyr 104  121.41  26.24  22||| -0.08 
 H3 Asp 105 HS  48.06  33.46  70||||||| -0.33 
 H3 Tyr 106  148.72  14.62  10|  0.11 
 H3 Asp 108 HS  82.66  37.09  45||||| -0.50 
 H3 Val 109   46.08  26.95  59||||||  0.43 
 L1 Ser  28   82.42  12.64  15|| -0.14 
 L1 Thr  29   97.95  42.89  44||||| -0.19 
 L1 Lys  30 HS 51.25  38.12  74|||||||| -0.18 
 L1 Trp  31 HS 114.19  66.03  58||||||  0.37 
 L1 Tyr  33   42.19  20.91  50||||| -0.11 
 FW2 Val  44   91.14  10.54  12||  0.17 
 FW2 Leu  45   78.06  12.84  17||  0.17 
 FW2 Tyr  48   45.42  0.98   2| -0.01 
Light  L2 Glu  49   43.99   2.09   5| -0.04 
chain L2 Lys  53   93.58   9.92  11|| -0.37 
 L2 Phe  54  127.23  80.58  63|||||||  1.19 
 L2 Ser  55   99.63  38.95  39|||| -0.42 
 FW3 Gly  56   83.26  59.71  72|||||||| -0.29 
 FW3 His  65   41.11   4.51  11|| -0.05 
 L3 Ser  89    1.12   0.95  85||||||||| -0.00 
 L3 Thr  90   13.39  12.26  93||||||||||  0.06 
 L3 Gly  94   33.82   2.51   7|  0.04 
 L3 Gln  95  158.72   2.04   1| -0.02 
 L3 Trp  97  146.90  13.81   9|  0.22 
 
FWR/CDR: Framework region or complementarity determining region of CAP257-RH1 
*H = hydrogen bond, S = salt bridge. 
Chapter 5: A Strain-specific Glycan-dependent CD4bs Antibody  Wibmer et al., 2016 
5 189 
 
  
Supplementary Table 3: RHPA gp120 interacting residues 
gp120 
region 
Heavy chain 
interfacial 
residue 
Bond 
type* 
Accessible 
Surface 
Area (Å2) 
Buried 
Surface 
Area (Å2) 
Buried 
Area 
(%) 
 ΔiG 
 Asn 279   53.85  26.73 50||||| -0.38 
Loop D Asn 280 HS  61.65  55.30 90||||||||| -0.48 
 Val 281  108.51  89.11 82|||||||||  1.30 
 Lys 282  S  78.92  19.52 25|||  0.17 
CD4 Ser 365   76.81  31.57 41||||| -0.01 
binding  Gly 366   42.88  16.80 39||||  0.26 
loop Gly 367   67.48  30.21 45|||||  0.19 
 Thr 455   36.44  10.58 29|||  0.13 
 Arg 456 HS  29.80   4.66 16|| -0.05 
β23 Asp 457 HS  45.32  19.96 44||||| -0.12 
 Gly 458   19.75   4.23 21|||  0.04 
 Gly 459   70.96  41.97 59||||||  0.11 
V5 Val 460  145.24  19.44 13||  0.31 
β24 Arg 469   79.21  10.89 14|| -0.12 
 NAG1276  357.39  14.70 04| -0.28 
 BMA1278  285.85  18.41 06| -0.22 
Glycans MAN1279  287.39  46.01 16|| -0.56 
 MAN1280  291.13  17.30 06|  0.28 
 MAN1281 HS 286.77 103.54 36|||| -1.12 
       
gp120 
region 
Light chain 
interfacial 
residue 
Bond 
type* 
Accessible 
Surface 
Area (Å2) 
Buried 
Surface 
Area (Å2) 
Buried 
area 
(%) 
 ΔiG 
Loop E Lys 357   62.41   3.01  5| -0.11 
 Gly 459   70.96   6.75 10| -0.06 
 Val 460 HS 145.24 125.80 87|||||||||  1.65 
V5 Asp 461 HS  70.34  40.34 57|||||| -0.44 
 Thr 462  126.91  99.54 78||||||||  0.80 
 Lys 465  127.60  11.97  9|  0.19 
β24 Arg 469   79.21   2.04  3| -0.08 
 NAG1277  358.92 35.73 10| -0.53 
 BMA1278  285.85  18.13 06| -0.50 
Glycans MAN1280  291.13  57.97 20|| -0.73 
 MAN1281  286.77  60.50 21||| -0.19 
 MAN1282  290.04  38.77 13|| -0.62 
 
*H = hydrogen bond, S = salt bridge. 
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Supplementary Table 4: List of hydrogen bonds and salt bridges 
Hydrogen bonds________________________________________________ 
gp120 residue    Distance (Å)  Heavy chain residue   
ASN 280[HD21]   2.47   ASP 105[ OD2]  
ASN 280[ OD1]   2.48    GLY 102[ H  ] 
ARG 456[ O  ]   1.90    LYS 103[ HZ2]  
ASP 457[ OD1]   2.21    LYS 103[ HZ3] 
MAN1281[ O6 ]   2.40    ASP 108[ OD2] 
gp120 residue    Distance (Å)  Light chain residue   
VAL 460[ O  ]   2.07    TRP  31[ H  ]  
ASP 461[ OD1]   2.35    LYS  30[ HZ3] 
 
Salt bridges__________________________________________________ 
gp120 residue    Distance (Å)  Heavy chain residue   
LYS 282[ NZ ]   3.71    GLU  31[ OE2]  
ASP 457[ OD1]   2.78    LYS 103[ NZ ] 
gp120 residue    Distance (Å)  Light chain residue   
ASP 461[ OD1]   3.24    LYS  30[ NZ ] 
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Supplementary Table 5: Frequency of glycosylation at position N276 and in the 
V5 loop of a multi-clade 196 virus panel 
The V5 loop sequence motifs for the CAP257 transmitted/founder clone, and the 196 
heterologous strain from supplementary table 1 are shown. Potential N-linked 
glycosylation sequons are highlighted in red. The presence or absence of the N276 
glycan for each virus is indicated.  
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